var title_f42_57_43920="Dermatographism 2";
var content_f42_57_43920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F61550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F61550&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatographism (\"skin writing\")",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These lesions occurred 3 minutes after stroking with the wooden tip of a cotton swab.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43920=[""].join("\n");
var outline_f42_57_43920=null;
var title_f42_57_43921="Malignant carcinoid ileum CT";
var content_f42_57_43921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F78186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F78186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radiographic features associated with small bowel carcinoids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 413px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan demonstrates a soft tissue mass containing coarse central calcifications (arrowhead) in the right lower quadrant. This carcinoid tumor is producing a characteristic desmoplastic response with spiculation of the adjacent mesenteric fat (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43921=[""].join("\n");
var outline_f42_57_43921=null;
var title_f42_57_43922="Colonic adenoma pseudoinvasion";
var content_f42_57_43922=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic adenoma with pseudoinvasion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 237px; height: 344px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFYAO0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwBpGPlB4z3o2DJwOnp3qw6+UCZCqAdC5wK57VvFuj6VZtdSymYCUwqsIyWcdQP8a9yp7u7PKhG+iNrbkBQCF96lVAAc8d+KwtI8X6LqkMTLO0DTP5SxzDB3/wB2rWr62NH1zRrKeECC/LIJs/ccHgEehrFSW99DXke1jZWEn7pBz2yM4p6xsGA2nPoa8M8dXN1o/jDWUt724REfICyHgkDge1XPCXj3XrfTb9pJkvXt4lmHnjn7wGM/QmlHExUuVo3lhZKKkup6VF4s06XVLazhEhWaRohMwwgYen40mreK4tH199P1G1dbfYGSdeeT6j0rkfGFtaXHhSx8YaFH9mLurXMCnIUk4JHoc5pvxEuo7m+0ednwZbBXkHXIOMYqnOVnbyZrTowk19zO9svE+jXURaC9VwvLgKcqM4ya27VobiBZraaOSBxwyHINfOlrqcljP51pvjyCJcciRTwQB34q54c8U32garPPp5jez5Z7aTJUj09jWSr9GaSwnVH0MidARyDjB6VJ5fRV/KuZ8I+O9F8SRKI5RZ3hwPs0xAJPqp711M0ixMysrYCF849OorVNS+E53Bp6oaIzjlTn86XZxgg5zXmN54q16+luJLVxbWSsVQIuTx3zTYvF3iC0CLcSw/vv3aCZB8rf3jj+VHOjoeDqKPMz1Dy/w+vejZxg8D2ryrw34v1281uRJLxJbNH/AHxeMABf9nuK3bPx/O+pyxS6butt5CSI2Nkf95s0KSauQ8NNbanbuhBzzjHWkK4zhc5qeKSKeFZbaVJ4n5Docg0pUoTuGBjv3q9TBoqNGQMsc0wpyQBke9XtvG4gVGygYyM5rKSY0UfLC9QPammM7ueR2q6UwwBOVPGKjK7eCDj1rO1mUUWjw/QAGojEwGQMn3rRKKBwMtUbIpGQenFCQrFEoQMkfhSKhxluD2q2yDIO3twailQuoCnB/rTRLRXKtkbRx35oK9+pqSONh8rnJHU+lOI54HArWJm0VfLAH1pCv0xVkLlug5p2zaOwB6cVrFoiSPngTPqVnE93e3TJDdJbuDIceU2cH6g1W1eFrXTLnTy2WsL5jnuVYYU1nXN1LbxzRJtCTqjNjsynPFafjn5dbeaP/V3ltDNx0PyDP6g15sndP+v66Hp8tpW6Fy0cXHhS51AIBJZalHMQP7rf/qr0X4uBrnwhYarbYPkzx3CsO24DH6muC+GsH9q22v6JjL3dmZI/99Of611Ph66PiD4QatYy7hc6bHgg9wDkfyxVQ1i13/QzmrST/rU47W1HibxfPIkv7qdRNIw/hCoM1keHWkN80EWWW5ieMqO4wTj8wKZp89xZx3EtuAC0DRSHPRWx/hXV6FosNhrPgqdyWi1IEyKeO+3j86hau50tKKsWvDOtwN8LfEWh3UipdQkSQq3/AC0BOCB9DmsXVrmS5mtw5bESJCAT0UdQDVK7sFj1q9tok/fRXciJ67Qx4x3rUNrDqeuXENxILa2UGSRh/Bgdvetk3a3bQqMEo3te5nayYEmVRHIsMbkxDP8AD/jXT6X4fsNH0hPEHjOMxWzjNhpIOJLs9mf0Wq/hG2020WTxHrcUl3bwy+Rpln/FdyjoWH90cZqxZ6B4i+IOv3V9JNDIyHbNO5/cwekafT2qEkOc+Z9jEudPvZLRPEF1FFYRXE5+yRx8Elf7g67R616/8N/GX/CRWx0rWCg1Dy9qNnBnH+Ncb448LXOi6Zb32oamb+e2ZbeRdpVIlI+UJnt0rJHhjX7PT7/WohJZf2YqsmG/eYbncvtiripQdwmoVIWX3nQeKbSbw5eTW8au1qzblBbpntWTqNjcTaGl7FdtMx5lQjJXB6iquseND4g8KRWmrox1u0mUW96gwJozwQ/vXWfDrZeWN1YALJIowhP3d3XH45rRcspaGiqSdO0jkNC1EW2kXsUe2SS4Y/vQcFR6Y71lajcTQoVWWVAmEZDwwXHf1rVns007W9zKVWObeo6bvQfTisO+urrUdXubyWICJpfmQ/cXPas5tqPoawir8vc9Q+Bwujo3iKYSuFUBIs8gOASSPzFcppnjrxTb28l/JqBnhE5iKSrlQ2CfywK9I+GSDT/hb9rGB5iT3DH17f0rxrTHT/hF76O7DpKt2lwR0OxkIyB+IoldQTXn+Ry01GdVxezaR6p4L+I2oeINSg0+XRRJO6lpJYG2hF/vEHPFegWl5bXbzrbTJI0LGORM4aM+hFfP/wAJvEtroniq7m1KZktJIDHkDqR0FR+M7l7vXW1exuriL+1naREDFSI1IAz60Ko+W71M5UIynaGh9F7TtAwCD3B6VHhunYcE14h4CuNSTxZpdvZX90VmkPnRu5ZXjHJODXYeFPiBfa/4xbRxpcSwF3Hmq53IqnqaSqxkhVsJUoy5ZbnelASc8Y9KjZcD5gD79qSzvrG+mnjsbuGee3bZMiNlkPvVl4WAyUZQeORVp9jma7lJhu45x29q53xH4jtdCVTdDKscH2rpgUkcqhJYcMCMVh+KPDFt4htDb3HDHvRLms1Hclol0S/tdYsftFpJuDdT6e1XfKUAelc94K8KzeG5DGs7PBngE54rrmQD+ED+daQu4pyVmZ9Sm0fz8r+NJsHORmrRTI4OQRVC4up45MeQrD1rS6jqyGj5Wdd6IpH31Jz6GtvxQDLpHhu4bktZtH9CrsKzktWjtIZJMMAxGBW/pdnN4huU055MRWVtNcA44RQC2PxriUb6dz1HHZyKfw/vzpHibSr45ESXIhlP+y3GK7nTY4vD3xd1bSHO2y1NWiK9vnXKn8zXn2mMW0XVYjw5Ed1Fgc7lYg/oa7rxHOL3xz4U1SBgxvLaFnZe5GAc0oOy+YpQvKz7Hnd7bvZvd2zBl8qUxsPXDV6l8QIY9Nu/h1LbELHCkYUeg3rzXL/EixSz8U6mwXckrCYJ6dM/yrf+Kt5b3un+EWh/c3H2ISGAg7olP3WP6VSXKpL+ty2r8rOb1mxdvHWoyR7iFvSQU5PPPH51oWVko0rWdSKIApMUcpOfmPVQPXjrVPRPPSS5u5pJJLi2iaQyLyGJGAxP04q1fyXCaHZ2UJTD/wCkyR9zI3Qn3xmqgnrJnRJRSjGK6amV4V0u/wBT1ey0+2d0ubgmJGPP2eI/fcDscZ5r6T0bS7Dw/pNrp9iFhtIfkXccGVz1Puxrw3wJrtr4QvdQvLq0kvNQkiEcJzgDJ5J7gdq6DRP+Et8aeIRqsN0tlBZkqssg2w2pPGFB6tjvTjaPmzCpSlPV6I6H4u6YbrSZLrVtUS2tLfAsbJQM3Endm9f6VjfCSe41LSPGQ1aV5d9uN7ucleMYHtgCo7SHSvD2t6jY+I76XUbq3IWAynd97nK9hk1hQeIptNn8UWthbrGuqp5YJ/5Y46keprR7qQRpNw5UcpK9u+jWVmIws6pJ57nvg/Jj3xWt4C1N7DUoGDHgB2A9QePxrqPDnw+fXPBU2q2t0fOQv5Ns68SqgOST6+lcHBvtrgSMg24529R7fWoScbM2i4ttI9B+JFkqR2usxhJ43UMIuh56j6jivNb9GimnDFjC6Gbg4BY//Xr2i0T+0fBMf2lWUKcgSc9R3x9K831WBGt0UqDHHKruQP4T6e2aurG65jSgrvlvseg63cjw58B7O3f5bq7tRAi9Gy5JJ/AYrznxbapc6PoGs2UqTW09mljcFePLmjGMMPXjNb90L/4j6vfy3UhstO0azaSOFOVjVQMAe7evtXFQWdzJbRCNfKtro+aI2bCSY4LD37VnLVeRlTpOMmnvcxr2wksk8xg21lyrEY5rqPG8hguvDEAA/caZBg+hYc5rP8l7y6ntJZCEXJTd06dKXU7ltUmt7i5RkEEKW4YHtH3rJxaTRr7OLkpR0R3/AMIIDP8AES4nblLOxYnB6E1y/hbxLb+HdV8QanktdNHLDaqO7u33j9MV2nhXHhL4Xa34muvlvdVBhtQRzjov6815Nolob/U7K1PPnXEcZz1OWyaiMXTpruGJkq+IqS6O56D4DDeHbfXTKxTWLjSjeebniJScqCP7xyDXL6f4y8SWip5ep3HmznJaRt38+laniC9WL4g+IYWfbBOstkTjhQikKPp8ormo4FS5tpJXURKn3hxTlePurzJpUVUvKW2n5nq3gPxxq2q6/b6HqVvDdSSIWN1FwVAGdx7Yrv7fVNMu5mhtdSs5pVJUrHKCQR14ry34Y2zWNsmqTIiz6qJ9rtwY7WNGyw9MsFrzeDyVV7hZfKbLOrqSG+8en4Yp+1cIpvW5isKsRVkqeiX9f15n1SExn1PQd6Ty+MLz9a8ps/G+p+FZtE0fVIZdQle3WW5B+adS/wB1R9B2r1GXU9Ot7y2tLq7itr25TzIoZGw5GO/p+NdUJJrU8+dOS2JSmWwOtJ5eAMLmrTIVfaRyaYVJ+6SPWt0tTBo+aPC8Meqa3o9lKm6KacRsnTIIOa2PBCJD4/vtLkI3PDd2AHTpu2/0qp4algsfiPZXFrG0lrDqBMZHePmpPGFnc6L43v7u2VkujdG8t51PG0nPH8jXM42V10Z6l5VHyvqjldGMsJnVCqHY0LEjJwTyB78VIyS2lzabWlCBgYmyRgZ6e1RWsrLdPK5ykqmTGM857VryXJupYYXcARRiYyEZwccisYpWsbLWxZ8T3cutXtxqiwyCOGNLeYsR8r9h+NW/D1rdeLfFFvaTzlZ1tT5sqr/qookO0H8QKpw+XN5n2dpHtr1MyJjGSO+PUf1r0T4d6tFD8NtejaJItR0sSQvLtG91cELk1aV5ajq/u4XWpx2iOIPB/iOZlXbcyR25KjGMMen1qjaxX2sahBa2iR/apFyJPupCqjlieygZ5pEmlj0X+zFGVeVbiVMc8AEc+5qfQtJ1LWNTm0jTrjyraYqbxk+5HCDzub06cU5PmSSHrTu+p2/gLw5p+parDfInn6HpTBTdSjH9oXGcljnpGvb6VynjTXruW6vtNN3nT2vGn8q3IVZ2OAACOT0rofiFr+nRWtv4T8OTSrpVkgE7wf8ALZuyg9+eTVDwwdU0O3aaHQNPvJuG+03ceZE9Mc4FK/RCjGUlzS17GH4y0LVdAWxu9QXedRiDZHzeSw5CMfWr11qNlq+lW8cULWlxG4kSTAIBwA+4+mAD+NdKPH1xdW81r4g8LrdwOdrrG5Ckd8ccNXKQW9vZ63EkcUtvptxdxFIbsfOEJ5B9q00WqKhzfb0PUfgPceZ4ev7KaUMbW7PTpscHOPavJ/GWkHSPFerWHIEUxdQTzsb5v616notrD4e+Od1punny7G/tvN8kfc5GcD6VP8dRDb6PpMwt4Xu2u8GYj5gABwT3FF9GmZRsq2mzRk+BG+1aJNbSyhklw0ZB5A9D71x3iWwSy1O8t42YCRAyEHITPJz7ZrV8HXvkavcRI6/Mv32GBv8AStK4sLnVpdTuVlykaCKPauVdgORWqd4WOrl5Ztt6HMaBqh0248RJcptXVbB4MAgBXAGCPY1mtNDL4K0/R9S3w39pNI0ZYcNE6sevqGxxU1zazPdWv2aNZWlBeMY6un3h/KlvdLj1LwR/b+mz+fcW07jU7Jz86Mx+WZfY5x+NY3s7IKsFu+pk6fZrdaJfXc77buzMZ8vOPNiPBI9xioXRrizJkVY181ULAcBCev5ZqWaWO9gt5Ld3afyws0WMbW6fiMYq2kAk069aV/KMckcW09GUAkn9KzeiNoxi9G9C38TPFf8AwkUljpWmxeVoWmIvlBhtaVgoBc+3HFc94evF0fUtO1GWATvBP5/l/wB7jitnU9IlfRodYuYxBZ3Uvk2kMnEkoUcy4/uj+lXoX0S28A3MV1avJ4ivpf8AR2UcRoOnP50NX3MfYqN2tUcVqs9zd301w6fv55ZLhj7uScfrWpDpv9oT2NgEEctzMsJlzwE6sfyqveWc1ofNdJAki7Fbs1W9QmYW1mYldXjiZc45B/pUNGkKdk09Db8Qa3DdjX7jTGK6daW0ejaagONyFhlvxCk1keDNJs7nVhcX7rHo2jqLq/lI4dl+7EvqSRiqFpBcXllaafZxhXWb92O0kjfxE+ijNXvFd1a2trB4Y0eVZrS1YyXVwv8Ay9XH8TZ/ur0H0qX7zv2MOR04uPWQxvGMy6vq/iCNA2u37lbckZFpH/eGf4sAAfjT/B2hal448SPDNdyGVl827u3O4xoOgHua5bzDDF8n3D8q8cue5r6e+EHhtdD8K20lxGBf6ltuJ27qmPlX6YwauEXOVnsc0nGjG8dzchktLcw2DXUQmjRYlR5B5rccZHXJq4qMuQAMjqD2r5/0m1h8dfE6+TUdUuLSSW4byJYV5k2HhQc/L9a+hoohsCj5toC5Y8/j7110pttrojirU1FJ31ep85XFgdD+IrafGCscE0eC5wCpB5z711PxOsY5bOO6DbmTkBOCVPUVT8bQPqmnaD4wjRovMtY47yM9WK9HFdc8a6nolvNC8ZjZMM7DJKn09KpK94nXF/DM8S0i4h027t7mOLz1tmYyBh8pRgRt/CmRhHLiMkzJtVFH3WXHQ103hfQraXxTqGjXjZjwxjjz949eDWbqOkppk9zaR5aP5dsoPLAnj6Y71ypWWp0auyRHJMo1O5EMTQwthvJbho2wAce3ArqpYYtA+EkamUfbPEE/mNxlnAYcA9sDtVvxDpMNt4XK20CBrZFYzZ3MRjn5vxrkRqUuo2+gaTO4e3trwPbKBz8zDcCabXLqOXvqz7nTrpkN9qepzpIFit4441kVQBuCKfmz0qhpuqx6N4Jn0/Smb7fqO6TUJ41J+zQZ+WMHsTVu7nDeHdQ06F913d6gRHGi/ewccn8K2Y7G2F5a+FbFYktbVft+s3JHMmwZ259M4H41VlYjR7k3gLw1ZaPZ2t9rogF3OVe1t3IJijPRmHcnr+NehvbWt1AwZI5Y2O7K9/fIrwxLi48T69JqcyyeXdzDeytjyYgfkAHYAAV7dYxWmjaGm7c0QQyEM33nxwfpVU3fQVeLjaV9Rsej2m5JIwxGc7WOQff61wXjXT473Tr/AFmfyLWGAfZ7ZzgvdSZ5UewGOaq6p43vJzDaBpEDNmWdUw2zuEHb6msLWr5debfezSwWtmm2ysoxwOTuGf7/AHJ96qU00XClUTO60u5W81b4b61cK63Msclk0h6SBAcHPrUPx3nEmtaHZTnCRI8zKvqSQP5VvfBuwsdT8P2V3cQNLPp8rwQM+cICchgOx4xmvN/Euqza18SLiW7DCR7oQRrt4jRPb36/jWKdk2VTgpVku367FaW1+yuYJcFm272U9G+tem/D+2X+yGaXlQ5AjJ4HPJrz6G0mv9SmtZjG8pPyAjaQo/ma7L4Z3zrcX2kXWfPX99GGGCF75rSLsb4mK5XbcwtasZLC21hbcKDpd6tymPvGOQYOD+Fcn4evINJ1fT72/sy2kT+Za3BXgyqcgn32nn8K9K8YeTB4gv45tyxapprLuUceYvT6da4nW18rQfC0EIMhjs5Z9gXJZ2bk/qamS/r+vUINuN+/9foYbwxJp17p0QR2jut9rcr94pnof+A4qOYotwVlt5JYN6jYpyrBeTn6+tal5pF3pVlZ3F3GscMy+ZD5f3iT2PpUPhvTZL3VrVXd0tmY+Yinnr3NRLyOiEVp/WhB4puNT1qb7bfxlJJFEVrEilYYoRwET/GofD2mtPqtrDK+9nOH7bV9Aa98fSYDZiPYvyrjc4DbeOwxxXK3lnDH4k0izhaALIT5wC4IX2PvVOOnNc5oVYt2SIfGGjQ2vgvMcQkmQq43EfKO2M+leSNfySPG7FipykigcP7/AEr17x9rckks2j6VC09w3Dll+VPQLXkWsW02mSC0vii3Eb5Kqckk9qzrJPY1oVp0488uplTyCaRWgyqopAUZAB9AKk0rTZry4eCwiFxceU0kn8KxRjlmJ7YoMVwzN5Kqqk7TITyT7VesdTl0uw1i0ihxc6lAtuZAeMZOT+IrOMddyZN257f1/X/AMnTLNru8VlYtvuI7dJMcAs3b8Aa+tvE9zF4e8LX1yWxHY2flqR3YLtX9RXy94ZsJrnxVoOlWvzbbhZWRjgBupP5Zr3L9oPVorTwYNNRiZtSuVRSP7iEMT+mK1ou15HDi4O8Ydbv9P87fI4X4FWFtCNZ8V6sxhgsMqJXHyAtyTn1HHSqfjP4vane6qV8ID7Np8WV810y05/vH06cCuIk1TUL3QbDRRMRpsbs6WqnaJH7u/qOnWs2aNSFU3KI65BVOg5pc0owUYlOjGc3KT0Wx7rcXUNnDcQ31xG2jXVmsSFgSEcAjaB26/pS+CZZb3w7HaRPsEBKNJ3ZQegrlfCmp/wBqQ6Va3kSm1WVskjIB2kAEeldV8P2WXRL23MgRY71oy4GMc8c12ykm1Yz5OWLOL1+A6L41tdTjzFGCCy5yW7Nz+VaHxEhjS50uWOOMxzphGUY3gnP6dKs/EnRWiSG5kncvvO1cA7fTHt71VEo1vRfDNvNMscsc8llJJt+6TkofzxXLL3Xsaxs9jsP7NRtCtmmyUX5tr8qMjjcO44rz/wAC6cLzxNdvdCEWenB7mcBtvIB2ke2ccV10WrTDwxDa3En+ntKbYqgzgqT1H0x+dcHY2zusM6eZGLxpPNIBEcqIcYz7HHFKpJaFQhKei6/qdV4CX7QZNQu1QQ6YJZQG7yOxIb64I4rPOoJb+GdUlhl83W9euPISMHLRw55P4nFZ1zevDo5tLUkxSSmW4IOOnAA9sAUyONrdIJRGsckqkLKGG5h2IHYD1q1Zqw3Bp3Wx0Oi2M2m6slql3HHZWMAS+nQYC7z9xiOpGelReOPEk2pa2p09bj+yoIxbqo/iA/i/EkflUVtdzW/hd9IuIystxeLctIvOVwOSe5zUl9qUU/gh9JsYoTeNcgxzqMs47496mTSdjohTfLzta7Hb2Umi+EvBVvezLY3024G8ZEEkkkxG5Yxnpj17VkaPYR+M9Uvte1aGC2tAgkmtY22LnoqFvXjJP0rj9N8Pa5eXJ02wsJXdWDtHKCgU9MsfXFd94jsofC/g610ZZg19fSgy+r/3iR2XoB9KcdjF0rS0erLHw5vzH8PvE4s/M863kcxOeDtYEBh9BXl+gO93f3JlRru6t4cpMwJLMf4if6mu4trk23ww1pIH2zm/SCWTvIpB4H5VxmlzXWn20iWs0azXcvlFhj50/uk9sVNr2R1U17KcpvX9bW/Vmg2ozW2pWl8kBk8llVscBj0OD+Ndvrf+gXOneII497wSBJNnBMTcEN64zWffeGRFpUhhQSTiMO0hYgAjk4GfyrodDu/7e8NOsgEfmxGNSy8MQMHn3rSPZkV9Zc39alP4jojf2RdoQ8LSuN2flCso4rgppri007Qrm0I8+3NzbgMM4Xcevtiu0vibz4az28qqt3psyrKucgEHg578GuMltZzJJbiQeTDmbAOHYN1P09qb1ClC0bdjuZZ7XXPhrd3I+d7JRIcjlWH9PpWR8ONOKQ317cTwGz8xVeInawbsQT2q34CnN9peuaPIv7t7UmJSu1m64rmLh57PTLyynOy5kZCqkYOFOf6VDfUqnTclKCfW53XibWbexhnuXk37SUgCyEbzjoR3FJ4K0eea5OvaiX+0yjMYB+XZ2GO1c6iw+IfEFkuIzbwwAsyjAHckD17V3V1qWl6ZpYvLiVligTBiGc7uwA75obuzGcXThyx3f5f8ETX9Rh0m3a58pZLuQbbePb88jnv9K5zSvBttNMdU1tvtWqP+83gYC56Kq+1amh217qOpvq+qRGGZ12QwNz9ni65+p/rW+6yTEmHZtBCoMdB3JoupbmV/ZK0d+55H8RND0nTL/T7tIDIJn3TRE4VjjPPpXM+IL7S9Vu7LULK2t7GaMGOe1gP7o46MPfHWvdNb8PW2rIIruONrfhmU/eLDvmoG8K6SYTbtZWzRlSRGI8Dp69aHTu7o0hioqNpK7OE+C/hgme58SXUSM8hKWiN0B7sPoKzPjPr1trviiyttHlFzHpkJhDKpIklJ+YAd8f0rqdX8U2fhTw/qOn2iBZoozHbwr1Dv157ACuk+Dngiw0TRLbWbgx3mqagm4SMgYQZ5IX39TTaVuRb9TKb5Ze1lstj5kuBcwzukkbwyt94OhV8emD0FXrKws1s47jUrgQNPny48dFHGfxr0z4vwwax8Q5MS29zOrCErGMbE7BiOCetZ/jD4cy22rQyRs81ncWkMsK9DHkHcpH1pODWwU2klKS1fR3+8otpV3oOp3mnyII5Qvm+cpzG49U9fQ/Wun+HskH2yxmt/MCX6SpewMPl8yMkq2O3AFcveX1zqb6ZLNG+zTYFjxuLb0PG/25xXT/Dy4ittZ+zyTBfPkKDccl9wxj605S18hunL2foaUMFxrOk67a3TB1t3Mlq5+8iDtmvL5GmuI3azZlUMx5OHV8dfcivQbLUYNJg8WWylyy5aBeTuGcf16VzL2RFs6pGFdhHLE7dWJxkY7VlJNoqDV2u5Ymur+9tE+2x2ovTAFkuFi2vIOgJNQi5a30u1s2LBIRsRMZwWPJ+mank81VQzzcRjaxPQD0rZ8P6ZLcXbX0hCQIBsjlTnaOSSfwrOC55eR21OXCU00ve1/wCD/l/w5yj2i/api2V2kJGmMc+31Na2r2Ok6Pp7WFov2/XWjEt1OXzHZp/cH+0ahW+P2+5u4V+03QkYwrjKgnjcfoMYqex0O51TVIfDtvDGrSSi41GVPvN/st6YGePcV0bHDa8V3KWp6VeWGm2U7MUluoTLbKx3blB+6a6z4Kx26JNHciP7YW3woVyY1749Mn+VW/iU2kWi6bo9vGzf2bGWU88Z4wT61i32qQ+GvDEJ8kpqerIHeVThoYicBAex4PSsnvdnRFKULrRv8v6R6HdeK9Pjl1Oztrxn1WytnuFUY2Bh2z/ERXj0M8k7R65qF491cTTlZXc5y4AOFHYAEVd0XRbiDS9a1iELLFEyxRs/JTP3sn1IzWn4a0K01LQmtbeylS7ZZG83kiNl52MOwIIw31o5nJjp04UrS/Eyri4m8hbF5NsUs32pUAOC3qfXGaTT4YbbxJYT3UeY0Jdv7ufXH61XbWikkYkXf5EJt0OOVGR19+Kr3t5HInzO4dCAihefrn6VTmkjrVNVHqex6XfLfMlujrMR87TxDCtnsSe49Kx/DavZSazpyoVaC48yKMnOEbqR+JrF+HmrpOv9kSuY2V/NgJ4LE9R9al8QaxFp3i4Pb5kljiEcyA4Dj0J9R/OtFK6ucrhaTijRhj8zXPEWlFGIvrXzFbPBYDqfeuRea3u1t2mykkVuscka/fG0YBH8q6DwXqf9o+P4LyV/mlDKsYyQoxwCaoa3p0Nh4tlSUB7eS6TJVf4XOSufahsF/L5Gh8PWjPi2I2822N4cYA788E1y2vq66te287SzyLMxJlPPXjmvRdH0G30r4h3UVmALaMoYdpz8p65NcVrRSfX9WaRgyfaHYHuozzUzdldF4e05tN7ol8PnUFuGi0x0ZmQKxZPlTPetLw5bS3fiW7i12SS5vLFl+z/88g/cn39q0PDDRaP4budTlbfNMcRADnHQYHrVvwpFMZBqIf8A0m4YTXce35STkLge3NLl0JrTbbOkeOVwsEBC24OZGHLM3pjsKtwQ+UjBj1OWNPZUtRGJnQXEvTnlqdKuQo2liT2ouedKV9CCNWLqBxC3zZLZbFch4z8XNpFu9vbRsbmSNmjiHoP4m9BXRa1drZ28qKP9VEZGI6DHQfnXj0txMfDN/r2oB59S1acW1sQvEaKfm/McVfNyo1oUlN+9sc3rzNfWQ1G8AN60o5D5DD1xU2naxrz6c9hY3t3a6aclkB4J9hVzT7JIreQXMUEsXDxksQVI6k+1XvD/AIc1/wAcPKfD9m0Fgn3rln2A49D2/CpXmehOCguaTt5ennsZemWs2l6xDqFyPNS2H2kx5yZWHRWrqW+LdvreoT3eqWX2RPLjSKGNs7cA7sn3NchrOhap4Yv57a5u7bzWwGAlEufese4j08MBNES/Usn8XvjtSs43toZTgqlpW27+fmjt7u6h1KeW2sbeK0S3zCrA8yoPUfXFYyr9l1INDIyyREPjOSjLzmuo1rTY9OuRbu6zzyZbzY0x8v8AjWNDbAasrAlXZMZx8rZHH5VVWVnqRRp80NNXcLCzd9WWSRxK0u6QtuxnPbH4VYvJ5JXDGZGZUWMGMcZHHHvUGpsSrugd9qbgYztP1+tRWOILCJCh81x5xbdkZPPH9a5pN8t2dNOMFW5YdOpqWNlJqGpW9ike+NT5jZPJx1z7VtX989+66XZTpBaK224vJD2Ay2PYAH6mqulTpp2lXtzE5S7lj8vexztX+IgfiKzIYBOAlpFJLciN5ok3BcAAljk9T7Ctad4ROTFTVWo5dERXeo2y3ATR7bybJYjb2ryfK0jAkmRvTOfyxXR6Pqf9h+CZDpuRqdzIwuLkjLpH6+7Ht+Nc5pN/NqkF3JZ6PbQ2CxLHuv033EjHrJu/hx2Aq5c3lnmaOZ2IkXejb+R+FCldXM6fvKzL/h21t31idr2GSSzsLT7S5mGPNkIyufqe1cjB9p1HWJ9TvcPa2sbmORl3bW44Ve+MjHpXUXTTW3gbzLd3N1qt4lsoGWKxrgd/cVswppWj6Vp1pHbtJelS90UYZHGAh7DJOTSa5nqW21dI27/TzZeCfDXh6zkj+1ahLDPIsjYMw3Bn5/OuJ8b3Dx+N9cj0qSWJA6xTxo20N8oHFPv7jW4xpOsXkb79GYQpIFykYA4X3OBkmm+GtMn1vxOJ73cIbjN3dn2JOF/T9aErKxpDfml5nM3CG3Luxyuz5lK5+U9Oe5plna7ZRNLIdq4PIyM445r0v4kWn2690Gwt40VJGKADjC56V1MVrp9rjT4oYlj8vY42fKe3X1zUuldnbHGckLqO54nfWqvMlzZ3LToEWRpMbSDzlfqPWtzwfor6/qbvclltIV3SoP48ngZ/nV3xBZxadc32nRqI7cyB0Veoz2zVr4fN9j1K8tmulX7XEQqk8hh0H1IqkveCpL91dbvqWb/Srfw/4j0i9sw0dq021kxwp9c+hqf4jLDDrthPuCLNERk92U8H9K0/G/mXmjTfMU+xqkkob1B6isbxxtubvS2RQ6NZLIA7cnplq0Zy05e9FvpcteGdYCaxrWpXDPHBFZiUqTkBhkAD3OOlcbFJHM7CYF5pvujupY0yeWSG0uCfMKt9yRc4JHQFadATbQiW7RHDEBUDEMwAznPb61MnsjpopRcpLsdRqkn2pbXTraBHS3HkwAHq+Pmc+w/nXaeHbGOBFEeUFvEEO09T9e4ri9BspLSWHWZ54ls3QoIef3CN1bcep55rZ/tzZcC00h/tDLH5nnRrlQo6hfU81T1Whx1k3eKNWylWTVGS+4kEuTvHtxz6Vs315BapJJJKmVBKopyXPoBXOWlrcaxHGyfuoCx/fSn95tPbjpVKV/7LjklltpN0eVOAWc4/unuKW70Od01INWcarp15HeMA5RpAI+CuAT0715zoIl1mfTbWG5eCO2jbg/dQZJaT9f0re8R+Jftlt9ksYZ8XGBIUGJZB2RcdBUWsadD4e8Nw2FwyxaxffPOiN/x7wAZ2Y9SP50XTaOynBwXZvZHE6u6/2g1tbeamnyuNzty0qA9cdu9dX448dXGtxxaR4elfSPD1tGkapEux5mAGSce9c7a2Rnu4LgtK9zP/AKiBc7to6f1qzd6Le28ybIneOcZDBSXU9wQecUfFsaexs7zfpf8Ar/hjGSaa0uUu4yLiSIiT978xZvU/4Vs6r461jVmjkubLSYygOCluEzn8aSw8MajLfohjAZBuYAcgdiw64ran+H6Xwjl+1ea20bliDYQ1Sg38KJcvZ2fNb+vmZ+k3z3V0A6tFFA2ApQltx6nJPIq3cMS3Lg28W47j3HU8etS6ZbQ+YzlW8vGTgZIx2B96tSxFxNPE8e1sbIU6Y759xXNVvd3ZvhI8tJRavuzkZbxnvhL5v2RRhWwhO4Guh8ldO86FtjvOhAZh80YI4yO2azNZyGitUhaXeFdWUYJ/3vetrSLJtQN5LfTtAlpECkw+4WHXf6/Shu9jmScHLW/+fULLTdQub+y01mgSaaESySOcLFFkgHHfoeKfeeH/ABDYXa29xoovreEsY50yN47cg8DHaqhtJL60lnuzCIoAN0sp2MM9BH398U6wvtZn0g2r/wBoXGjWBYvJCCrTAn+Nzj5fYZq+Z9zncb9C/LdRSWm26itIZFOGt4GLLAPVmz8zE8AdqzNa07T47CBoZFZ7hd0gQZ8pu6hvpn6VZ8OW8fix4rK0nFnc26vL86/uLaIddij7x/2jirepiHWbzStI8ONLPp0aqnnkbASM+bJz9KXMrh7O2xLJJFqyaZFpG9YLO1CpC5wS4bO4HuSarvbXCXAunh2z35BRA3yvt649/fvis83F0bu5urWUm304tFBcMn/LPPB29snvWtL9rtbnT7wqjSqolhO75DjPyD6Zz+NUn2NLak+rakW8MLaMZANzsx3f69nOG4/2QT+VbngHShY6YTHdO5utuCRllC9Pwrk7GNLvU4hNummmcqkYUkDccu7egzkCu31q+i0PSdsSBXZWigVeCGA+8Pah2vctRsuRbmXDKmq/EZnkU/ZNNiJJVuQemfzrq9PvYHsrgXZ8iV8ybnXoo6NXLfD63P8AZM90yF5L+baBjkIK09dvYL1pNFsXMl6vMihfkwBwpNCd9RyitIfiZM+nXuu3l1fsI1DjbFuPLqOhH+NclqlrPZ30JmV4Z0dWjYDGSOn5V6z4Y07ULKAS6oymaOIRqcY+UVk+ONPiMcd3HGcbsMRyEz/L1oUr7gprn9mn/XYo33iG3utDu0nVf7TZPLktByWyPvZ7is7XFiI0QRqHjXTxkv15Ix+FZ0VuHn+0up3r8isvJZKLmZrm5gG0nyIgq8ZGB296vmtoaKiouLT0epmCGZsMhYFWKoX6SZ9R2FWb2OQadJ50QLrFuYrwE9veq1jGyrN5jO/lzeYp671PQD0wQa1w6pCGlkBMn3h03egrOcveOzCRjOm9bHQS+VB4BQbPP/0QuVJ4YFcYqPwPABppmiIUqoQ448tB2X6/0rkxPPY6dqOmxK0sN5xA7niE5+ZTVrwwl9JrkP2JltrKxj8u4kk48zA7+mPX3q1LY5pUdJJ+p6zZwrbrGtuCPMXfI2Oua5Xxfq621rcSxSgOF8iEjo2epH0qS28c6HcMtnaXLTTEFZGxhdvc5/lXCeItXh1O8jW2QJbQFlUnnzT3/Clexx0KLlO8kX9IvLfwjai8lEF3q9wv7mEHcVHZie1cy0Wo+JfEsc123mXEqncGHyxoOSxPeqOnCVzKGiVfOI8tDwVArf8ADeoyafqq+bbCZZl8qRw20oD9f60r30OyVJRvLd/1/wAOdroWgadpsiCO1eSZyFe+cnIyP4f7ozitl7Y6dMWkQrKq7FZxyR6j2rFi8RLdXixabA80b4CyyrhMdwMdSMCuzs7iDU1FtqjxSArujzx0PPJ/lW8Xynn1JN629Tm4LG7vJ0WOEH7WNpuVBHyd8mu9tLRNPgSK3SJIwAAdvLY4yTT4V8tY1RAIx8qhfSrcbnbhFVlBPLdc+lXFt7nFicR7T3YqyPnlJsXEtvao+6MB3lOdqj1qxE8DlpJIhwuCAMMcnrmqlpes99JDa3CR3iN+/wBh3FQR0PYj2zVm6WFoZJFBnXZsQocAMe7e/tXnyu9T6SlOLWjvba36ehWZC9+y28jS2Rm3s20Bn4/MCrXh/SW1XWZYrWcW9u6mafzOY4VBxu29z+lZ9nYzbo5JNyFo/MUg9R6/TirkQ1yzH27RmS0kmt2dIZGzJdQqcl1X0GKa23Oauko9mP1C10vUbK+v7EXvlWR2JcXTKUvx0ZUAHBHas+61m/h0W10/dJJaxRGNzAxBkQsCFI6KcgD1prtd65cQ3187XUQUERRgRRjH4/ep17dh7KZxsmtRw+zpuHO36DGc+1F9QpUlypS3G3+mz6Tf3G2cw3b28f2iOzHDxv0jJ7EDqaksbhwjR2KvBIB5DROfvR99pFZ10llLptpLDHeGaQl7m6mY7XXoiD1wRWvp3nQ2szzyh7yU7eEGY4x0xz70tzWNrNmpDcxWui63ZLsLSXMCInBZI1VWyx/u5pNRmF1a2MVqiwxWcX7tGHc/fb8eMfSn+F7OJ9VktxFHNJb2Ml1dy443YIjVj7cGsFp2ntbeaKRg7E5JyGYE9B7e9ap6XOZQi6lt/wCrDtCvptP1E30QaI5KP5jYBQdAB1OatSi+8Q6osUs0b3M3ygKflgTOcfWsy8mkiZWYfaGhcjBHyjP88Gu4+HlnseW5mQC424HIOSepA+mKhzv7p1ygqcXVtqdDmLStLZ0HlQ2UBUHgZbHUfjWV4LsjDJDfXEZWe5y2GOeOoPr1pviO5g1m9sNEsHWSTzfMuT2RR3P44rp9ORYpRIxdkP7tDt+9jvjtVrscDnyxb6sW4LyXZjebC5BcA5AJ7VX163luraRYJWTCFhGBlZCO31rPl1ZY7828sqsFuFEspHAHPGfXpW9qLwWltcSSk5bgR5+Zsjt/jVNtM54+600ef6arJFcQWpVpQmeBlx6qBWbDNFeXAVT5DgBgCMdB3+var+ixC4tr6aJWhgt90jsOGUE8Jnvzms2GExXwmydznBUdiO1Ko7R0PToLmqJCT26Pst5LkAgkbUIDBT60y60+Kby/PZzJbuHRl6ZHTIrG1TStQutZZoGaK1mcMxDcjHSugspHVGhkTDBcMTzu/Hua51JyPRjCEW4Tjb9TlPE1nqs+uwTRljA6Eps4VXAyMj1zXRiwM6vLcXEyNcKqXIiOFlHcEHp9RV64PmRiMudmAGGOoqOH9zGyqSyAYTcOg/wpp2dynhYXb3v+Bzc2mWFrczLY29wojHzc4VgOcfhXS2Og2t94dsrlEdru9VnR04WLb0BxVK4RRckooJIwSvORjkmtnwBqsMdn/YNzMIbyJ2e18zgSqeoB9a2jK7OHE03CCcdjN8PaQsGozxajBMphUElxuUt2Kt6CsuG2N34kmwFa03GRvM6Pgc8D+VdF49udQsrYXMCLFKkgjQk5cnuMfTNcBpcN3rF3OkavNckFjtPU+ntW17HBrI6+S6MWp2ws7wSafY7URoB8pyeV49K7++WOVoCoV43kGF6buc/XBrzPT4JpdPtra1/cO8gQkcFGB5z+Fey+Hfs8Ftc3N35IhV1jDsPlAAHP1pRle6NMVBYdQkt7J/edBcG3trMO4KQxgAMOuf7orkNd1W9lmQWQMUSAjGQST707Xdbgmne5klxplup+c8At/exXh/i3WLjX9WaW2kure1jG2JYzt3D+8fc10QtBXZ5lKhJvVamx4ct7a1EVvokEalchlkIXjucnk/jVlVJkZkClCcGNRwzdjj1qjo7LCEkt18yZWwwI4UdiPUVd1W+hcfKq7g+9ip4B9BXBUio6I9bCybipSXp5EeoyNBpo+2OIINyiSXkHy85OAOgGMfjWlquqaVf6zNq2li5kvGshZadC6sFjVhtLnttwa52zmu9T1I26SeUJQUG8b1kI5Ix6U6wnK20haVpFQl2eLhI8HkfTNJO6sZVYe0ndl99LkSYWktvdppUEYUsoO1z1ZgenXtVfTngvWs7PUlfT4Y1cvjPzIvJH+82Ko6ZciVpkvJWfzJDPCI5SEAxgnnrjHSpmm0+XwlEst5IDJcu6lRulVVBVM+g5pct2TCdSK52/T+vK5syTJrVrKxEcOWRbG1Dbha246s5HG9ueOtT3dpa2MczzyqJY41YRDlpJD91V9gMk1zlvdzPB/wAS+R2lkVULiPjA6nNdINS0sWcf2e0eLU1yjTs29UU9WX/aNPcpNwdomNbX91DFewQs8UF/g3TqwywVeVQds45NX1sdS1GRGt7XaJY8xs5yFXtk9BUnhzSFv9SO2VrdYOTI6bvov413sskUSF3ZYraNAxlPyo30H4dKu9xOTg9DyC6ga1tik0bvdW7sFy+FPPzADv8AWtnRPDmq6oq3tpeC1tyGAkMnsPl+Xt711+g6ZDq0F/d30aq15KTEJhwkQ6EfzqXwUUXS5LJCJGtpnXaowCp6MPaocUndFyrycbMwNDaHw7cXEWpyIjgeXJInJ9QR65x1rbufGVtcW0raUkktwkR5cY2n1IrntTgfxJ4pniURPIj4wn3EQcbveuk1Dw3YWWjTfY49t5ChcOx+aQdwfrWidnYzkotJyItO0G8u/Dxmu7tRLcDzBBIow3uT1z71mXMs50FLaWZmuY3ZUlL5LJnOM+o6V2uhyQ6jpFrKirg26jaDwmOuTXnupB5dSZAGNkkzbs8AgVSdk2yINznZ7k4khtLOEK0koUKdhOFlkGfmPrjPT2pogmGyONWeaQ+YZ5VKoxPUZPpVi2t7qW4mngVnSLoGYLtU/wB0Y6cdal0vTbrVzM73LR20R3PO3I/3QPWplBvWRvSr8nwleeFo1eWWWLZnadjA4PtUEeYxI0aAjAAJGR9RV/XNJn0toZmdtR0+UAKwwhH4etZyNLbQltrRoXy0eeCp7ms/Y22Z6CxzmveV0TKFnj3SxsSByIzgD65qNpIZI38hyxTpuPzY/rTUuLAspaWS1kzs3N9wjqBSXVtcWwaSQBY25gnT5kB/vZFQ047m1OUJ6weq2XUhuRHauBLcQpuTzC+RhR7n19qqalbpfRLsdW2DcGHJ9iPT6itVIAFMjWkVwMAyAfMsv4f0rMtLSG5FuNMH2YecQgJ9f4fpU7O6NFUclyTV7/L8DO1G91O8tZPtV4BdwJ5cIYH5l6Zz647muk8Fy6KsAtdLnK3W3dIJkOXcDnB+tUb+xju4pbadCJl+V17qw71z0gn09ZXlZkvYCGgdR36Zz9BzWsal3ZnHiMLyx5oPRnRaZa3Uni2+jtZ4zbIwmmkYfdY/wrXda1eWuk6eFupUCKvmyL2ZzzwPpXLeHr/StD0r7ZqF6Lq7mIdokX52f39q5/Vby41rUHmvZRAvLpHIPvD1Fbxklqc8qE6suV7LQoeK/Ed1qb+WUlWEvmO2Qbjj1asuGOYlnncRs2PlTBx7Zq9Ov2El0cKzcyD/AJaSA/wj0FdN4Y8C3fiqxa9trpNPtFby4oSMkY65rRNy+EmcY0Lyq6W6f5lJNOvLuC5tLSAlwNxW3yfLTrhj36U7wz4QTXnfzblY4bYAuoYjexOAG7gV6h4Af7L4VtCiqJJJZHkwBknI4zWJrFrcaLr76npcKmK5BE0RHyPz39Kxnq7WPLVZ6rqcTfaKYtWsp7KaO1NlKykMcZB6gD8PxpDo1vfh5LvULfT9FEzHy+A87A85X610+oajZ6i5i1vS3hmAyGP3f+AkdazP7K0m0vGdZmeWZG2tcYKqMdT6ZpSXYuFRfaMbWrzSbu7gj063mOn2sXlxxouMufvHA6jp1rLsrWTT0ivLuFLwu+5lZtm2L09fau9udX0jSIzJDGHUYUvEoIY47H0rlrGN9d1qRo4jIJMNErDCREdGb29qjlsjaNW+yLr65Ct9JJo1n/Z9pOnlhWBzjH+PSueudQSGVkSHdK37z5Dnb6AjoK9EXS4jbi1v4lmuApea4UYIPYqOg+ledw6Ld6xeXMkSsqq4JMQzj0DY70n5GkZW3/zNzQtd1OyuXFtCqC5CvKbgb1lwABjGcfhXc6VZm+hi1HV1SdZh5kcPSCBB0O3oT1rgLfS55pkjQ3BmjyqpGpBTHc54rYPhrWfJKmW48iNd4iWThh3OKFfZodSMXqpItaj4gktXvbTT4g6vIywSsTuXceVVR654pdP8N69Db/abacW7yrgwvJiQDuPSqelKbK/tLi+k81WkXnjcV7N+FeiXDxQF57iX5FHzM45UHo1U2Zybp6HM/Dq2jtZtSimiMd1EQrE8fL7j64rptVlMWmTyyOkcmCEYjcDngCuUvdTiTxNLJaFJpxGIpZDny5SOeT7Yq7HBqGuyebey/ZLBB+7XGS//AOqhWvqKafxMl8FXH2e2u7W5kJEIZypPIGKxLHTvt1nd6rLJKkSSiPyMZE2Tn5vb1qC7uZraM+WAVHyySEYL/wCNdbHEo8IyW8SRkBS7qp4I9c1cnZkLS9iDVNFitNMtLuzGbmNNzqOrD0B7DmqXhfXoLdINO3GKeWRwuY9yOpyeau6Pqkosre1traRp9pEZlGY41H8THuOeB3rmPEVrPpF5HJFLLK0jeZuCgFXzk4HYH0pp3VmUlf3WdHryNfW00EjPu/gxwoYdBj0rlmvrmTZbXseyQMECoe46Z960pPEMpDbNJmWVRukWZ9v1IFUbFb4XR1m4t2MSvvYpjlD3CnqPem2rGsLryIhbXdxd/YHihhuCd24jPXqR61LcQ3ejSNZ2rBJYk3gEZjm9cr0NXvE86JFpepWjK7CYA5/5aI3GAB7c1HdzLr+sWdvA7QtFkvPjBJ46A9PxqLFqb07FS3g/tAeZayCwv8fJb5/dSn/2U+gqul0ztFC0Jtmg+VlVSCpB71Pf+HbmxlnlN5DHaYaQSE5dj1xj9M05bj+2FSUXIEqJslWfCs3oQR3+vpXPKk1qj0aWNg7Rqarv2/4HqZ9/PLHcb4lO6RMFh0DD+99aoatFI8MTTXKW+cB4nGTn29q6HTriKQMkgBiceWxYYIz0b8Dis6+ihito5bmRblVJLyDkoASM4/DNKPQ3btzQlt0M2y08K0jCNZGP3c4GKsJbXN9cw21sFluscv1CLnrjufSq93dBkRrZwLZkzGM/NIT0+lejeFtHXwposd1fvD9ruUEpyeVGO9dFOm5tNmdfFxow5aS3/rQg0fwfZafAYnsY7m4b5neXmVh3PsK46Gw1Y6rqlt4emun0+3nKq0Mu0ZPUe+K3db8S/wBrzvHp90bO3OY5Lsrh5B3Uen1q/Z634esNOtrWG7EMca4A2kMT3J9Sa9CnGO2x4UpVV71r3Op8L2TWPhDSYSCkoi3sMcqzVYuY8REsflbOR/e9TWpIuI0CEbNoCsORiqV1OC8YK8j7wI6/SvOnuebTndnO3/h+yubZ1hDxsFOxS2VzXA6ppJ8tRp940qseIRktGccqQewr1SVoZt6gskh5yBxio3tbcTkiJAwUgttwRn0qOfsdSaXxq54Xq2hanBMIpWZ7eLC+WzDBc81b0CXUNDvBIVD5QhkLYD57E+tdr4xtoooba2uzGJJn/dOqkf8AAmPr7VzGoWnnO8gnZViGPLYcg/TvVRTbbOtOHIrLVmlqPiQzaZJa2iTRyOoEkpUKEXvz69s112m2VtpllFY2irGY1BdyufMJGSc9682s5po7u12pHdWAO2S1c7Sx/Hr9K7a51uxgsWlK3bRIAFhA5Ddl9fxosTPR7G5psRkE0xkVZZWGFX+6OAKvQhHRkXkAYXB/PNYNnrHkWFpPqdt9mEgYvtcM0foMDkn1q9bXumz7JxewtFLzs3bcn1YdRSMZXb1MbxB4e854DpCxEOS0yZxhs/fH8qdcDXoIxbTopiC7A6LlmX3Pet8JF9runLJtAVOHG1R9f1p8txBp1ubo3BlRBwobg1Vmy1PocaLeaWY26cXAfaIkX7q45I/Ct3S9XieN9O1ON7Z4V2ojjHmL/jUXg1llvNWuJJC168mCHPzKh6cipfFMQd7QlIi43BUckMR7H/Gmtypy5nysj1mayXQJLXTvvOdm7rsXv171jRXTx6d/Z/8AaLwxHjryTn164NWmlgjnki3b7cKomIGTnB4x2q3oNnpcmn6glyAZo33mSUZPlkZzntST1sacsVDmZc8PQCG0juzLOskq7DHvHl7V6HPc81He6XJe6kLu6uZdkTB4AnyhPXPqTWF4e1q8tLOa1tNO/tC2Vifmyvl89T+lao1fVo0bOheVKowWe4BX8iafUlpp3LOuafDqUZLRtJPCu8TdCB/drJ8M6xaYhsr1Xa4PyKTxtTscn09O9OutZvLstpywfYZeC0wcHzPUD3rFug97Bd21uIxcKgyx5A/Hsap7F04XVmReMFitNXi+zNC8THczIPlz7Y74q3oWkLqqtdR3zQzAnyxBwVx3J96qW+nwvaxRxO11MAB5arjB7k+mary217otw8wVreF1yGibco9mFIpxW1zQ13SL+0SOe5vRex7h8pb5l9sVnpp00dhHrEH75XVhKxPywkHoR78flW7pOhSa1ZJfXV6VSXJATA+Xtx61j+SIrqXSzdGKx8/94c/Lnsfc0dCoSV7XAsix28gRjHMpEi54z6expZBDFbkTL5aBGSVTz8p/+tVi4AgkntnZJVhO8SRn7+e+PX1qoIxd3tkkEmCZEVlbkMGPO6ueUdT1aFa1NSbMN7eO0t4Vii8uH71uV+ZlXPU59a29D0678T6mllFNNMdu53kb5EUd8dzR4hhNtfzww7ZQj+Wsi4wQPSk0LVLzQmvRZQ/PNgCV32qi4559a6aPRGNeLs3Ba2Xpsdimi6PoFrIJnW4vF5e4l5UAfwqK5LxH4hhurlBaWdvJboCEkmXbu9ce1Zt/dy3I829uPMwfuKSEHv71QNrZyTSSX5mnRv8AU+W2AF+ldqlaNoHnOl7yc3d/h+B6V4T8UHTpFs7sO2lOcK//AD7ueoP+z7dq9CniS4tgUdHTqkinIx7V4Mq+RDJHLczNGJBvUg5HB5B7/StnQ9Y1TSpf+JPMr9/ssqnypV/ow9q5JxUldM8yph5wnZxs/wAH8z0eXhmjf5ZB17ce1Yuk6xt1ibQdQeZ7+OMzxyumEmj7bTnt0NTW3ivTNXlgt5xJp2pSfKsc4+Vz6K3Qj8az9Qayg8a6ALuOU3zpLFGAeEBBySPTNcrTTNLaWluP8YxWb6Spvmk35HlYP3TnqK4+5uIoZppGjScyZDLknccdenH1rv8AXXtre2MmoMIo0bZuZcgHsK4rWbpHSaG2gWNVAAKcmTA4yPT2rRJ2NaTTSOXhRUaKUyKsy5YJnJHPA963dPvFBigudscYkWRmJ7/4Vb0+9tZZY7fR9MhubpkDvPcLgIe5buR249KW68O38ltIXuLXziCEiQEc+uaG7m6ktebQ6y7trS6h33Biktj+9OWAz3/L2qjd+F7e4k87TG/s+5Yg7yN6YPbFclYWIjd4NQt3aeLaJIzJlUwckjHtXqNiB9lUWrqtucFGZt35Z7VMtDnvyK6Z55dWU+kXsi3RdhF84UHCsMfez3rotF8P2QhS7uy11LMomO5jsUE8Kg/Cp7pdP8Q+MGgmmR7XTrY+aC3yO5P3R647/Ss22kuYbua20WR5LNHzGrgMEHqpPAHtV7he9i1r+n2Nrc21xZxS2cmCEWM/KQP4m/Hj8azb+4unt3F44d3XJJ5I47HtxQGla9ll1C6HmKTHsfomOuMdq2dL0RdbgF3eXDpYk/LBGMGXsSW9KbdkaxtBc0jC04yxWbARLJOfnU53Ek/zqKWNrphHBDKZUQs5xg7RyTj0B7Vtanax2WrXsWmxssMKqYgDkIcHODVJbt9M1fSrsyubSW2MUokfG0l87yT71nf3jdSbp6FnRb1Yytrp20sYzM7Ou7efYdq0dR1OzsYxLdzLEVXcqj5jI2OgHc5rmorO81C+1C80RliDSEIxbAkHcCpPDFnHLql3cXySG/gYJ85zs45P51raxi0nq9xNK0nUo7H+0Z0ZnctIIDy6gnv6Gm6U76zK7SLttYifu/LvP936jvVrXfEE1pLNaW4Ecsh5csSOnAGO9Y1t4g8rQ47OK2aKSInMgO7Bz/WhtlxUkrHdWmmwW1qzpCqo4BKp1ZsVTupoNStJYiY3XDRNhecgcgfpWBdeKvt1pFBZpLHPKQrO4wsPGDg+pq5orL9mYeZlIgWVQeSO4B/KpWouSUfekcxpWsXdjYPawSIIVZmUyKS6nPStTRpdIn0681DUgksufliY4Yfh70XOs2k9nKxssXADbJHADH6/SufutFntLO21KT5EklAKH7xB9arY0t20uSx7GuE8tCFZi2zPKj61c0yRY55/3Y8+JtzHOd47Cn31/ZXuoaXFp9mYI0YRyY6uSec0RxKurX06ReWjucANlsLxk/lUVDrwiTm1bS2pTu9iuBEFyWGwE4HPXNMc3F5NJHAsWyE7XL9M+gqO9ZJ7szv8yghRH/dPrQYXlFwtrdSDzG3yJgALjqSx6CtqMfdN8TVXO2Z0nnMoS08oTK5LBuVNTyXd5HtT93JIv3yowAfYVq6ToN9qQMljZp5CA5uZiVQDuR61cSy0G3XbqOuXH2rOGWBdoX8q6LNq0Tji4xd5Nt+RQgnkknia4EfnYwYJehX1zVy3bYrIuQFk3oH4bdnoDWLHKJWKXaASx888Z/3T2HtUl5cQrFGt2w2Ocnb0Ue/vXDLTRmkJxnFS28/8+xo3cSTSPb3UizKz+Ysq/eH0H8Jq7bQHxPbyaLqd9JHrtufN0++fh3hPVQRjkf0rDuvNE8d5D5HnKAmWzl09x60XCrcmNo2+yXkB3wSq2PLfOVx/snjNTdS0ZyVsM1dW1Rt3eoav/Zkmma9cwzy2synei8sg6Z9T6msi7N7bpcXtlayyuhztAyo9ST64zW9DLaeItUU3rvYawbYpNa3DAQzHH+siOcdulZw1G5Hh6TTYodzM5PnNjaMn5gfftWkdrHLBP7jQ0ZluEkZG8o+UkisCNyknkD2roriNlWJXKCST7x3en92uCNvqOiara7PKhSVAFR2JQexPrWw1xrGqwzm1htI0QlAWUtuI644/Wp0NXzP3h+lwRazql7JHujtRIIkccF3HGD7Vb1LRLvSzF9ol32oBDMpOFHbjNZ3hOVUL2EsTW95DL5yuDnPqF9T3q94l1SURpYBpHmn53qecf7X1/pTMm3ew51sluoIJ28pmA8yVf4BjJx7npmta6vrGz0xF0mcSSL8oVR2PUn3rj4rO7ln+02WZ5Eba20AD04z1q+kj21tCQIZBKxViw+dfUEdsVRXKm9TW03T5b55Yo4S5kG2beP8AVAnk575rvoYUt7ZbeEKqRKERQO2KxfChtLew3POAZ5SrEjAJH3R7VtsxTzHyCmDzkc/jWLeplVnd8q2RxWtyrD4kuY5WcwSyos23/lmpB+asrxEgt/8AQyFmAQRhZRnjd8p/HrV3xnFLD4ige3HyXkILMTn5h/k1U8Q41GfT0jlAMqGFt3AGDjNNXbTOqk0kvRmzZ2sdrpUUAJe5iK+Qo4z/AHifT/61czq8p/tu7+wMZLgsBhDg5xyme5zT7l9Tt7g2M0z8cbkG0v2Bz6VuaPo8WlQNNPjzpDiQ9c59M9vetloJvl95mbZ6GscKT3i+dc8ZhHRSeoz3NRas2nGOb7KITcIwCmMEgH3rU1e9YvHp2luEuJGAMvUQL3+rGn6jLaaPozW0MauNgBJ+87H0+lD00EpNtM4XU7oyXUdvEQqONzYXgkck1oTSXsOmteLbyx2iIFLoeWX1K9qg8NWyza2ReFT8hMeTgFvX0zXQ+Ib6a+SbRNMg3o6hZ5CRuT2z61CV2bzqyT5UcTbx3+pXjPaxO0cTfMR90N1AzWx4j1ie/ht7W7t2tXjIUqeshHf/AOvWh4S1O30rTJ7e8gCXFvMwmD85Oev17VVjsrjxRNPffIsIYrAjr1H9PrVK5PNrdrTuQarJaRz6a+mrykGJXXoZMjH44om3HBd8yFSeOACf51Vto/JtIkVsEyszYOeBwBTJZszxkHe7HZ8o4X3JrKo9bdj18DT9zm7/AJL/AIJTjIkvrkySNIBxJuwEXH92uj0PSLcaXPrWuzfZtOAC28DD5rlh0JHpWPYrbLeyyXbrcQQYkW1XrM/Zfp3P0qW5lv8AU71nYSahfEbRDbAlLfPQYHAx711w01Z59S+qT/r+v8zRml1rxP5sdlLDa20C5MTSeWAO2fU+1Y7W3hy3t4kvr64mu+fMx8qr7D1qGVPIMiXNq8U0HyTyM/llT6HFc7JfWttcS+bbqgY/KT8xYDvWzqLdo55JRV27IYt1NeMiLAiPFkkFyCwJ5GD39K1YLqC6s3guIg0gO0qep/8Ar4rMsXtra/eSCKWQy/KgkO7a319TV+zCk3oaB/P27vJ/i344zXBNSk9RYRqmml1v9xpyN9lUPJGfuAI27kH0NSbY5EiIVRKcE46AVgWWrC4XbOhjRDhv9lvf0rXhmjkVlQyI6Hk9Q3+FYzg47no0MRGpblf3lyQW1yPJuPLmVWwA7cqD3U9VqhqUEtpEYmE/LcRknkeo/CpYnwScL+8yG4/U1P8AOyIUc/KNgPXinGpYKuE5/hLdrrFzqekyWVxarfCJcC4Y4MS9iR602zm1CC5t7XTLtoprgEEO37tcY7+p9KoQW8VxkkM8SkEKH2kkHOcj0NXYII5ZdmpPM0KL8hgGcemR3+taKaPPdKUVfdE8kU/9r29jf74boTgvKp5BI4A9jVvVrNNL1FQpf/SgWbJJJK8ZBPT73SqcMKTQ+UoETK4kWdm/ebh0b6e1Xru5u7y4il1O8tjDC2USBNvOMbj7U3JXJVOctkQ2guI9Lazub6NlRsRPbgiTb6MasIVjmjt41C/aF/dRlsFj3LMe9V5dMnt3EMaITKgkVkYZcZ659PakeC7mWSZY2lVUJxkE8d//AK4p81+pSgkr2O8sLEy6Yka3VleOzl5BFIBgnsPpV+C70aS7j05ryM6gq4EKvuAPoa8vRJ5LZC5bjG0SD7vP1p91bwhUMVq5uEJcXETYZG7Vm0r7mKouUW3t6HYfETy4H0aVG4i3x8Hqf8isLNnPGLi9maBJ7TdDKRwkinlf0rCuZZi8rOs81wEOZpm3ge+O34ZrojDFqPgJp4VjlS22tJDKMBZN2OPStLctkZwqR0UWZ0kpu1h2JM8jbdj7+Wx79hWq8up6qVsm+YIAXVDyF7ZP+FV1tdPh06Hbci51BsSyyxEhUA6rk9qqR+PtI8PwXLqW1C/nbcI4SAiDsGfp+Wabnyo1nUjGLlIualbTaa0cc8caNJ+8X58MSO/4VFo1rHrF497eCSS0tsq7u+AzegHp9Kj0rW5dV02bV9YtIpbu5ytpbxrjYgyM888nufQYqx4SvI7aGHSmiYFS00ch+6STyD+NS3dFwqSlDnS/ryE1jRbW10y5vY4XgKMHiTec49T6Vr6Jax2WgorlJHI3oP42J5LE98VL4t1KKDSpI5AGnuUMKoOeWGM/hXFWV7q2pwpYQEq8SeW8g4aTHr6ULTcV5VI6kWo3EF54huW8tvI3gsM4LlTzXS33iCxjsphpAla6mQQhwm1EU9ce9c5Lp/lXDQXClbm2wZAO655YeuKdq8badAU81ng+17FmDZz8qkAD1Gau9tSmouyb2IDIYpLeEqQmCoIHTHr9aUxHEjF1VX+UZ4OPQVHcsEhMchKy8BZM5G73psswijYSOxWNNxJHSufVu57kZwjS5E9v8hbK1ubzWE0/TRGL24Ul36CCLjLE+tbmta/DoVoNL8LyLZwwn/SrnH7ydvXPU/SqjkeHfB6ux8vUtTBklcj5gv8ACo9BjNZHgnTRrM5nnu4I7S1feySPy3GSx9q7qTsl3/r+vQ8Kq1OTvt/l/l+ZBYa5LaalHemGHUXOWZLtiVLdmYd8e9YHiK8fWdQa9uzHA8hJ2xIFT8B6V614s1Xw3Z6Jcx2CxTXc8WEdQGI+leRwW7MgjAZ2QDdhcgE1pK73MLc3R/1/X4HW+ILjRZLuG90hAkc6kTxZ+4fUVzcNzdRamLl8qVU+WA3zbR0z/wDXqnpgg065DXO+4s4WD7Qe/vWoXTVdaDzZD3ZJABwAvRRWFVJ6rcujUlFcj2/rqSahEmoarNqWizWxjuU/fWs7BHVh1PPBplkh8oCN2EqAJIV53ntg+g9ajvrOPTNTNtdBRcIMAFeGX2PepomeNQYCDIWwEHGzHrXO5c2ljppU+R86lda7EkMynMayiaRCAyqcEf41ci1GLzGDkIkn3SwwD9fQ1T8PeHLfWvE/2SaYwfacyLIp54610OoeDbuyikOlXaaqtv8AMbaVdrkDuvrSdNdCo4+UHyT/AK1KNv5MkC+SrKxYkMvAq0CAkbx+YdvO5eGPqMf4VjWFxC7+Zbl/Pb/WQPwUPr74rXjklQt5TlZE5Qjkn1x+FZtW0Z2Rcavv09GWEjVwssDiRhgsXXaB7EnrU8amGRjNCvmBSFQnIA9feqRuTGxkiVEiPzKjchj7/U1Asr3myYiJGY7mUttGfQego6ClOV1GWt/vNG5aN3Qs3CDapBIAHUg+n4UrLuw0W5WA+VxJlQtQHydoW53NHKCrHH3fcHvUFnAbWEJK5umYlUUHHy0kU58jSexaaR4X3NHIw2sD83cnr7msx7uaYPHHKUZWG3Pyn3H41qXDJcQfZ5Q4wMMOjH05rJntYYZ5I2MxhlXif+6w7t+PatqUop+8efj6VWUf3ez7EbTXUOwnfJChby4wNoHrk9/xrsPh3fDUpNRtrqNTYT2hNxlflRl6N+OO9cIjfaHMU0riJflaRT27D68V2L6naaNoVlq9kwtWvYpLK7i27lnCKQDjs3AGfWnVqJs8+nTdOD7fqZOpXdolqLPU5ylrKHJljjy0ijGFUf3jxXLx+BNbXVdNtrywuLeG9YFZWXOxOpLY6EKCcHnitHTLSa+uI7m5kkt5ImxbR9fs5yCGOepP9Py9H8BXWtX8WrzapdGeKKRYkk/vEdhUtc2rLrUXNcz0Rp3fg+zuoraSyuZLdYFEUQ7gAYAPtXKuLrQdVnMuy4khOzawwZATxgeteg28h85CjFB/ntWDPEjfFNY513qVWRN3QfKadzSFRxTi9rC2Hhe61S7W/wBdKQ5B226E5AI6Godc8KTafKbrwuWW4Qb2iYk7vpnqfau6TDzNK8YLgbd2e30pJ2G0uNxdOQE659qmMnfU5XiJXueSazqU139lmu7dBegFVmjGQyn7ysOzDng1k3M3nwxNMN0VuWIULj5zgZHrwBXQ/EN7aDxGFiYxmaDM4Q8eZ2B98VzNrLJLGqrGUBJ+9/Q1c5aJHqYSCqLmKdwqXEyYEkcSnLndwT2NWdOU6jf6bpQ6Pch2BGdyD371IEiAMpTCn5GI6kD2qPw9tXxbpjJdJEAw+Y+m4/rUwbOjEQUUpdX+hX+Juqte67cwpE4MREQVgMAH+Q4q9oXhLTTZNLqmpR2NuoViikqXXupPWqfjeSKfxXNLqCPBZligfZycdj71DpukXeomX7FFIsUQyss77mb0wMcV16c2p5cFeN+pT1O203+3/sOjsSskqx25JxtQ/eJ759K7rRPDHli5i0vc8Mcm0u3O4+x71X0rwPAUW/vbiOHadzTytgk+wqtr/ieSO5Sy8NfvLO2XBdeMsetaRai+Z6BZy92L1PPZD/oMT2wWSKQ7gH5P0OKtaJcBbpBNCU2OCSn8K98e9XPGukReHfFqWtqVFrOgmMSnmNPQ+/vWPbXbeaxjVtzklI267c9DXPJW2Lo1Yya5nodT4wvIdQkjt9NXdFbDcsrn5pSepyemMCsOKdgY2njkeZjgOnIf8qmt7bTb6y3LqCvcrktGw2hD6VkwThbTbE5Mizcbe47VnUV3zDpNQVo7HSW941je2l9anMsTZXj81PvXZSeOtNEkF6mn3K3IXHUbUz1I9a8xtHlWR3yBI5wQTwrf7QrU8hpLZQ6ZBGRsbAQ9yKlVOhvUwyrvnsXZL+0vddElr5uxZGnkBGdox0/Gm2dw3lKsRYoxLHd2/wAKwpHvo9Qt/sT7rhhwFXhh7itFLuWCRo7qKSCVyNyMMc+q+1OorrQeHreyqPn22N2Fv3bguueG55x6Zqt53nzrG8YZM5OOp/8ArUp+Yq0D4JGSAOPxqaxjaS6igjgBnn4QJ1Nc+rPUkqcdW/dv/VyaAzBvvKiovUHORUm2Hy1cyHe3QMvGPWpdR0rVNLnRLyBow/3MDKkdxn1qkJEU5lG0ZzgnkfSm/McOWcb03dFlIZopd8qrJbyRbCi4JYkgjDdulI0cVziIeYXCkurnCgDsD60Rq6R5iYscbgG4X6UOwdCq7vMXhlHJXjrSuxeziutipdrZ2Nqbx3UNGwyMd+wA7mp/BpUa3p93rEO9MulrbkZWAtk7yO7ZOfy9sE0Kkxlo0maEgxBl4z6/Wpp5t8Z8rbFOuP3QH3T6qaV9TmrYfnvdXS7d+7/r1Jms459Yu7QSMEL5ikYbA47YPTOc9a0NG1y/8NXDaVrsBj0l3JaRFw8UhOc+49+lYOshkM1xd3CyxKBHKsZyTIfT2HHNaUHiTU1tIBLHFexRJ5QWcBty46Hv0rWDtuclZe1Vlbz/AK/rU9LRYZlSWxuILqNwCrRyAk/hXNeO7trDWNE1QIUlXMR4I3EEfnxmuSRdGV1udOt7vSb1SJAYJd6RP2IX09qTUdR1C4iK6lqEl6I23pujwQcdc9qu67nMsPUvqj1e5+ytPFqn25IU8sH/AFg2lTyRjPWuY8SePbe3jaLRiplII+0SfdH+6O9eb/aZGj3wlVHRlYkkH2B4qIWctwEe52K23kAc+2KhyUdUXRwUXK0ncJrq5vZSY3yztmRpPmcn+8K1lRlVYiyEKNxP+e9Z1lZrZ7hG2S3JJ61pKQI2Y4+70bvUyk5M9bD0fZK7Qx3WO3J34dASuepGKxYJNktveaeiI4BKrN82w/3vrV2Zw2Q7k7lxkDrVWPyoYssoVS4TOeceoHeqg2npqTiYQcE5uyVy5e6zd6jJbHVvLvRCcvJEuwke/qa27jxnci28rw/YpZ24wHnuMFnHf6Vxkjv9oSFFJjYktGRg49zTylxd3aWkCySluVjjHQdyfaupylF26nlQ9jUjfVpdDV1W61DXb2NGLyl1Cx21t029zV/RvDF9epKtg+n2hhbbIk0oBzWbaXl7Y2txbafMkYd/LdyuJFb0J7DmvS/DHhWw07Tl+2xi9u5gHkfccL6AVfJzP3tTOriVRj7it+J498Q9esNU8VTXdvMfIktliDSLypHUVnedozafH9nW+S8bBkdwQo/3awwD5kaMR9pZ8q7YKA46c9atNPsjQo032knDu5GM+gX0qW227nJTkoaLbzFMlvJdGR43du8igqG9yPWrNrJJJFJIyqkhbAfGM+gq94h0pdD0jTpb24lkv79DKirxGidsnu1Q+HtPl1XUtPsZZDtuXwu08AZ5/GsnG5tTqqDaeqHvlQ+/dG7AM5X5t1SXxu4bOPfHLDFInmRq4+Yr/QVZ8TSW2m+JriLSlKwWMiou7nc47mk1C5utbu5LzUXZwwCNJ91V44UDtily2N1WlPSLtc7TwfbRaRai+lhDXrKPnYZ257KD3qXxFcRX+j3stwiO8Kkq7AFlbPr2NcRZateQTRNBctK8Y8seacgjsQP61uwXATwbcm4DyzTAq20ZG/IyT3q7I5bPmuzOgMqwRb3bcQGbjhhirVtqN1Y/Zrqwtnub2ZXWHLY8gY6/X0qjNNJBFAVYGMKDuPRx2x+NMF4BqBeKaXaoGSg6HHYfjWSTuelVknSUb9jtvh3qlxf291pGqXZ1EC1+1QvMcyBu65/OsOYvBduk2d5JwrdvSnfDpLDTLm5vbu5le42NGg2/JCmcklvWrV5438LXzy/brK8hZfuSxrkvjjPSiUOYww2KeFm3ayZWjlyynnCjBAPSpJdpufMhbDKgGc9vf3qGy17RpLJprzQdQe2yRFcRMf3h9+wNPk+z7IZ4ZN9tcjdC54YHupHqKylCSPUp4ylWna1rkryyq7KV3xuNyvnlvqKhmjZtskGWhxteRuOemBSqzb14VghyVU9avlYpLeWaCaITLnzIifvA/wCz6+9Lc0qSlTtfbuU7K5FuuJE3MAV2H7uPf1FRsgkY3MsJX5So+bCkk5zjuavWlvBNcW1vA22O7QxybhyH9qq3Fm2nlIp4vNiC7V+fn8R6ikrrYE6dSXLOOr1I9qwwCSTcZSfXH0xVS+lmJdlUukMRd3kO0Dkce9WL53FszpGVmX7rP0Kj2q7anzPCNzcqhZ5H2yxkgkL7e3vVxi1qc2MktIK6/ruckElubaG5eI+Wx2qI+CB+HWtWENF5EcCeYuNuSePqarSzzNpKyw+VFhvk2Ng4Bx+VW7JvtjKI3i8zHz/NgZrSackrmOE9lSk1fVrfy6l5j5j4kUbVxjaoAbFUp28w4VjnHIB6CkjuQCHTLIuVI7enBqlHPdT3UqW8TNHHjLr3+tRax2OtCKSEv5JXhKw/KgxuJPJ+lZ89yqyrFmYbCAFH3c9ifStJ4riEM99hdx27V5C/jUclzbRjYpDMcZC8nPbrSSaOerJVFfm0fzFaTE8qyP8AvC4Uuq8Y9K6LwvdWml6BdXsgUy+cUYg4YgdABXJl4liPnvK25iF28laLi2+xwWxubiGZJlJVoTuKN/tAd666bad3uebP4VBbIvXMV5Bp8mqXSqLbUJSyrnlemDXa6X8SLAWMSXdq3mxjaccdK881Kee5itLM3TGCLgJINu38Ki04abZxuuqWVzO5bKNC3AHv71ak09DGcVNWl0M+01aD+w7nSdRtRdWznzLaVRh4ZO/PpWeqpJEsbM4IO4SFeSfQetVrYByzSSmFduTj+I+gFbfh3SptZjaNblo0hUcdcn0FZXuZJpayLqalJqvhePRtUkV4o5S9pO4w6ADkfSjwJdrY+JtLuLpgIbbuOoBPWr//AAiRjtEeaRpVHVVABTNc1qiJZ6i6QSmfYMBxxx6GntqCcGrG1HANR8WXbxSDy5rh5Flb+L0xmtnxZ5Fpoq2UTRKzY2rG27Pqc+tcZazKxczEqnt1X6VJdOhUrbxAZxtwc49aSkkbOF4qTew6ay84KzNLDMAPlK5B9xWzo1/JZatGGYx28rBGDjKn6j1rFnvblrlZCwTcAoP3ioFMae4ZneT7pwqY5DH1+tFyvdu7I63UYEbUpNP+0pHYwkzRkj7mRkqD9SaLO2VfD73k9uYDNcfuARgsg7j2NYVta3peSK7DJM0ZbyZGwXHqCev0rQmvpNlsbmR5PKRU2k52r6Vm5Kx1UafNJN7LUfrWpLp/hubT4HDXl8weZEH+qjHQH3Ndd8Lv7OvvDpc6bBJLCdkrSjcfY/SuLh8s3l3NPblpZ5crHjA2noc+lb/gHWbbS/EMkMi+TDICjEHIP49DVSStaxzTi3ed9X0PSYwsRWKKNDb/AMKIgCKByePwryiOcXOla1NH8sdvqG8KnVFbA3AelenXHinQNNc20t/DHJj7hOeo9a888QWunaHIt5pt23mXjkNCcFXjbrx3pW6WMaEmncW1mENrFlBJE2OW4+X0+v8AhV/UJbS58P6e+nQRPNDcOsqM3LAg459fb1rDsrwLarJJwq5TbjHXuPerVncMkxhS1SWGYlDuO07hwNvofesD2a2q5o3S7fI0b+MpDiNXRZEVkIPIYehqm8kL3b3V0jSXMiASZY4fHcehrotYEEBtIkxGzRsGjLbl3AD7p9ea5pLlMb+jKduCOAf8aq2pdKrGpBXWqZctJpog115IuILcEyxt02HqT6cd6ZpepHTotasrYPDJqRD2txJ83lxH+HH9a0fCbrNc6hZXbr5eowG1MinmIHoSO/Peua1uaeb7NFq0Hk3OkwNAkkK4aRsgKzDvxmhOzOTE1PaScHHb8jJn1Ca1sLbT7YbZILkyhz8zOem0+2a6mTVJ59Mh0iYWwmDFr+Zo9jAHlYh6d+f0rCtreW3QzzwxkKQsbgn75Gc49s0+S7t7h7qK8P2jUGYM5B5dvbsT0rSKb0OJxTfMy5d6lcXhWONUSJAEWMcqq4wB/wDXqOygudRvBZ6arzzn77q2I19sd8VH4V0mTV9Wj0/e8MUitJIejYHavVNB0Wx0IeVZpIXYEb2XAA71rykTrqmrdTyfV7C/06+k0t5FEwAkyo4Of5mqWyQ6fLN5O7c2wgcyZHqK9P8AiPop1PSkudOh3alA25CvBYdxXlr3IjZ55IZVuExv3AqyH+tFkOnV50OuLn95FNLbwocbRFF/G3v6U0W9zp17bXEkUlrOBvTcN4Y+9S6JY3Gva2yxuU06zIeSRRgIO5J9an8Ta4NV1Lba7TCi/Z4mIxntuNUnuS3dqw6OK2Fu/iDxZcuLCZ8IiAeZcOOwXsorotA0nwt4os2v4oZtJg3lENxIB5+OrAZ6DpVPxL4Gl1y+0WW2mhl0e3t1SRonycjkhR71h3Ohavqc7ma3t7RIvlit55xH5adgoz0pRb5tUc7nzPSVjhUL+b5oyDnGT29q07G+ubCTdZu0THkrjOfeqDm1uriJLK1mQsQrCR8lz/SrurCSxYQyTr54GQkbBtvsSKhXWpSktmW7nxJqFwSZb58EYCoMVT060m1O52WELuyDMrMcIvuSah0rTNS1NTHptjJMHPMoGB9Mniprywv7GC4t72F7dY9vmIz4DHtgd6XM3uNPsiSSIwX62zTLO/3NsHzAt2ArWWDSrCQtr08yy4yLG1GWPpub+GuQtFuQ7SQRuUjOWKjhfqexrUu9JubMW01xGfJnQSrIoyOexPrQpFXk9EWb3ULe6ZBaWcdmN2URGLMB7mtjwSiT6zK9wq+VGh2EfdjfI/WpdMSyuYb9RZxWl7aWxkjkibiU+/4VL4D1ewtbC5tLtliLymRs9HB9/amlcqo+Vb6nQeM7mMjSIZdqw+Y0hz1LBflAPoTXNzMTas42LK43Avxu+ntR4j1C2v8AWIkikaaztlxG2OpPX9Khu7uxmsp3lBkvZmCqccQIOgWplHmZ0YatKjTst3/X6kKtLcB5JZm2BeB0z7VXhVpuIGG3GctxtxW5Y+G7y7gE8iJZ2wUshuWwTjuB1psOlWjfuI9TLmSNnBihAXI9T1xSV7Ezqxvb7ynZ3scURVrOym3cSl0LF+Ouc1BcAF4kjjJkIyjSHdsHoPaqenhJrndOzR2yJvkmXt6D8als1mne3tYo3kuJ5CIogeQp/kKLD54pLQvQOzllZ9+35sHtWraSiOVJF3KyMGGT0IrIMDw3c8CyrKEby3Zfun1A9cetWLcsZo4Y2LBYmZvoOufespK2h2U6yUeaR0urahEbayhkXCRlrh3Hdmx+nFZ6Tq1oxiIBL7gVGQR2NZ9zK11YgCUpNEAIjg9O6miJ1S1SBH2kN82Bzz2o3HQtCduhp6iIIFLtuEd2oYNGcMq9GGfwqqt9Jc6v5N5fK8xAQTTrj5f4SfX61NdXSva6TBKN6hGjCKeckmudiyscCXkpnkiQqqY5ZfT3qtzLmnGSf9W2Nl7e7srRrO9WZJFutwbGVZuo/AjFWNFtLDUDe6PqUi2zSt9osbojaA3cFv6Vm/2xJNbrDLLJJbkrs3clSOin27VV1dpbiMopDSo2dhHAH8xWkGupyzTjojT1y01Hw+8En21Z2IBju4HGRx9012Phv4g2l5FHbawwt7kAKJh/q3P9DXlTrBJLbh5JLS1I2zKCWww7gdq2T4YmuYo7jSrqO8hPXzPlP41rfsc048ytI9Y1PxTpGm4+1X0chYZCQfMxxXmN1ev4s1yaa+vLbTLYRnLycYjBPC+rVF/wi2pmFsy2NuG5ZScEVmavYyaNaQie5t5Zy2FiwGCr60bmcFGOz1NfXdc0yx0QaB4Ykka1Lbri5xhpj6E1ivYW/wDwjUmo/a0juFm8sWufn2VXsrObUZJZV8uNIlyxYgAH2qqZYZblHlh3hVIfb29DSuWjsfhlrK6RqLWdyJvKvvuhnxHEQOv61QkktLXUr6TXb+5v7iaUlBatuWNATgE+vNcv553tC4LoDk7uvt9K7DTPB02pWyzm6WKLACJCcgeuaUVfQyq8jfM9DzyzjaeeOIyhA+TvPTgcc1AF2T/vAc5wy55ooqA2Vzr7zxtq01vFY6XHFp8KKExbjk03TvDmsam/2rWZTa2vV7i6f5gvsPWiii7bsRJ+zjzR6jNf1izWGLTNAVk0u3O55SObl+7H2rOsY77UMWunNcXIchhEjZVSfWiilzM2gh2oQS6ffNbSTrJNGu1/JOQCf4fen39p/Z81vDKQ90V3yxj/AJZ/7J96KKu24KWz7j9zTRr5Z2sASQBjj0qay1D7BqcFxEscpiO5Aw+U/UUUUmtDRSbabOkvfH2pTXCzeRaeQq7TC43KfxqjqXioz2b21tZ2liXGHeM5Yg9h7GiimyFFR2RkW0V1cOba2t3kbG5okGcAdyK1LK9vNMsZorawkhunH766Zcuqf0ooqW9TVblC2vGS3aONcurYAPQk+pq0129uxbywVfAfb1UdeKKKztdnSm/Z77EkVwrSABjuY/KTxmp451RmCp8+euaKKRrSk5WbDy3ngW4iG6WKXkZxtAA5FKskM8yO5A3MSOOA3bmiirRhKclJ2MW6uNl27spVyei+o9qme/L+S7kbWzzj5iPT3oorRRWhx+1ldq5WnKyhvKZgufmOKbamYSnynljTGcRvjPuBRRRsxqXMkyWaV1Xm4uCrHBEjZzVSZ1bfsyVOOTyfYc9qKKb1B6DQ0kcbFXwjjDKecn1FTaVBaStJ9quvIVPl56k+1FFJbhPSxU2pCks43MNxRff3NdP4Y8YafoenC02y3DDksTgZ9qKKTfLsZVEpKzP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a benign colonic adenoma containing a central focus of \"misplaced\" pseudoinvasive crypts in the polyp stalk (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43922=[""].join("\n");
var outline_f42_57_43922=null;
var title_f42_57_43923="Gram stain abscess 1A answer";
var content_f42_57_43923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66191%7EID%2F78035%7EID%2F80137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66191%7EID%2F78035%7EID%2F80137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Streptococcus pyogenes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of an aspirate from a neck abscess (x1000) shows Gram positive cocci in long chains. Streptococcus pyogenes (group A streptococcus) grew from this specimen on blood agar and tested negative by catalase.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Streptococcus pyogenes on blood agar",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Culture of Streptococcus pyogenes on blood agar showing large zones of clear beta-hemolysis around the small colonies. The susceptibility of this organism to bacitracin is demonstrated by the zone of inhibition around the bacitracin-containing disc (A) on the left side of the plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Test for production of catalase",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 132px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Catalase splits hydrogen peroxide into water and oxygen. The streptococci (left) are catalase-negative while organisms such as staphylococci (right) are catalase- positive and produce bubbles when mixed with hydrogen peroxide.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43923=[""].join("\n");
var outline_f42_57_43923=null;
var title_f42_57_43924="Lidocaine and tetracaine: Drug information";
var content_f42_57_43924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lidocaine and tetracaine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/34/31267?source=see_link\">",
"    see \"Lidocaine and tetracaine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/13/35028?source=see_link\">",
"    see \"Lidocaine and tetracaine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F1181967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synera&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F1181970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic, Topical;",
"     </li>",
"     <li>",
"      Local Anesthetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1181995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Venipuncture or intravenous cannulation:",
"     </b>",
"     Transdermal patch: Prior to procedure, apply to intact skin for 20-30 minutes;",
"     <b>",
"      Note:",
"     </b>",
"     Adults can use another patch at a new location to facilitate venous access after a failed attempt; remove previous patch.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Superficial dermatological procedures:",
"     </b>",
"     Transdermal patch: Prior to procedure, apply to intact skin for 30 minutes",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F1181994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/13/35028?source=see_link\">",
"      see \"Lidocaine and tetracaine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Venipuncture or intravenous cannulation:",
"     </b>",
"     Children &ge;3 years:  Transdermal patch: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Superficial dermatological procedures:",
"     </b>",
"     Children &ge;3 years: Transdermal patch: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F1623501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F1181996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution in patients with severe hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1182001\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Synera&reg;: Lidocaine 70 mg and tetracaine 70 mg  (10s) [contains heating component, metal; each patch is ~50 cm",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3362805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1181997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Transdermal patch: Apply to intact, healthy skin. Use immediately after opening pouch. Patch begins to heat once removed from pouch.  May increase skin temperature by 5&deg;C, will not exceed 40&deg;C.  If irritation or burning occurs during application, remove patch. Wash hands after applying. Do not cut the patch or remove the top cover. Do not cover the holes on the top side of the patch. Carefully dispose of used patches as they contain large amounts of lidocaine and tetracaine. Fold adhesive together following use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1181971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical anesthetic for use on normal intact skin for minor procedures (eg, I.V. cannulation or venipuncture)  and superficial dermatologic procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F11394984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Transdermal patch may contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F1181979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Dermatologic: Erythema (71%), edema (12%), blanching (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Dermatologic: Application site reactions (contact dermatitis, rash, skin discoloration)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Allergic reaction, anaphylactoid reaction, angioedema, bronchospasm,",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1181974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to lidocaine, tetracaine, amide or ester-type anesthetic agents, para-aminobenzoid acid (PABA), or any other component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1181975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: May occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Class I antiarrhythmics: Use with caution in patients receiving class I antiarrhythmic drugs (eg, mexiletine), since systemic absorption occurs and synergistic toxicity is possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Methemoglobinemia: Has been reported with local anesthetics including tetracaine. Use caution in patients with lung diseases (asthma, bronchitis, emphysema, in smokers), inflamed/damaged mucosa, heart disease, children &lt;12 months of age, concurrent use with methemoglobin-inducing medications, and hemoglobin or enzyme abnormalities (glucose-6-phosphodiesterase deficiency, hemoglobin-M disease, NADH-methemoglobin reductase deficiency, pyruvate-kinase deficiency).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Other local anesthetics: If being used with other products containing local anesthetic, consider potential for additive effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acutely-ill patients: Use with caution in acutely ill patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pseudocholinesterase deficiency: Use with caution in patients with pseudocholinesterase deficiency; greater risk of lidocaine/tetracaine toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Avoid contact with eye; loss of protective reflexes may predispose to corneal irritation and/or abrasion. Application to broken or inflamed skin or mucous membranes may lead to increased systemic absorption. Not for use at home.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MRI: May contain conducting metal (eg, aluminum); remove patch prior to MRI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple patch application: Although the incidence of systemic adverse reactions is very low, caution should be exercised when applying simultaneous or sequential application of multiple patches to adults; this practice is not recommended with children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Topical application: When topical anesthetics are used prior to cosmetic or medical procedures, the lowest amount of anesthetic necessary for pain relief should be applied. High systemic levels and toxic effects (eg, methemoglobinemia, irregular heart beats, respiratory depression, seizures, death) have been reported in patients who (without supervision of a trained professional) have applied topical anesthetics in large amounts (or to large areas of the skin), left these products on for prolonged periods of time, or have used wraps/dressings to  cover the skin following application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F1181984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F1181983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antiarrhythmic Agents (Class III): Lidocaine (Topical) may enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III). Antiarrhythmic Agents (Class III) may increase the serum concentration of Lidocaine (Topical). This mechanism specifically applies to amiodarone and dronedarone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the arrhythmogenic effect of Lidocaine (Topical). Disopyramide may increase the serum concentration of Lidocaine (Topical). Specifically, the unbound/free fraction of lidocaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F1181972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1181973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5527499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Lidocaine enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7827425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to Lidocaine (Topical) monograph.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321913\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Pliaglis External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-7% (30 g): $54.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch",
"     </b>",
"     (Synera External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70-70 mg (1): $15.36",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1181999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Effectiveness of anesthesia",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ralydan (DK);",
"     </li>",
"     <li>",
"      Rapydan (GR, IE, NL, NO, PT, SE);",
"     </li>",
"     <li>",
"      Rapyden (CZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1181988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Local anesthetic action occurs by stabilization of neuronal membranes and inhibiting the sodium ion fluxes required for the initiation and conduction of impulses. A heating mechanism within the patch enhances drug delivery.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1181990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-4em;margin-left:4em;\">",
"     Onset: Within 20-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Related to duration of application and area where applied.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10241 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43924=[""].join("\n");
var outline_f42_57_43924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181967\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181970\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181995\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181994\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1623501\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181996\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1182001\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3362805\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181997\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181971\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11394984\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181979\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181974\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181975\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181984\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181983\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181972\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181973\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5527499\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7827425\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321913\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181999\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038861\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181988\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1181990\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10241\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10241|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/34/31267?source=related_link\">",
"      Lidocaine and tetracaine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/13/35028?source=related_link\">",
"      Lidocaine and tetracaine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_57_43925="Dyshidrotic eczema hand";
var content_f42_57_43925=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55722&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dyshidrotic eczema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Small vesicles are visible on the lateral fingers.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's photoguide to common skin disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43925=[""].join("\n");
var outline_f42_57_43925=null;
var title_f42_57_43926="Palmoplantar pustulosis - heel";
var content_f42_57_43926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62582%7EDERM%2F75404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62582%7EDERM%2F75404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pustules are present within an erythematous, scaly plaque.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palmoplantar pustulosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple brown macules and pustules are present in an erythematous, hyperkeratotic plaque on the plantar foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43926=[""].join("\n");
var outline_f42_57_43926=null;
var title_f42_57_43927="Umbilical artery aneurysm";
var content_f42_57_43927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66178&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Umbilical artery aneurysm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 511px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of the placenta shows an abnormal vascular dilatation at the base of the placenta cord insertion site (upper panel). Dye injection studies demonstrate aneurysm of the single umbilical artery (lower panels).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sepulveda W, Corral E, Kottmann C, et al. Umbilical cord aneurysm: prenatal identification in three fetuses with trisomy 18. Ultrasound Obstet Gynecol 2003; 21:292. Copyright &copy; 2003. Reproduced with permission from: John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43927=[""].join("\n");
var outline_f42_57_43927=null;
var title_f42_57_43928="Catatonia in adults: Treatment and prognosis";
var content_f42_57_43928=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Catatonia in adults: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43928/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43928/contributors\">",
"     M Justin Coffey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43928/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43928/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43928/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43928/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43928/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/57/43928/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6714227\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catatonia is a behavioral syndrome marked by an inability to move normally and is associated with many psychiatric and general medical disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1\">",
"     1",
"    </a>",
"    ]. Prompt treatment of catatonia with benzodiazepines or electroconvulsive therapy (ECT), as well as treatment of the underlying cause, generally leads to remission of catatonia. However, failure to recognize and properly treat catatonia can lead to poor outcomes; malignant catatonia in particular can be fatal.",
"   </p>",
"   <p>",
"    This topic reviews the treatment and prognosis of catatonia. The epidemiology, clinical features, assessment, underlying disorders, diagnosis, and differential diagnosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10661798\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catatonia is a behavioral syndrome marked by an inability to move normally which can occur in patients with underlying psychiatric (primarily mood and psychotic disorders) and general medical disorders. Small prospective studies of catatonia and case series have found that catatonia is marked by heterogeneous signs that are observed or elicited (",
"    <a class=\"graphic graphic_table graphicRef53391 \" href=\"mobipreview.htm?34/31/35324\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66229 \" href=\"mobipreview.htm?7/25/7580\">",
"     table 2",
"    </a>",
"    ); the most common are immobility, rigidity, mutism, posturing, excessive motor activity, stupor, negativism, staring, and echolalia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subtypes of catatonia are based upon the specific nature of the movement disturbance and other associated features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1\">",
"     1",
"    </a>",
"    ]. The three principal forms in order of incidence are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retarded &ndash; Mutism, inhibited movement, posturing, rigidity, negativism, and staring",
"     </li>",
"     <li>",
"      Malignant &ndash; Fever, autonomic instability (labile or elevated blood pressure, tachycardia, tachypnea, and diaphoresis), delirium, and rigidity",
"     </li>",
"     <li>",
"      Excited &ndash; Excessive and purposeless motor activity, restlessness, stereotypy, impulsivity, frenzy, agitation, and combativeness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about the clinical features, subtypes, assessment, underlying disorders, diagnosis, and differential diagnosis of catatonia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87533411\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85682923\">",
"    <span class=\"h2\">",
"     Setting and management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of catatonia reflects that the patient is severely ill with an underlying psychiatric or general medical disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/2,5\">",
"     2,5",
"    </a>",
"    ]. Patients are commonly hospitalized to treat the catatonic syndrome and underlying disorder, as well as to prevent and manage complications of catatonia such as aspiration pneumonia, venous thromboembolism, constipation with impaction, and urinary retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malignant catatonia in particular is life-threatening and generally warrants admission to an intensive care unit to monitor and treat [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperthermia &ndash; Management of hyperthermia requires ensuring adequate airway protection, breathing, and circulation; initiation of rapid cooling; and treatment of complications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=see_link&amp;anchor=H10#H10\">",
"       \"Severe hyperthermia (heat stroke) in adults\", section on 'Management'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypertension &ndash; Oral or parenteral medication may be necessary for severe hypertension. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=see_link\">",
"       \"Drug treatment of hypertensive emergencies\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiopulmonary instability &ndash; Arrhythmias may occur from electrolyte imbalance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all patients with catatonia, clinicians should try to prevent and manage:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dehydration and malnutrition &ndash; Patients who refuse to eat or drink should be monitored for input and output and may require parenteral fluids and feeding.",
"     </li>",
"     <li>",
"      Deep vein thrombosis and pulmonary embolism &ndash; Treatment for preventing venous thromboembolism includes graduated compression stockings, intermittent pneumatic compression, and anticoagulants. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in medical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contractures &ndash; Contractures may be prevented by passive range of motion",
"     </li>",
"     <li>",
"      Pressure ulcers &ndash; Pressure relief is the most important factor in preventing pressure (decubitus) ulcers and can be accomplished with proper patient positioning and appropriate use of pressure-reducing devices. Positioning of bed-bound individuals includes a regular turning and repositioning schedule (eg, every two hours), with attention to vulnerable tissue covering bony prominences such as the sacrum. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=see_link\">",
"       \"Prevention of pressure ulcers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Excitement and impulsivity &ndash; Catatonic excitement and impulsivity are most safely treated with a benzodiazepine such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      , although seclusion and physical restraints are occasionally required as well. Antipsychotic drugs should be avoided. &nbsp;(See",
"      <a class=\"local\" href=\"#H6714262\">",
"       'Benzodiazepine safety and administration'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=see_link&amp;anchor=H13#H13\">",
"       \"Assessment and management of the acutely agitated or violent adult\", section on 'Physical restraints'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13927951\">",
"    <span class=\"h2\">",
"     Underlying disorder",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of catatonia includes treating the underlying cause as soon as it is identified, which may improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/7\">",
"     7",
"    </a>",
"    ]. On acute inpatient psychiatric units, catatonia is most likely to occur in mood disorders (especially bipolar disorder) with psychotic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Catatonia is also associated with schizophrenia and other psychoses. A broad spectrum of general medical conditions can progress to catatonia, including infectious, metabolic, and neurologic disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,2,12\">",
"     1,2,12",
"    </a>",
"    ]. Treatment of the general medical condition may need to be prioritized over catatonia (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link&amp;anchor=H4567399#H4567399\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Underlying disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13927994\">",
"    <span class=\"h3\">",
"     Avoid dopamine blocking drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should try to avoid antipsychotics and other dopamine blocking drugs (eg, antiemetic agents) in patients with catatonia, including patients who are psychotic, impulsive, or aggressive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1\">",
"     1",
"    </a>",
"    ]. First-generation antipsychotics do not appear to provide any benefit for treating catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/13\">",
"     13",
"    </a>",
"    ]. Although there are reports that second-generation antipsychotics may treat catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/3,14-17\">",
"     3,14-17",
"    </a>",
"    ], all antipsychotics can precipitate and worsen catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,9,18\">",
"     4,9,18",
"    </a>",
"    ]. In addition, treating catatonia with an antipsychotic is a risk factor for the neuroleptic malignant syndrome (NMS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/10,19-23\">",
"     10,19-23",
"    </a>",
"    ]; the risk may be particularly elevated in patients who are dehydrated, receive the antipsychotic parenterally or at rapidly escalating doses, or have a prior history of catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/24\">",
"     24",
"    </a>",
"    ]. Antipsychotics are contraindicated in malignant catatonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link&amp;anchor=H14470950#H14470950\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Malignant catatonia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After catatonia has resolved and the patient is moving normally, eating and drinking, and autonomically stable, an antipsychotic drug may be used to treat an underlying psychotic disorder without undue risk of precipitating NMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/10\">",
"     10",
"    </a>",
"    ]. During this time, patients should be examined regularly for recurrence of catatonic signs. If a benzodiazepine resolved the catatonic episode, it should be maintained during treatment with an antipsychotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    may offer the best risk-benefit ratio. High-potency first-generation antipsychotics carry the highest risk of NMS. However, all second-generation antipsychotics can cause NMS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/22,25\">",
"     22,25",
"    </a>",
"    ]; one case report described NMS in a patient who was treated with low-dose clozapine soon after recovering from catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NMS is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172176516\">",
"    <span class=\"h2\">",
"     Treatment algorithm",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatment for catatonia is a benzodiazepine or electroconvulsive therapy (ECT), depending upon the subtype of catatonia, clinical urgency, and availability of treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,13,27-31\">",
"     1,13,27-31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with malignant catatonia, we recommend a benzodiazepine plus immediate preparation to administer ECT as soon as possible. If the benzodiazepine provides a substantive response during the first 24 to 48 hours, it can be continued in lieu of ECT.",
"     </li>",
"     <li>",
"      For patients with retarded or excited catatonia, we recommend treatment with a benzodiazepine (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      is used most often).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No randomized trials have evaluated benzodiazepines or ECT for acute catatonia. However, prospective open-label studies, cases series, and retrospective studies suggest that benzodiazepines alone, or benzodiazepines followed by ECT, lead to recovery in approximately 60 to 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,13,24,32,33\">",
"     1,13,24,32,33",
"    </a>",
"    ]. Treatment guidelines from the American Psychiatric Association, United Kingdom National Institute for Health and Clinical Excellence, and World Federation of Societies of Biological Psychiatry recommend treating catatonia with either a benzodiazepine or ECT, depending upon the clinical urgency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of open-label studies, case series, and case reports found that treatment of catatonia is the same regardless of the underlying disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85682819\">",
"    <span class=\"h3\">",
"     Malignant catatonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT is first-line treatment for patients with malignant catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,4,13,24\">",
"     1,4,13,24",
"    </a>",
"    ]. We recommend that clinicians concurrently start a benzodiazepine and the process of obtaining informed consent and medical consultation for ECT. If the patient does not measurably respond to a benzodiazepine within the first day or two, ECT should commence. Reviews of case reports have found that mortality for progressive malignant catatonia increases if ECT does not begin within five days of symptom onset [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/24,34\">",
"     24,34",
"    </a>",
"    ]. Another review of case reports found that in patients with malignant catatonia, response to ECT occurred in 9 of 11 patients (89 percent), whereas response to a benzodiazepine occurred in 2 of 5 patients (40 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/13\">",
"     13",
"    </a>",
"    ]. During the first week, daily ECT may be needed.",
"   </p>",
"   <p>",
"    The safety and administration of benzodiazepines and ECT are discussed separately. (See",
"    <a class=\"local\" href=\"#H6714262\">",
"     'Benzodiazepine safety and administration'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H6714269\">",
"     'Electroconvulsive therapy safety and administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85682827\">",
"    <span class=\"h3\">",
"     Retarded or excited catatonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon prospective open-label studies and case series, we recommend initial treatment with a benzodiazepine for patients with retarded or excited catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,13\">",
"     1,13",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    has been studied most frequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,10,13,32,35,36\">",
"     1,10,13,32,35,36",
"    </a>",
"    ], but case reports also describe successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/45/26328?source=see_link\">",
"     clonazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14023?source=see_link\">",
"     clorazepate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/37-46\">",
"     37-46",
"    </a>",
"    ]. In a review of case reports of 104 catatonic episodes that were treated with benzodiazepine monotherapy, 70 percent remitted; among the 72 episodes treated with lorazepam, 79 percent remitted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/13\">",
"     13",
"    </a>",
"    ]. Other reviews estimate that 60 to 80 percent of patients with catatonia respond to lorazepam monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,37,47\">",
"     4,37,47",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/7/36982?source=see_link\">",
"     amobarbital",
"    </a>",
"    was significantly more effective than placebo in a randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/48\">",
"     48",
"    </a>",
"    ], most authorities consider benzodiazepines as first-line pharmacotherapy because they are generally effective and safer than barbiturates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,3,4\">",
"     1,3,4",
"    </a>",
"    ]. In addition, benzodiazepines have been studied more often, are familiar to clinicians, and an antagonist (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/6/41062?source=see_link\">",
"     flumazenil",
"    </a>",
"    ) is available. (See",
"    <a class=\"local\" href=\"#H6714262\">",
"     'Benzodiazepine safety and administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical factors may be associated with response to a benzodiazepine. Successful benzodiazepine treatment may be more likely in patients with a significant reduction of catatonic signs after the first dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    or other benzodiazepine (positive lorazepam challenge test) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/34\">",
"     34",
"    </a>",
"    ]. Acutely catatonic patients with an underlying mood disorder may respond more favorably to a benzodiazepine than schizophrenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/11,49\">",
"     11,49",
"    </a>",
"    ]. In addition, benzodiazepines at low doses do not appear to benefit chronic catatonia in schizophrenic patients. A randomized trial compared adjunctive lorazepam with placebo for treating slow-onset, long-standing (&ge;4 years) catatonic signs in severely disabled and treatment-resistant chronic schizophrenic patients; lorazepam 6 mg daily provided no benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/50\">",
"     50",
"    </a>",
"    ]. It is not clear whether a longer duration of catatonia prior to treatment is associated with a poorer response to treatment, due to contradictory study results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/11,32\">",
"     11,32",
"    </a>",
"    ]. Age, sex, and the number and pattern of catatonic signs do not appear to be associated with response to a benzodiazepine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,9,24,32\">",
"     4,9,24,32",
"    </a>",
"    ]. The lorazepam challenge test is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link&amp;anchor=H4567794#H4567794\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Lorazepam challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with retarded or excited catatonia that does not respond to a benzodiazepine, ECT is the treatment of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1,4,24,32\">",
"     1,4,24,32",
"    </a>",
"    ]. In addition, if the underlying cause of catatonia is a mood disorder, or for patients requiring a rapid treatment response, ECT is the most effective treatment option. Based upon open-label studies, case series, and retrospective studies, it is estimated that approximately 60 percent or more of catatonic patients achieve remission with ECT, including patients unresponsive to a benzodiazepine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,27,32,33,35,51-53\">",
"     4,27,32,33,35,51-53",
"    </a>",
"    ]. As an example, a review of case reports of 55 catatonic episodes that were treated with ECT alone found that 85 percent remitted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/13\">",
"     13",
"    </a>",
"    ]. A subsequent chart review of 27 catatonic patients treated with ECT found that 59 percent improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/33\">",
"     33",
"    </a>",
"    ]. For patients with a mood disorder or acute psychosis, ECT can relieve both the catatonic syndrome and the underlying psychopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,24\">",
"     4,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6714269\">",
"     'Electroconvulsive therapy safety and administration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There are no established predictors of response to ECT for patients with catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/3\">",
"     3",
"    </a>",
"    ]. However, acutely catatonic patients with an underlying mood disorder may respond more favorably to ECT than schizophrenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/49\">",
"     49",
"    </a>",
"    ], and ECT does not appear to benefit chronic catatonia in schizophrenic patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6714262\">",
"    <span class=\"h2\">",
"     Benzodiazepine safety and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benzodiazepines are generally safe and well tolerated in this setting. At doses used for treating catatonia, benzodiazepines are not associated with respiratory depression in otherwise healthy adults. However, clinicians should be cognizant of concomitant drugs that can cause sedation or respiratory depression, eg, opioids. In addition, benzodiazepines cause varying degrees of motor incoordination and increase the risk of falls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benzodiazepines can be administered intravenously, intramuscularly, or orally (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    is available in all three formulations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,32\">",
"     4,32",
"    </a>",
"    ]. Intravenous administration is preferred to assure adherence and rapid, complete absorption (intravenous access also permits administration of fluids for dehydration). Intravenous benzodiazepines should be injected or infused slowly. As patients improve, they should be switched to oral medication. &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     Lorazepam",
"    </a>",
"    has been studied most often, and is typically initiated at 1 to 2 mg three times per day. Close observation for a clinical response can substantiate the diagnosis of catatonia. The dose is then increased by 3 mg per day every one to two days, depending upon patient response, tolerability, and clinical urgency. A dose of 6 to 21 mg daily is effective for most patients, but a dose of 30 mg per day is occasionally necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1\">",
"     1",
"    </a>",
"    ]. For patients with excited catatonia, lorazepam 1 to 2 mg is given at more frequent intervals until the patient is calm but awake.&nbsp;A more cautious approach is suggested for patients at risk of cardiorespiratory compromise or oversedation (eg, older, obese, or volume depleted patients; patients with cardiovascular or respiratory disease; patients receiving opioid analgesics). For patients with these risk factors, the initial dose may be reduced to 0.5 mg three times per day and closer monitoring provided [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/10,35\">",
"     10,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link&amp;anchor=H4567794#H4567794\">",
"     \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\", section on 'Lorazepam challenge'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of treatment required to achieve remission of catatonia with a benzodiazepine is typically 4 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/34\">",
"     34",
"    </a>",
"    ]. The benzodiazepine is usually continued at the effective dose for three to six months to maintain recovery and is then slowly tapered and discontinued, although longer maintenance treatment may be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional information about the clinical use and pharmacology of benzodiazepines is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6714269\">",
"    <span class=\"h2\">",
"     Electroconvulsive therapy safety and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;ECT is generally safe, even in patients whose general medical status is compromised [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/56\">",
"     56",
"    </a>",
"    ]. However, safety concerns necessitate preprocedure medical consultation. ECT is typically administered with the same technique used for other indications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=see_link\">",
"     \"Medical consultation for electroconvulsive therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    There are no absolute contraindications to ECT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. Underlying general medical conditions may increase the risk of adverse effects of ECT or general anesthesia, but modern ECT technique and preprocedure consultation to optimize the patient&rsquo;s general medical status reduce these risks. As an example, catatonic patients with motor immobility and muscle damage are at increased risk for transient hyperkalemia associated with the muscle relaxant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"     succinylcholine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/3,12\">",
"     3,12",
"    </a>",
"    ]. This increased risk is eliminated by using a nondepolarizing muscle relaxant (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/26/19879?source=see_link\">",
"     rocuronium",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Electrode placement and other aspects of ECT technique for treating catatonia have not been standardized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/12\">",
"     12",
"    </a>",
"    ]. However, bilateral electrode placement and brief pulse current are generally preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1\">",
"     1",
"    </a>",
"    ]. ECT is generally given three times per week on alternating days. However, clinical urgency may necessitate daily treatments for malignant catatonia until the patient is physiologically stable, which often occurs within two to five treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1\">",
"     1",
"    </a>",
"    ]. At least six treatments are given regardless of the catatonia subtype to reduce the risk of sudden relapse. Most patients receiving ECT regardless of the indication remit with 6 to 12 treatments, but some patients may require 20 or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/56\">",
"     56",
"    </a>",
"    ]. ECT is usually terminated after the acute catatonic episode has remitted, but one case report described maintenance ECT for a patient with recurrent catatonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/63\">",
"     63",
"    </a>",
"    ]. Additional information about ECT is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=see_link\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=see_link\">",
"     \"Technique for performing electroconvulsive therapy (ECT) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports describe catatonic patients who responded to ECT plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The decision to continue a benzodiazepine during ECT is determined by the patient&rsquo;s initial response to the medication and the modifications in ECT technique that are required. For patients with a partial but incomplete response to lorazepam, the drug may be continued during ECT to maintain the drug&rsquo;s therapeutic benefit. However, the benzodiazepine should be discontinued if it interferes with ECT (increases seizure threshold and shortens seizure duration) despite adjustments in the ECT technique. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of electroconvulsive therapy (ECT) for adults\", section on 'Concurrent medications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4932579\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative treatments may be available for patients with catatonia who do not respond to benzodiazepines and either decline ECT or do not have access to it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4\">",
"     4",
"    </a>",
"    ]. Case reports describe other treatments that were added to an existing pharmacotherapy regimen and may possibly be beneficial. These other treatments include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/64\">",
"     64",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/65\">",
"     65",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/66,67\">",
"     66,67",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,68,69\">",
"     4,68,69",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/16/24837?source=see_link\">",
"     memantine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/70-73\">",
"     70-73",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/40/8840?source=see_link\">",
"     bromocriptine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/74\">",
"     74",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    has also been used, but has dopamine agonist activity that can potentially worsen an underlying psychosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/73\">",
"     73",
"    </a>",
"    ]. Additional case reports describe treatment of catatonia with repeated transcranial magnetic stimulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6714290\">",
"    <span class=\"h1\">",
"     LONG-TERM PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the long-term outcome of catatonia has not been rigorously studied, catatonia appears to have a generally favorable prognosis, especially the retarded and excited subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4,75\">",
"     4,75",
"    </a>",
"    ]. Long-term prognosis appears to be linked to the nature and severity of the underlying psychiatric or general medical disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/3,24\">",
"     3,24",
"    </a>",
"    ]. Retarded or excited catatonia in patients with an underlying mood disorder or toxic-metabolic disorder usually resolves with treatment of the catatonic syndrome plus the underlying condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/24\">",
"     24",
"    </a>",
"    ]. However, catatonia may persist for years, particularly in patients with schizophrenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/50\">",
"     50",
"    </a>",
"    ]. In addition, patients with malignant catatonia may be left with permanent morbidity (eg, cognitive deficits, apathy syndromes, and limb strictures), and death rates of up to 20 percent have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports describe recurrent catatonic episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/13,63\">",
"     13,63",
"    </a>",
"    ]. One case series of five patients reported that the mean interval between consecutive episodes was 11 months (range 5 to 20 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43928/abstract/76\">",
"     76",
"    </a>",
"    ]. The motor signs were generally consistent across each patient&rsquo;s two episodes. For cases with complete information, the same treatment worked in the two episodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2451081\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catatonia is a behavioral syndrome marked by an inability to move normally that is associated with many psychiatric, neurologic, and general medical disorders. Signs of catatonia are listed in the tables (",
"      <a class=\"graphic graphic_table graphicRef53391 \" href=\"mobipreview.htm?34/31/35324\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66229 \" href=\"mobipreview.htm?7/25/7580\">",
"       table 2",
"      </a>",
"      ). The three primary subtypes of catatonia are retarded, excited, and malignant. (See",
"      <a class=\"local\" href=\"#H10661798\">",
"       'Definition'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=see_link\">",
"       \"Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of acute catatonia generally occurs in hospital settings where the patient&rsquo;s general medical health can be monitored and optimized. Malignant catatonia in particular is life-threatening and generally warrants admission to an intensive care unit. (See",
"      <a class=\"local\" href=\"#H85682923\">",
"       'Setting and management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Concurrently treating the underlying psychiatric or general medical disorder along with the catatonia may improve outcomes. Clinicians should avoid using dopamine blocking drugs, even if patients are psychotic, impulsive, or aggressive. Treating catatonia with an antipsychotic is a risk factor for the neuroleptic malignant syndrome (NMS). Antipsychotics are contraindicated in malignant catatonia. &nbsp;(See",
"      <a class=\"local\" href=\"#H13927951\">",
"       'Underlying disorder'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13927994\">",
"       'Avoid dopamine blocking drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mortality in malignant catatonia may increase if electroconvulsive therapy (ECT) does not begin within five days of symptom onset. For patients with malignant catatonia, we recommend ECT rather than a benzodiazepine (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). A benzodiazepine should be administered during preparations for ECT; if malignant catatonia improves significantly with the benzodiazepine during the first 24 to 48 hours, it can be continued in lieu of ECT. (See",
"      <a class=\"local\" href=\"#H172176516\">",
"       'Treatment algorithm'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H85682819\">",
"       'Malignant catatonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with retarded or excited catatonia, we recommend a benzodiazepine rather than ECT (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). For retarded or excited catatonia that does not respond to a benzodiazepine, we suggest ECT rather than other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H172176516\">",
"       'Treatment algorithm'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H85682827\">",
"       'Retarded or excited catatonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benzodiazepine used most often is intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      1 to 2 mg three times per day, which is increased by 3 mg per day every one to two days. A dose of 6 to 21 mg daily is effective for most patients, but a dose of 30 mg per day is occasionally necessary. The benzodiazepine is usually continued orally at the effective dose for three to six months and then tapered and discontinued. Following remission of catatonia, the benzodiazepine should be continued if an antipsychotic drug is used to treat the underlying disorder. (See",
"      <a class=\"local\" href=\"#H6714262\">",
"       'Benzodiazepine safety and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no absolute contraindications to ECT. For catatonic patients with motor immobility and muscle damage, a nondepolarizing muscle relaxant is used in order to eliminate the risk of transient hyperkalemia associated with the use of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      . ECT is generally given three times per week on alternating days, but malignant catatonia may initially require daily treatments. ECT is typically administered at least six times with bilateral electrode placement and brief pulse current. (See",
"      <a class=\"local\" href=\"#H6714269\">",
"       'Electroconvulsive therapy safety and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Retarded and excited catatonia both appear to have a generally favorable prognosis, especially in patients with an underlying mood disorder or toxic-metabolic disorder. By contrast, malignant catatonia may result in permanent morbidity, and death rates of up to 20 percent have been reported. (See",
"      <a class=\"local\" href=\"#H6714290\">",
"       'Long-term prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/1\">",
"      Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/3\">",
"      Zisselman MH, Jaffe RL. ECT in the treatment of a patient with catatonia: consent and complications. Am J Psychiatry 2010; 167:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/4\">",
"      Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep 2010; 12:180.",
"     </a>",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. World Health Organization. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on May 04, 2011).",
"    </li>",
"    <li>",
"     Mann SC, Caroff SN, Campbell EC, et al. Malignant catatonia. In: Current Clinical Neurology: Movement Disorder Emergencies: Diagnosis and Treatment, Frucht SI, Fahn S.  (Eds), Humana Press, Totowa, NJ 2005. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/7\">",
"      Fink M, Taylor MA. Catatonia: subtype or syndrome in DSM? Am J Psychiatry 2006; 163:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/8\">",
"      Taylor MA, Abrams R. Catatonia. Prevalence and importance in the manic phase of manic-depressive illness. Arch Gen Psychiatry 1977; 34:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/9\">",
"      Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/10\">",
"      Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/11\">",
"      Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull 2010; 36:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/12\">",
"      Daniels J. Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009; 21:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/13\">",
"      Hawkins JM, Archer KJ, Strakowski SM, Keck PE. Somatic treatment of catatonia. Int J Psychiatry Med 1995; 25:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/14\">",
"      Mart&eacute;nyi F, Metcalfe S, Schausberger B, Dossenbach MR. An efficacy analysis of olanzapine treatment data in schizophrenia patients with catatonic signs and symptoms. J Clin Psychiatry 2001; 62 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/15\">",
"      Angelopoulos EK, Corcondilas M, Kollias CT, et al. A case of catatonia successfully treated with ziprasidone, in a patient with DSM-IV delusional disorder. J Clin Psychopharmacol 2010; 30:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/16\">",
"      Levy WO, Nunez CY. Use of ziprasidone to treat bipolar-associated catatonia. Bipolar Disord 2004; 6:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/17\">",
"      Grenier E, Ryan M, Ko E, et al. Risperidone and lorazepam concomitant use in clonazepam refractory catatonia: a case report. J Nerv Ment Dis 2011; 199:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/18\">",
"      Lee JW. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol 2010; 30:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/19\">",
"      Carroll BT, Lee JW. Catatonia is a risk factor for neuroleptic malignant syndrome. J Clin Psychiatry 2004; 65:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/20\">",
"      Berardi D, Dell'Atti M, Amore M, et al. Clinical risk factors for neuroleptic malignant syndrome. Hum Psychopharmacol 2002; 17:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/21\">",
"      White DA, Robins AH. Catatonia: harbinger of the neuroleptic malignant syndrome. Br J Psychiatry 1991; 158:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/22\">",
"      Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/23\">",
"      White DA, Robins AH. An analysis of 17 catatonic patients diagnosed with neuroleptic malignant syndrome. CNS Spectr 2000; 5:58.",
"     </a>",
"    </li>",
"    <li>",
"     Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/25\">",
"      Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs 2009; 23:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/26\">",
"      Paparrigopoulos T, Tzavellas E, Ferentinos P, et al. Catatonia as a risk factor for the development of neuroleptic malignant syndrome: report of a case following treatment with clozapine. World J Biol Psychiatry 2009; 10:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/27\">",
"      Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6:132.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia, Second Edition, 2004 file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 10, 2011).",
"    </li>",
"    <li>",
"     Bipolar disorder: The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Institute for Health and Clinical Excellence clinical guideline 38, 2006 file://guidance.nice.org.uk/CG38 (Accessed on May 11, 2011).",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients With",
"Bipolar Disorder, Second Edition, 2002. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 11, 2011).",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Treatment of Patients with",
"Major Depressive Disorder, Third Edition, 2010. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/32\">",
"      Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996; 93:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/33\">",
"      van Waarde JA, Tuerlings JH, Verwey B, van der Mast RC. Electroconvulsive therapy for catatonia: treatment characteristics and outcomes in 27 patients. J ECT 2010; 26:248.",
"     </a>",
"    </li>",
"    <li>",
"     Fink M, Taylor MA. Catatonia: A Clinician's Guide to Diagnosis and Treatment, Cambridge University Press, Cambridge, UK 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/35\">",
"      Koek RJ, Mervis JR. Treatment-refractory catatonia, ECT, and parenteral lorazepam. Am J Psychiatry 1999; 156:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/36\">",
"      Schmider J, Standhart H, Deuschle M, et al. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 1999; 46:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/37\">",
"      Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/38\">",
"      Hung YY, Huang TL. Lorazepam and diazepam for relieving catatonic features in multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/39\">",
"      Tsai MC, Huang TL. Lorazepam and diazepam for relieving catatonic features precipitated by initial hemodialysis in a uremic patient: a case report. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/40\">",
"      Hung YY, Huang TL. Lorazepam and diazepam rapidly relieve catatonic features in major depression. Clin Neuropharmacol 2006; 29:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/41\">",
"      Huang TL. Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia. Psychiatry Clin Neurosci 2005; 59:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/42\">",
"      McEvoy JP, Lohr JB. Diazepam for catatonia. Am J Psychiatry 1984; 141:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/43\">",
"      Delisle JD. Catatonia unexpectedly reversed by midazolam. Am J Psychiatry 1991; 148:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/44\">",
"      Benazzi F. Parenteral clonazepam for catatonia. Can J Psychiatry 1991; 36:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/45\">",
"      Kumar R. Acute severe catatonia in a young woman with chronic schizophrenia responding to parenteral clonazepam. Aust N Z J Psychiatry 2001; 35:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/46\">",
"      Cottencin O, Warembourg F, de Chouly de Lenclave MB, et al. Catatonia and consultation-liaison psychiatry study of 12 cases. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/47\">",
"      Northoff G. What catatonia can tell us about \"top-down modulation\": a neuropsychiatric hypothesis. Behav Brain Sci 2002; 25:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/48\">",
"      McCall WV, Shelp FE, McDonald WM. Controlled investigation of the amobarbital interview for catatonic mutism. Am J Psychiatry 1992; 149:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/49\">",
"      Ungvari GS, Caroff SN, Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull 2010; 36:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/50\">",
"      Ungvari GS, Chiu HF, Chow LY, et al. Lorazepam for chronic catatonia: a randomized, double-blind, placebo-controlled cross-over study. Psychopharmacology (Berl) 1999; 142:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/51\">",
"      Nisijima K, Ishiguro T. Electroconvulsive therapy for the treatment of neuroleptic malignant syndrome with psychotic symptoms: a report of five cases. J ECT 1999; 15:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/52\">",
"      Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/53\">",
"      Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand 1994; 89:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/54\">",
"      Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. Cochrane Database Syst Rev 2005; :CD000076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/55\">",
"      Manjunatha N, Saddichha S, Khess CR. Idiopathic recurrent catatonia needs maintenance lorazepam: case report and review. Aust N Z J Psychiatry 2007; 41:625.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Task Force on Electroconvulsive Therapy. The Practice of Electroconvulsive Therapy: Recommendations for Treatment, Training, and Privileging. American Psychiatric Association, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/57\">",
"      Fam J, Lee TS, Lee HY, Ng BY. Electroconvulsive therapy for catatonia in neuropsychiatric systemic lupus erythematosus. J ECT 2010; 26:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/58\">",
"      Gupta N, Pennell I, Hargovan H. Relief of catatonia associated with concurrent relief of sigmoid volvulus after electroconvulsive therapy. J ECT 2010; 26:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/59\">",
"      Romanowicz M, Sola CL. Electroconvulsive therapy-responsive catatonia in a medically complicated patient. J ECT 2010; 26:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/60\">",
"      Petrides G, Divadeenam KM, Bush G, Francis A. Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry 1997; 42:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/61\">",
"      Esp&iacute;nola-Nadurille M, Ram&iacute;rez-Berm&uacute;dez J, Fricchione GL. Pregnancy and malignant catatonia. Gen Hosp Psychiatry 2007; 29:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/62\">",
"      Martyn JA, Richtsfeld M. Succinylcholine-induced hyperkalemia in acquired pathologic states: etiologic factors and molecular mechanisms. Anesthesiology 2006; 104:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/63\">",
"      Pontikes TK, Dinwiddie SH. Electroconvulsive therapy in a patient with multiple sclerosis and recurrent catatonia. J ECT 2010; 26:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/64\">",
"      Kritzinger PR, Jordaan GP. Catatonia: an open prospective series with carbamazepine. Int J Neuropsychopharmacol 2001; 4:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/65\">",
"      McDaniel WW, Spiegel DR, Sahota AK. Topiramate effect in catatonia: a case series. J Neuropsychiatry Clin Neurosci 2006; 18:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/66\">",
"      Kr&uuml;ger S, Br&auml;unig P. Intravenous valproic acid in the treatment of severe catatonia. J Neuropsychiatry Clin Neurosci 2001; 13:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/67\">",
"      Yoshida I, Monji A, Hashioka S, et al. Prophylactic effect of valproate in the treatment for siblings with catatonia: a case report. J Clin Psychopharmacol 2005; 25:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/68\">",
"      Zaw ZF, Bates GD. Replication of zolpidem test for catatonia in an adolescent. Lancet 1997; 349:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/69\">",
"      Thomas P, Rascle C, Mastain B, et al. Test for catatonia with zolpidem. Lancet 1997; 349:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/70\">",
"      Carpenter SS, Hatchett AD, Fuller MA. Catatonic schizophrenia and the use of memantine. Ann Pharmacother 2006; 40:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/71\">",
"      Thomas C, Carroll BT, Maley RT, et al. Memantine and catatonic schizophrenia. Am J Psychiatry 2005; 162:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/72\">",
"      Munoz C, Yulan N, Achaval V, et al. Memantine in major depression with catatonic features. J Neuropsychiatry Clin Neurosci 2008; 20:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/73\">",
"      Carroll BT, Goforth HW, Thomas C, et al. Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007; 19:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/74\">",
"      Tang CP, Leung CM, Ungvari GS, Leung WK. The syndrome of lethal catatonia. Singapore Med J 1995; 36:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/75\">",
"      Clark T, Rickards H. Catatonia. 2: Diagnosis, management and prognosis. Hosp Med 1999; 60:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43928/abstract/76\">",
"      Francis A, Divadeenam KM, Bush G, Petrides G. Consistency of symptoms in recurrent catatonia. Compr Psychiatry 1997; 38:56.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15869 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-9B44C2D3FB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43928=[""].join("\n");
var outline_f42_57_43928=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2451081\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6714227\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10661798\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H87533411\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85682923\">",
"      Setting and management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13927951\">",
"      Underlying disorder",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13927994\">",
"      - Avoid dopamine blocking drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H172176516\">",
"      Treatment algorithm",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85682819\">",
"      - Malignant catatonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85682827\">",
"      - Retarded or excited catatonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6714262\">",
"      Benzodiazepine safety and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6714269\">",
"      Electroconvulsive therapy safety and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4932579\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6714290\">",
"      LONG-TERM PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2451081\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/15869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/15869|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/31/35324\" title=\"table 1\">",
"      Observed signs of catatonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/25/7580\" title=\"table 2\">",
"      Elicited signs of catatonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/22/25962?source=related_link\">",
"      Assessment and management of the acutely agitated or violent adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5017?source=related_link\">",
"      Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/41/21145?source=related_link\">",
"      Medical consultation for electroconvulsive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/21/41305?source=related_link\">",
"      Overview of electroconvulsive therapy (ECT) for adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=related_link\">",
"      Prevention of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16007?source=related_link\">",
"      Severe hyperthermia (heat stroke) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/52/13128?source=related_link\">",
"      Technique for performing electroconvulsive therapy (ECT) in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_57_43929="Drug reaction with eosinophilia and systemic symptoms (DRESS)";
var content_f42_57_43929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drug reaction with eosinophilia and systemic symptoms (DRESS)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43929/contributors\">",
"     Jean-Claude Roujeau, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43929/contributors\">",
"     Maja Mockenhaupt, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43929/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/57/43929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H27761005\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, potentially life-threatening, drug-induced hypersensitivity reaction that includes rash, hematologic abnormalities (eosinophilia, atypical lymphocytosis), lymphadenopathy, and internal organ involvement (liver, kidney, lung) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DRESS is characterized by a long latency (two to eight weeks) between drug exposure and disease onset, a prolonged course with frequent relapses despite the discontinuation of the culprit drug, and frequent association with the reactivation of a latent human herpesvirus infection.",
"   </p>",
"   <p>",
"    DRESS will be reviewed in this topic. Other types of cutaneous drug reactions are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=see_link\">",
"       \"Drug eruptions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24360?source=see_link\">",
"       \"Exanthematous (morbilliform) drug eruption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3848?source=see_link\">",
"       \"Lichenoid drug eruption (drug-induced lichen planus)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/50/9000?source=see_link\">",
"       \"Fixed drug eruption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33801?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/60/42951?source=see_link\">",
"       \"Acute generalized exanthematous pustulosis (AGEP)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2153359\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous terms are used to describe adverse drug reactions with rash, systemic symptoms, and visceral involvement, including drug reaction with eosinophilia and systemic symptoms; drug rash with eosinophilia and systemic symptoms; drug-induced hypersensitivity syndrome; or drug hypersensitivity syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Terms that were used in initial case reports include anticonvulsant hypersensitivity syndrome, drug-induced pseudolymphoma,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    syndrome, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The confusing nosology reflects the large variability in the clinical manifestations of this type of adverse drug reaction and the lack of widely accepted diagnostic criteria. In this topic, we will use the term &ldquo;drug reaction with eosinophilia and systemic symptoms&rdquo; (DRESS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761041\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of drug reaction with eosinophilia and systemic symptoms (DRESS) is unknown. A prospective seven-year study in a West Indian general population estimated an annual incidence of",
"    <span class=\"nowrap\">",
"     0.9/100,000",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/6\">",
"     6",
"    </a>",
"    ]. DRESS may occur in children, but most cases occur in adults without sex predilection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency varies depending upon the type of drug and immune status of the patient. It ranges from 1 to 5 per 10,000 patients exposed to the anticonvulsants,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and appears to be higher among patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    (1 per 300 adults and 1 per 100 children exposed) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761048\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug causality is determined as &ldquo;highly probable&rdquo; in approximately 80 percent of cases of drug reaction with eosinophilia and systemic symptoms (DRESS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7,10\">",
"     7,10",
"    </a>",
"    ]. In 10 to 20 percent of cases fulfilling the diagnostic criteria for DRESS, a relationship with a drug cannot be established.",
"   </p>",
"   <p>",
"    Antiepileptic agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    are the most frequently reported causes. Sulfonamides (particularly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    ),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    may also induce DRESS (",
"    <a class=\"graphic graphic_table graphicRef86760 \" href=\"mobipreview.htm?21/56/22411\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pharmacogenetic studies have found an association between HLA haplotypes and susceptibility to DRESS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/11\">",
"     11",
"    </a>",
"    ]. In populations of Han Chinese ancestry, HLA-B*5801 was strongly associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    induced severe cutaneous drug reactions, including DRESS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761056\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A drug-specific immune response and herpesvirus reactivation are key factors in the pathogenesis of drug reaction with eosinophilia and systemic symptoms (DRESS). A drug-specific immune response has been demonstrated in many cases by positive patch test reactions and in vitro lymphocyte proliferation assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During the acute phase of disease, there is an expansion of activated T lymphocytes in the blood, including both CD8 and CD4 cells that harbor activation markers and a skewed repertoire of the antigen receptor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38456?source=see_link\">",
"     \"Drug allergy: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38456?source=see_link&amp;anchor=H15#H15\">",
"     \"Drug allergy: Pathogenesis\", section on 'Type IV (T cell mediated)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reactivation of herpesvirus infection concurrent with drug hypersensitivity is considered specific to DRESS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a study of 100 patients with DRESS, an increase in the antibody titer against HHV-6 was detected in approximately 60 percent of patients two to four weeks after the onset of symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/21\">",
"     21",
"    </a>",
"    ]. Quantitative real-time polymerase chain reaction assay detected a significant amount of HHV-6 DNA in serum samples of approximately 30 percent of patients with increased anti-HHV-6 titers, indicating active viral replication in those patients. Disease relapses (eg, fever, hepatitis) were temporally related to the detection of HHV-6 DNA in the peripheral blood, suggesting that viral reactivation contributes to the phenotype and severity of DRESS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another study including 40 patients with DRESS, evidence of EBV, HHV-6, or HHV-7 reactivation was found in 29 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/22\">",
"     22",
"    </a>",
"    ]. EBV-specific CD8",
"    <sup>",
"     +",
"    </sup>",
"    lymphocytes were found in the blood, skin, and liver.",
"   </p>",
"   <p>",
"    These findings led to the formulation of two main pathogenetic hypotheses, neither of which is proven:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DRESS is primarily a drug-specific immune reaction acting as a trigger of viral reactivation by as yet unknown mechanisms. The amplification of regulatory T cells may contribute to virus reactivation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The initial event in DRESS is a clinically inapparent viral reactivation that induces the expansion of a T cell population cross-reacting with the drug. Tissue damage is caused by activated cytotoxic CD8",
"      <sup>",
"       +",
"      </sup>",
"      lymphocytes directed against virus-related antigens [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872901\">",
"    <span class=\"h1\">",
"     HISTOPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathologic examination of a skin biopsy reveals mild spongiosis and a lymphocytic infiltrate in the superficial dermis, predominantly perivascular, with eosinophils and dermal edema. Occasionally, the lymphocytic infiltrate contains atypical cells or is dense enough to raise the suspicion of cutaneous lymphoma.",
"   </p>",
"   <p>",
"    Although not always performed, the histopathologic features of lymph node, liver, and kidney biopsy are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pathologic findings in lymph nodes range from benign reactive hyperplasia to presence of atypical lymphocytes suggestive of lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/24\">",
"       24",
"      </a>",
"      ]. Most often, lymph nodes demonstrate benign features similar to viral-induced lymphadenopathy, with partial or complete effacement of nodal architecture by a polymorphous infiltrate of immunoblasts, small lymphocytes, eosinophils, and plasma cells.",
"     </li>",
"     <li>",
"      Liver biopsy demonstrates an acute hepatitis injury pattern with lobular inflammation, scattered foci of necrotic hepatocytes, and granulomatous infiltrates containing eosinophils [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/25\">",
"       25",
"      </a>",
"      ]. Portal inflammation and cholestasis also may be seen. Confluent hepatocyte necrosis and lobular disarray due to inflammation and regenerative changes are seen in severe cases. &nbsp;",
"     </li>",
"     <li>",
"      Kidney biopsy demonstrates tubulointerstitial nephritis with interstitial edema and infiltrates of lymphocytes, histiocytes, eosinophils, and plasma cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761063\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most patients, the reaction begins two to six weeks after the initiation of the offending medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/10\">",
"     10",
"    </a>",
"    ]. The latency between drug exposure and onset of symptoms is considerably longer in DRESS than in most drug eruptions (typically, 4 to 9 days for morbilliform eruptions and 4 to 28 days for",
"    <span class=\"nowrap\">",
"     SJS/TEN)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fever (38 to 40&deg;C [100.4 to 104&deg;F]), malaise, lymphadenopathy, and rash are the most common initial symptoms, but they are not invariably present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872883\">",
"    <span class=\"h2\">",
"     Skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eruption starts as a morbilliform rash that progresses more or less rapidly to a diffuse, confluent, and infiltrated erythema with follicular accentuation (",
"    <a class=\"graphic graphic_picture graphicRef86763 graphicRef86859 graphicRef86860 \" href=\"mobipreview.htm?35/17/36122\">",
"     picture 1A-C",
"    </a>",
"    ). The face and upper part of the trunk and extremities are involved initially.",
"   </p>",
"   <p>",
"    Facial edema develops in approximately one-half of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/10\">",
"     10",
"    </a>",
"    ]. The facial edema is symmetric, persistent, and associated with erythema. Inflammation and pain of mucous membranes is present in nearly one-half of patients and usually involves a single site (most often the mouth or pharynx), and does not progress to erosion.",
"   </p>",
"   <p>",
"    The extent of the body surface area (BSA) involvement is an important marker of disease severity (",
"    <a class=\"graphic graphic_figure graphicRef53352 \" href=\"mobipreview.htm?29/55/30583\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50237 \" href=\"mobipreview.htm?32/9/32924\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=see_link&amp;anchor=H16#H16\">",
"     \"Classification of burns\", section on 'Percent body surface area estimates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In most cases, more than 50 percent of the BSA is erythematous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/10\">",
"     10",
"    </a>",
"    ]. In 20 to 30 percent of patients, erythema progresses to exfoliative dermatitis (diffuse erythema and scaling involving &gt;90 percent of BSA). Vesicles, tension blisters induced by dermal edema, or pustules can also occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872928\">",
"    <span class=\"h2\">",
"     Systemic symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic symptoms include fever (38 to 40&deg;C [100.4 to 104&deg;F]), malaise, lymphadenopathy, and symptoms related to visceral involvement. (See",
"    <a class=\"local\" href=\"#H872993\">",
"     'Organ involvement'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Diffuse lymphadenopathy is reported in 30 to 60 percent of cases, with slightly enlarged (1 to 2 cm) and tender nodes at several sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7\">",
"     7",
"    </a>",
"    ]. Lymph node biopsy, occasionally performed to exclude lymphoma, demonstrates features similar to viral-induced lymphadenopathy or benign lymphoid hyperplasia. (See",
"    <a class=\"local\" href=\"#H872901\">",
"     'Histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872951\">",
"    <span class=\"h2\">",
"     Laboratory abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory abnormalities detected in patients with DRESS include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7,10,22,28-31\">",
"     7,10,22,28-31",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Leukocytosis with eosinophil counts",
"      <span class=\"nowrap\">",
"       &gt;700/microL",
"      </span>",
"      (in 50 to 90 percent of cases) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Atypical lymphocytosis with large activated lymphocytes, lymphoblasts, or mononucleosis-like cells (in 30 to 70 percent of cases) &nbsp;",
"     </li>",
"     <li>",
"      Increased serum alanine aminotransferase (in up to 80 percent of cases)",
"     </li>",
"     <li>",
"      HHV-6 infection (in 40 to 60 percent of tested patients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H872993\">",
"    <span class=\"h2\">",
"     Organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of at least one internal organ occurs in approximately 90 percent of patients; in 50 to 60 percent of patients, two or more organs are involved, most frequently kidneys (10 to 30 percent of cases), and lungs (5 to 25 percent of cases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761078\">",
"    <span class=\"h3\">",
"     Liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver abnormalities develop in 60 to 80 percent of patients. Hepatomegaly and jaundice may be present, but most often hepatitis is asymptomatic and detected by routine liver function tests (LFT). Liver biopsy demonstrates necrosis of hepatocytes with granulomatous infiltrates containing eosinophils. (See",
"    <a class=\"local\" href=\"#H872901\">",
"     'Histopathology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no consensus on the definition of liver involvement. In the scoring system proposed by the Registry of Severe Cutaneous Adverse Reactions (RegiSCAR), liver involvement is defined by the finding of a serum level of alanine aminotransferase (ALT) greater than twice the upper limit of normal values",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    alkaline phosphatase greater than 1.5 times the upper limit of normal values on at least two different dates.",
"   </p>",
"   <p>",
"    LFT abnormalities are generally mild and transient, but severe impairment of liver function may occur. Prolongation of prothrombin time (international normalized ratio [INR] &gt;1.5), increase in serum bilirubin, or evidence of impaired consciousness may be clues to acute liver failure. Severe hepatitis is responsible for the majority of deaths associated with DRESS. Markedly elevated aspartate aminotransferase and bilirubin with jaundice are the most important predictors of death or liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/32\">",
"     32",
"    </a>",
"    ]. There are isolated case reports of life-saving emergency liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=see_link&amp;anchor=H64479183#H64479183\">",
"     \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\", section on 'Idiosyncratic drug reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761085\">",
"    <span class=\"h3\">",
"     Kidney",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal involvement, manifesting as acute interstitial nephritis, occurs in 10 to 30 percent of DRESS cases, most often in those induced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/29,31\">",
"     29,31",
"    </a>",
"    ]. Older age and preexisting alterations of renal function may be predisposing factors.",
"   </p>",
"   <p>",
"    Renal abnormalities include a moderate increase in creatinine level, low grade proteinuria, and abnormal urinary sediment with occasional eosinophils. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27209?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A kidney biopsy demonstrates tubulointerstitial nephritis with interstitial infiltrates of lymphocytes, histiocytes, and eosinophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H872901\">",
"     'Histopathology'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27209?source=see_link&amp;anchor=H853752222#H853752222\">",
"     \"Clinical manifestations and diagnosis of acute interstitial nephritis\", section on 'Histology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761092\">",
"    <span class=\"h3\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary involvement presents with nonspecific symptoms, including cough, fever, and",
"    <span class=\"nowrap\">",
"     tachypnea/dyspnea",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/34\">",
"     34",
"    </a>",
"    ]. The measurement of hemoglobin oxygen saturation by pulse oximetry may reveal an unsuspected hypoxemia. Chest radiograph or CT scan may provide evidence of interstitial pneumonitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural effusion. Drug-specific CD8",
"    <sup>",
"     +",
"    </sup>",
"    T lymphocytes and eosinophils may be found in broncho-alveolar lavage fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761099\">",
"    <span class=\"h3\">",
"     Other organs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many other organs can be involved in DRESS, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heart (eosinophilic myocarditis, pericarditis)",
"     </li>",
"     <li>",
"      Gastrointestinal tract (diarrhea, mucosal erosions, bleeding)",
"     </li>",
"     <li>",
"      Pancreas (pancreatitis)",
"     </li>",
"     <li>",
"      Thyroid (autoimmune thyroiditis, appearing often late, as a sequel of DRESS)",
"     </li>",
"     <li>",
"      Brain (encephalitis, meningitis)",
"     </li>",
"     <li>",
"      Muscle (myositis, increase in creatine kinase)",
"     </li>",
"     <li>",
"      Peripheral nerves (polyneuritis)",
"     </li>",
"     <li>",
"      Eye (uveitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare cases of multiple organ failure associated with disseminated intravascular coagulation or hemophagocytic syndrome also have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761113\">",
"    <span class=\"h1\">",
"     CLINICAL COURSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin eruption and visceral involvement generally resolve gradually after drug withdrawal. The average time to recovery is six to nine weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7\">",
"     7",
"    </a>",
"    ]. In up to 20 percent of cases, the disease may persist for several months with a succession of remissions and relapses. Relapses have been reported concurrently with human herpesvirus 6 reactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although there have been case reports of relapses induced by the introduction of new drugs, particularly beta-lactam antibiotics, it is not clear whether these were relapses or evolution of the natural course of DRESS, which includes spontaneous flares [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, in the case reports, the beta-lactam drugs were initiated to treat suspected bacterial infections before a diagnosis of DRESS was considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761127\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2711286\">",
"    <span class=\"h2\">",
"     When to suspect DRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of DRESS is suspected in a patient receiving a drug treatment who presents with the following signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin eruption (morbilliform or diffuse, confluent, and infiltrated) (",
"      <a class=\"graphic graphic_picture graphicRef86763 \" href=\"mobipreview.htm?25/62/26596\">",
"       picture 1A",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fever (38 to 40&deg;C [100.4 to 104&deg;F])",
"     </li>",
"     <li>",
"      Facial edema",
"     </li>",
"     <li>",
"      Enlarged lymph nodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical suspicion can be substantiated by a history of exposure in the previous two to six weeks to a high risk medication (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"     allopurinol",
"    </a>",
"    , antiepileptic drugs (",
"    <a class=\"graphic graphic_table graphicRef86760 \" href=\"mobipreview.htm?21/56/22411\">",
"     table 1",
"    </a>",
"    )); laboratory",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    imaging studies demonstrating organ involvement; and a skin biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2711189\">",
"    <span class=\"h2\">",
"     Assessment of drug causality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The latency between drug exposure and onset of symptoms (two to six weeks) is considerably longer in DRESS than in most drug eruptions (typically 4 to 9 days for morbilliform eruptions and 4 to 28 days for",
"    <span class=\"nowrap\">",
"     SJS/TEN)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications taken for more than three months or initiated less than two weeks before the onset of DRESS are unlikely to be the causative drugs. Medication(s) known to have a high risk of inducing DRESS (",
"    <a class=\"graphic graphic_table graphicRef86760 \" href=\"mobipreview.htm?21/56/22411\">",
"     table 1",
"    </a>",
"    ) and taken two to eight weeks before the disease onset are considered plausible culprits and withdrawn. (See",
"    <a class=\"local\" href=\"#H23263789\">",
"     'Drug withdrawal and supportive measures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Causality may be further supported by positive patch tests",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in vitro tests (eg, lymphocyte proliferation assay) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Both types of test seem to have a good specificity but a low sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269651\">",
"    <span class=\"h2\">",
"     Laboratory investigations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial laboratory evaluation in a patient suspected to have DRESS is aimed at confirming the diagnosis, excluding other conditions that mimic DRESS, and evaluating the extent and severity of visceral involvement (",
"    <a class=\"graphic graphic_table graphicRef86762 \" href=\"mobipreview.htm?33/6/33899\">",
"     table 3",
"    </a>",
"    ). Laboratory tests include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Complete blood cell count with differential and peripheral blood smear",
"      </strong>",
"      &ndash; The finding of peripheral eosinophilia",
"      <span class=\"nowrap\">",
"       &gt;700/microL",
"      </span>",
"      suggests the diagnosis of DRESS. In some patients, lymphocytosis (absolute lymphocyte count",
"      <span class=\"nowrap\">",
"       &gt;4500/microL)",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the finding of atypical lymphocytes on peripheral smear also support the diagnosis of DRESS. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Liver function tests",
"      </strong>",
"      &ndash; Serum alanine aminotransferase (ALT) greater than twice the upper limit of normal values",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      alkaline phosphatase greater than 1.5 times the upper limit of normal values on at least two different dates indicate liver involvement.",
"     </li>",
"     <li>",
"      <strong>",
"       Serology for viral hepatitis",
"      </strong>",
"      &ndash; Serology for viral hepatitis (hepatitis A IgM antibody, hepatitis B surface antigen, hepatitis B core IgM antibody, hepatitis C viral RNA) may be useful in excluding acute viral hepatitis in patients with abnormal liver function test results.",
"     </li>",
"     <li>",
"      <strong>",
"       Serum creatinine and urinalysis",
"      </strong>",
"      &ndash; A moderate increase in creatinine level, low grade proteinuria, and abnormal urinary sediment with occasional eosinophils indicate kidney involvement.",
"     </li>",
"     <li>",
"      <strong>",
"       Skin biopsy",
"      </strong>",
"      &ndash; The histologic findings of mild spongiosis and a lymphocytic infiltrate in the superficial dermis, predominantly perivascular, with eosinophils and dermal edema, although not specific, supports the diagnosis of a drug hypersensitivity reaction. (See",
"      <a class=\"local\" href=\"#H872901\">",
"       'Histopathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Testing for herpesvirus infection",
"      </strong>",
"      &ndash; The search for active infection with human herpesvirus (eg, Epstein-Barr virus [EBV], human herpesvirus-6 [HHV-6], human herpesvirus-7 [HHV-7]) has no or minor impact on treatment of DRESS. However, testing for EBV, HHV-6, or HHV-7 is increasingly performed in patients with DRESS, since viral infection reactivation may be a marker of prolonged course and increased risk of complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no standardized protocols for viral testing in DRESS. If a decision to test is made, serology should be performed at admission and repeated one or more times at two to three week intervals to detect a change in the antibody titer. Quantitative polymerase chain reaction (PCR) assay on serum or plasma is considered the best way to document active virus infection or reactivation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=see_link&amp;anchor=H22#H22\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'EBV-specific antibodies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=see_link&amp;anchor=H27#H27\">",
"     \"Infectious mononucleosis in adults and adolescents\", section on 'Detection of EBV virus'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10265?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14201?source=see_link&amp;anchor=H15#H15\">",
"     \"Human herpesvirus 7 infection\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269682\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients presenting with nonspecific symptoms of pulmonary involvement (eg, cough,",
"    <span class=\"nowrap\">",
"     tachypnea/dyspnea),",
"    </span>",
"    chest radiograph or CT scan may provide evidence of interstitial pneumonitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pleural effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2711277\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high variability in the clinical presentation, the diagnosis of DRESS in many cases requires a high degree of suspicion and clinical judgement. (See",
"    <a class=\"local\" href=\"#H2711286\">",
"     'When to suspect DRESS'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In typical cases, the diagnosis is based upon the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of exposure to a high risk medication, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      or antiepileptic drugs (",
"      <a class=\"graphic graphic_table graphicRef86760 \" href=\"mobipreview.htm?21/56/22411\">",
"       table 1",
"      </a>",
"      ) in the two to six weeks before the onset of symptoms. (See",
"      <a class=\"local\" href=\"#H2711189\">",
"       'Assessment of drug causality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Morbilliform rash progressing to confluent and infiltrated erythema",
"      <strong>",
"       or",
"      </strong>",
"      exfoliative dermatitis involving &gt;90 percent of the total body surface area (BSA) (",
"      <a class=\"graphic graphic_picture graphicRef86763 \" href=\"mobipreview.htm?25/62/26596\">",
"       picture 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H872883\">",
"       'Skin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The extent of BSA involvement can be assessed by using tables or charts (eg, the modified Lund-Browder charts (",
"    <a class=\"graphic graphic_figure graphicRef53352 \" href=\"mobipreview.htm?29/55/30583\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50237 \" href=\"mobipreview.htm?32/9/32924\">",
"     table 2",
"    </a>",
"    )), the &ldquo;rule of nines&rdquo;, or the palm method (the patient&rsquo;s palm and fingers account for 1 percent of BSA). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=see_link&amp;anchor=H16#H16\">",
"     \"Classification of burns\", section on 'Percent body surface area estimates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hematologic abnormalities (eosinophilia",
"      <span class=\"nowrap\">",
"       &gt;700/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atypical lymphocytosis). (See",
"      <a class=\"local\" href=\"#H872951\">",
"       'Laboratory abnormalities'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic symptoms and organ involvement which may include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fever (38 to 40&deg;C [100.4 to 104&deg;F])",
"     </li>",
"     <li>",
"      Facial edema",
"     </li>",
"     <li>",
"      Enlarged lymph nodes",
"     </li>",
"     <li>",
"      Abnormal liver function tests",
"     </li>",
"     <li>",
"      Renal impairment",
"     </li>",
"     <li>",
"      Interstitial pneumonia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pleural effusion",
"     </li>",
"     <li>",
"      Myocarditis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H872928\">",
"     'Systemic symptoms'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H872993\">",
"     'Organ involvement'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The diagnosis is uncertain in patients with atypical presentations, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Unclear relationship to drug exposure",
"     </li>",
"     <li>",
"      Transient or absent rash &nbsp;",
"     </li>",
"     <li>",
"      Absence of eosinophilia",
"     </li>",
"     <li>",
"      Mild or absent systemic symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is possible, though uncommon, to make a diagnosis of DRESS without &ldquo;D&rdquo; (no patent drug cause), without &ldquo;R&rdquo; (rash was absent in 2 out of 176 cases included in a literature review), without &ldquo;E&rdquo; (absent in 10 to 50 percent of cases), or even without systemic symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/28\">",
"     28",
"    </a>",
"    ]. To help clinicians in confirming or excluding the diagnosis of DRESS, the European Registry of Severe Cutaneous Adverse Reactions (RegiSCAR) devised a scoring system based upon clinical features, extent of skin involvement, organ involvement, and clinical course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/28\">",
"     28",
"    </a>",
"    ]. DRESS is classified as definite, probable, or possible (",
"    <a class=\"graphic graphic_table graphicRef86761 \" href=\"mobipreview.htm?27/43/28348\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Since the score incorporates some information that is only available later in the disease course (eg, duration &gt;15 days or worst value of laboratory parameters over time), it is more helpful in retrospective validation than early diagnosis of DRESS. However, the RegiSCAR scoring system may serve as a guide for the collection of patient information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761157\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other severe cutaneous drug eruptions, viral or bacterial infections, hypereosinophilic syndrome, lymphoma, and autoimmune connective tissue disease may present with skin eruption, fever, and systemic symptoms and mimic DRESS.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stevens-Johnson",
"       <span class=\"nowrap\">",
"        syndrome/toxic",
"       </span>",
"       epidermal necrolysis",
"       <span class=\"nowrap\">",
"        (SJS/TEN)",
"       </span>",
"      </strong>",
"      &ndash;",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      usually starts 4 to 28 days after drug exposure. Severe mucosal involvement with erosions and ulcers on at least two sites occurs in over 90 percent of cases of",
"      <span class=\"nowrap\">",
"       SJS/TEN.",
"      </span>",
"      In contrast, mucosal involvement occurs in approximately 50 percent of patients with DRESS, usually involves a single site (most often the mouth or pharynx), and does not progress to erosion. Eosinophilia and atypical lymphocytosis are not observed in",
"      <span class=\"nowrap\">",
"       SJS/TEN,",
"      </span>",
"      whereas leukopenia is frequent and lymphopenia is nearly constant. Mild elevation of liver enzymes is frequent in",
"      <span class=\"nowrap\">",
"       SJS/TEN,",
"      </span>",
"      but definite hepatitis is present in less than 10 percent of cases, versus at least 50 percent in DRESS. In",
"      <span class=\"nowrap\">",
"       SJS/TEN,",
"      </span>",
"      kidney involvement, when present, has the features of &ldquo;prerenal azotemia&rdquo;, whereas kidney involvement in DRESS manifests as tubulointerstitial nephritis. Lung lesions result from necrosis of epithelial cells in",
"      <span class=\"nowrap\">",
"       SJS/TEN",
"      </span>",
"      and from interstitial and alveolar infiltration by lymphocytes and eosinophils in DRESS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/18,38\">",
"       18,38",
"      </a>",
"      ]. In",
"      <span class=\"nowrap\">",
"       SJS/TEN,",
"      </span>",
"      histology shows full-thickness epidermal necrosis due to massive keratinocyte apoptosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"       \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Acute generalized exanthematous pustulosis (AGEP)",
"      </strong>",
"      &ndash; In contrast to DRESS, AGEP usually starts less than three days after drug exposure. Although pustules occasionally can occur in patients with DRESS, AGEP is characterized by hundreds or thousands pinpoint nonfollicular pustules disseminated over the body surface. Internal organ involvement is rare. Complete blood cell count shows leukocytosis with neutrophilia",
"      <span class=\"nowrap\">",
"       (&gt;7000/microL).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/60/42951?source=see_link\">",
"       \"Acute generalized exanthematous pustulosis (AGEP)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Hypereosinophilic syndromes",
"      </strong>",
"      &ndash; The hypereosinophilic syndromes (HES) are associated with marked peripheral eosinophilia",
"      <span class=\"nowrap\">",
"       (&ge;1500/microL)",
"      </span>",
"      and involvement of multiple organs such as the heart, gastrointestinal tract, lungs, brain, and kidneys, without an alternative explanation for the organ damage. Skin manifestations of HES include eczema (involving hands, flexural areas, or dispersed plaques), erythroderma, lichenification, dermographism, recurrent urticaria, and angioedema. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=see_link\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Angioimmunoblastic T cell lymphoma",
"      </strong>",
"      &ndash; Angioimmunoblastic T cell lymphoma typically presents as an acute-onset systemic illness. Common symptoms include generalized lymphadenopathy, hepatomegaly, splenomegaly, rash (50 to 60 percent of patients), and systemic B symptoms (fevers, night sweats, or weight loss). The rash is usually pruritic and may demonstrate lymphohistiocytic vasculitis on biopsy. Histopathologic examination of a biopsied lymph node confirms the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34023?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       S&eacute;zary syndrome",
"      </strong>",
"      &ndash; S&eacute;zary syndrome typically presents with generalized erythroderma (",
"      <a class=\"graphic graphic_picture graphicRef72342 \" href=\"mobipreview.htm?11/30/11745\">",
"       picture 2",
"      </a>",
"      ). The diagnosis is based upon the finding of S&eacute;zary cells in the peripheral blood (absolute S&eacute;zary count of at least 1000",
"      <span class=\"nowrap\">",
"       cells/microL),",
"      </span>",
"      or increased number of CD4",
"      <sup>",
"       +",
"      </sup>",
"      lymphocytes in the peripheral blood with a",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      ratio &ge;10, and a clonal T cell receptor rearrangement in the blood identified by PCR or southern blot analysis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9722?source=see_link&amp;anchor=H10118613#H10118613\">",
"       \"Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome\", section on 'Diagnostic criteria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Acute cutaneous lupus erythematosus",
"      </strong>",
"      &ndash; Acute cutaneous lupus erythematosus (ACLE) may present with a generalized morbilliform eruption, often focused on sun-exposed areas, and systemic symptoms (eg, fever, fatigue, lymphadenopathy, myalgias, symmetric small joint arthralgia) (",
"      <a class=\"graphic graphic_picture graphicRef86900 graphicRef86901 \" href=\"mobipreview.htm?30/17/31000\">",
"       picture 3A-B",
"      </a>",
"      ). The rash is typically precipitated or exacerbated by exposure to UV light. Autoantibody testing demonstrates high titers of antinuclear antibodies (ANA), anti-dsDNA, or anti-Sm. Histologic examination of a skin biopsy reveals interface dermatitis with a lymphohistiocytic infiltrate and mucin in the upper dermis. Direct immunofluorescence shows a continuous band of granular fluorescence at the dermoepidermal junction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=see_link&amp;anchor=H10330927#H10330927\">",
"       \"Mucocutaneous manifestations of systemic lupus erythematosus\", section on 'Disseminated (generalized) ACLE'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=see_link&amp;anchor=H2#H2\">",
"       \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97599699\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23263789\">",
"    <span class=\"h2\">",
"     Drug withdrawal and supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification and prompt withdrawal of the offending drug is the mainstay of treatment for patients with drug reaction with eosinophilia and systemic symptoms (DRESS). We also suggest avoidance of introducing new medications, if possible, during the course of DRESS and in patients in whom DRESS is suspected.",
"   </p>",
"   <p>",
"    Patients with severe cutaneous adverse drug reactions usually are hospitalized for treatment. Those with exfoliative dermatitis require fluid, electrolyte, and nutritional support. Additional measures include a warm and humid environment and gentle skin care with warm",
"    <span class=\"nowrap\">",
"     baths/wet",
"    </span>",
"    dressings and emollient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13385?source=see_link\">",
"     \"Erythroderma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H626586002\">",
"    <span class=\"h2\">",
"     Patients without severe organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DRESS without clinical, laboratory, or imaging evidence of renal or pulmonary involvement and those with only modest elevation of liver transaminases (ie, &lt;3 times the upper limit of normal) can be treated symptomatically. &nbsp;",
"   </p>",
"   <p>",
"    For symptomatic relief of pruritus and skin inflammation, we suggest high potency topical corticosteroids (groups two and three (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 5",
"    </a>",
"    )) rather than systemic corticosteroids. Topical corticosteroids are applied two to three times per day for one week.",
"   </p>",
"   <p>",
"    Topical corticosteroids for symptomatic treatment of pruritus in patients with DRESS have not been evaluated in a randomized trial and their use is based upon clinical experience in other pruritic inflammatory skin conditions.",
"   </p>",
"   <p>",
"    In case series, complete recovery is reported in patients without severe organ involvement treated with only supportive care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In such patients, it is unclear whether systemic corticosteroids shorten the clinical course.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97704236\">",
"    <span class=\"h2\">",
"     Patients with severe organ involvement",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97704096\">",
"    <span class=\"h3\">",
"     Liver involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main treatment of drug-induced acute liver injury is withdrawal of the offending drug. Systemic corticosteroids are of unproven benefit for most forms of drug hepatotoxicity and there is no consensus on their use. Patients should be followed by serial biochemical measurements. Hepatology consultation may be warranted in some cases.",
"   </p>",
"   <p>",
"    Severe hepatocellular injury may evolve to acute liver failure and the only effective therapy may be liver transplantation. Patients with severe hepatitis, particularly those with jaundice, should be promptly referred to a liver transplant specialist for further evaluation and care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link&amp;anchor=H29#H29\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H97704053\">",
"    <span class=\"h3\">",
"     Lung or kidney involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest systemic corticosteroids for patients with severe involvement of the lungs (dyspnea, abnormal chest radiograph, hypoxemia) or kidneys (creatinine &gt;150 percent basal level and proteinuria or hematuria). We use a moderate to high dose of systemic corticosteroids (eg, 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or prednisone equivalent). Systemic corticosteroids are given until clinical improvement and normalization of laboratory parameters are obtained and then tapered over the ensuing 8 to 12 weeks. A more rapid tapering may increase the risk of relapse.",
"   </p>",
"   <p>",
"    The use of systemic corticosteroids for the treatment of DRESS with severe organ involvement has not been evaluated in randomized trials. However, there is general consensus among experts on the use of systemic corticosteroids for the treatment of DRESS with severe organ involvement, particularly in patients with renal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary involvement. The optimal dose and duration of corticosteroid therapy are not known. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34245?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of acute interstitial nephritis\", section on 'Glucocorticoid therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=see_link&amp;anchor=H18#H18\">",
"     \"Nonspecific interstitial pneumonia\", section on 'Glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In retrospective observational studies, most patients with DRESS, with or without severe organ involvement, are treated with systemic corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7,29,39\">",
"     7,29,39",
"    </a>",
"    ]. Systemic corticosteroids do not appear to be detrimental in patients with DRESS. The risk of death is related to the severity of visceral involvement and does not appear to be increased by treatment with systemic corticosteroids. In a series of 60 patients, the death rate was similar among patients treated with and without systemic corticosteroids (5 in 45 and 1 in 10, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1269162\">",
"    <span class=\"h2\">",
"     Role of antiviral treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no studies evaluating the treatment of DRESS with antiviral agents active against HHV6 or CMV (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29575?source=see_link\">",
"     foscarnet",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/2/20517?source=see_link\">",
"     cidofovir",
"    </a>",
"    ). Given the substantial toxicity of antiviral agents and the natural course of spontaneous resolution, we generally do not use antiviral agents in the treatment of DRESS. However, they may be warranted for patients with DRESS in whom virus reactivation is demonstrated and suspected of contributing to severe complications (eg, encephalitis, hemophagocytosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101654720\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DRESS should be monitored for progression of the skin eruption",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    development of clinical or laboratory symptoms related to organ involvement. Laboratory monitoring may include complete blood count with differential, liver function tests (serum aminotransferases, bilirubin, prothrombin time), blood urea nitrogen (BUN), and creatinine. Laboratory tests are performed at weekly intervals in patients with favorable disease course. More frequent monitoring may be warranted in patients with severe or progressing disease. (See",
"    <a class=\"local\" href=\"#H27761063\">",
"     'Clinical presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52408472\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with DRESS recover completely in weeks to months after drug withdrawal. The prevalence of sequelae is unknown. Autoimmune diseases have been reported in some patients months or years after the resolution of the drug reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. In a retrospective study of 43 patients with DRESS followed-up for at least one year, four patients developed autoimmune diseases (Graves disease, diabetes mellitus type 1, and autoimmune hemolytic anemia) and two patients developed chronic renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/43\">",
"     43",
"    </a>",
"    ]. The author of this topic review suggests that patients recovering from DRESS be monitored by their primary care provider for manifestations of autoimmune diseases; laboratory monitoring, including autoantibodies and thyroid stimulating hormone, also may be warranted based upon clinical findings. &nbsp;",
"   </p>",
"   <p>",
"    The mortality rate for DRESS is 5 to 10 percent whether or not they receive systemic corticosteroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7,29\">",
"     7,29",
"    </a>",
"    ]. The main causes of death are acute liver failure, multiorgan failure, fulminant myocarditis, or hemophagocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/42,45,46\">",
"     42,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H873157\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be educated about the need for a strict avoidance of the offending drug as well as cross-reacting drugs. Cross-reaction to chemically related drugs has been documented in patients treated with antiepileptics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Avoidance of the causative drug should also be recommended to family members of patients with DRESS because of suspicion of genetic factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43929/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27761185\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, potentially life-threatening drug-induced hypersensitivity reaction that includes skin eruption, hematologic abnormalities (eosinophilia, atypical lymphocytosis), lymphadenopathy,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      internal organ involvement (liver, kidney, lung). (See",
"      <a class=\"local\" href=\"#H27761005\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiepileptic agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ) and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/40/25223?source=see_link\">",
"       allopurinol",
"      </a>",
"      are the most frequently reported causes. Sulfonamides (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      ),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      may also induce DRESS (",
"      <a class=\"graphic graphic_table graphicRef86760 \" href=\"mobipreview.htm?21/56/22411\">",
"       table 1",
"      </a>",
"      ). There is evidence for a genetic predisposition to DRESS when related to allopurinol. (See",
"      <a class=\"local\" href=\"#H27761048\">",
"       'Etiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most patients, the reaction begins two to six weeks after the initiation of the offending medication. Fever (38 to 40&deg;C [100.4 to 104&deg;F]), malaise, lymphadenopathy, and skin eruption are the most common initial symptoms, but they are not invariably present. The morbilliform rash can become confluent and progress to exfoliative dermatitis in some patients (",
"      <a class=\"graphic graphic_picture graphicRef86763 graphicRef86859 graphicRef86860 \" href=\"mobipreview.htm?35/17/36122\">",
"       picture 1A-C",
"      </a>",
"      ). Additional systemic symptoms may be related to visceral involvement. Hematologic abnormalities include leukocytosis with eosinophilia",
"      <span class=\"nowrap\">",
"       &gt;700/microL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      atypical lymphocytosis. (See",
"      <a class=\"local\" href=\"#H27761063\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Liver involvement occurs in 60 to 80 percent of patients. Kidney (tubulointerstitial nephritis), lung (interstitial pneumonitis), and other organs can also be involved. Rash and visceral involvement resolve gradually in six to nine weeks after drug withdrawal. (See",
"      <a class=\"local\" href=\"#H872993\">",
"       'Organ involvement'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27761113\">",
"       'Clinical course'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of DRESS is based upon the combination of clinical features (history of drug exposure (",
"      <a class=\"graphic graphic_table graphicRef86760 \" href=\"mobipreview.htm?21/56/22411\">",
"       table 1",
"      </a>",
"      ), cutaneous findings (",
"      <a class=\"graphic graphic_picture graphicRef86763 graphicRef86859 graphicRef86860 \" href=\"mobipreview.htm?35/17/36122\">",
"       picture 1A-C",
"      </a>",
"      ), systemic findings, such as fever, lymphadenopathy, and visceral involvement) and laboratory findings (",
"      <a class=\"graphic graphic_table graphicRef86762 \" href=\"mobipreview.htm?33/6/33899\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27761127\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Identification and prompt withdrawal of the offending drug is the mainstay of treatment for patients with DRESS. (See",
"      <a class=\"local\" href=\"#H23263789\">",
"       'Drug withdrawal and supportive measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DRESS without clinical, laboratory, or imaging evidence of renal or pulmonary involvement and those with only modest elevation of liver transaminases (ie, &lt;3 times the upper limit of normal) can be treated symptomatically. For symptomatic relief of pruritus and skin inflammation, we suggest high potency topical corticosteroids (groups two and three (",
"      <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"       table 5",
"      </a>",
"      )) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H626586002\">",
"       'Patients without severe organ involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute drug-induced liver injury, the main treatment is withdrawal of the offending drug. Serial biochemical measurements should be performed to monitor liver function. Severe hepatocellular injury may evolve to acute liver failure and the only effective therapy may be liver transplantation. Patients with severe hepatitis, particularly those with jaundice, should be promptly referred to a hepatologist for further evaluation and care. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=see_link&amp;anchor=H29#H29\">",
"       \"Drugs and the liver: Patterns of drug-induced liver injury\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with severe interstitial nephritis or interstitial pneumonia, we suggest systemic corticosteroids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      0.5 to 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day is given until clinical improvement and normalization of laboratory parameters are obtained and then tapered over the ensuing 8 to 12 weeks. (See",
"      <a class=\"local\" href=\"#H97704053\">",
"       'Lung or kidney involvement'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/1\">",
"      Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/2\">",
"      Shiohara T, Inaoka M, Kano Y. Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses. Allergol Int 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/3\">",
"      CHAIKEN BH, GOLDBERG BI, SEGAL JP. Dilantin sensitivity; report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950; 242:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/4\">",
"      Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk. J Clin Invest 1988; 82:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/5\">",
"      Halevy S, Feuerman EJ. Psuedolymphoma syndrome. Dermatologica 1977; 155:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/6\">",
"      Muller P, Dubreil P, Mah&eacute; A, et al. Drug Hypersensitivity Syndrome in a West-Indian population. Eur J Dermatol 2003; 13:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/7\">",
"      Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011; 124:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/8\">",
"      Tennis P, Stern RS. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study. Neurology 1997; 49:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/9\">",
"      Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999; 40:985.",
"     </a>",
"    </li>",
"    <li>",
"     RegiSCAR: International registry on severe cutaneous adverse reactions (SCAR) unpublished data.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/11\">",
"      Phillips EJ, Chung WH, Mockenhaupt M, et al. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011; 127:S60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/12\">",
"      Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 2005; 102:4134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/13\">",
"      Cao ZH, Wei ZY, Zhu QY, et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 2012; 13:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/14\">",
"      Elzagallaai AA, Knowles SR, Rieder MJ, et al. Patch testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. Drug Saf 2009; 32:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/15\">",
"      Santiago F, Gon&ccedil;alo M, Vieira R, et al. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). Contact Dermatitis 2010; 62:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/16\">",
"      Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/17\">",
"      Mennicke M, Zawodniak A, Keller M, et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am J Transplant 2009; 9:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/18\">",
"      Guillon JM, Joly P, Autran B, et al. Minocycline-induced cell-mediated hypersensitivity pneumonitis. Ann Intern Med 1992; 117:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/19\">",
"      Descamps V, Valance A, Edlinger C, et al. Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms. Arch Dermatol 2001; 137:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/20\">",
"      Kano Y, Hiraharas K, Sakuma K, Shiohara T. Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease. Br J Dermatol 2006; 155:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/21\">",
"      Tohyama M, Hashimoto K, Yasukawa M, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol 2007; 157:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/22\">",
"      Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. Sci Transl Med 2010; 2:46ra62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/23\">",
"      Takahashi R, Kano Y, Yamazaki Y, et al. Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. J Immunol 2009; 182:8071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/24\">",
"      Brown JR, Skarin AT. Clinical mimics of lymphoma. Oncologist 2004; 9:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/25\">",
"      Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis 2009; 29:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/26\">",
"      Praga M, Gonz&aacute;lez E. Acute interstitial nephritis. Kidney Int 2010; 77:956.",
"     </a>",
"    </li>",
"    <li>",
"     Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions (cADR). In: Adverse Cutaneous Drug Eruptions, Book Series: Chemical Immunology and Allergy, French LE.  (Ed), Karger Verlag, Basel 2012. Vol 97, p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/28\">",
"      Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2007; 156:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/29\">",
"      Chen YC, Chiu HC, Chu CY. Drug reaction with eosinophilia and systemic symptoms: a retrospective study of 60 cases. Arch Dermatol 2010; 146:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/30\">",
"      Kano Y, Inaoka M, Shiohara T. Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia. Arch Dermatol 2004; 140:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/31\">",
"      Peyri&egrave;re H, Dereure O, Breton H, et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br J Dermatol 2006; 155:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/32\">",
"      Bj&ouml;rnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/33\">",
"      Augusto JF, Sayegh J, Simon A, et al. A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol Dial Transplant 2009; 24:2940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/34\">",
"      Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res 2012; 13:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/35\">",
"      Descamps V, Bouscarat F, Laglenne S, et al. Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome. Br J Dermatol 1997; 137:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/36\">",
"      Ben m'rad M, Leclerc-Mercier S, Blanche P, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009; 88:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/37\">",
"      Mardivirin L, Valeyrie-Allanore L, Branlant-Redon E, et al. Amoxicillin-induced flare in patients with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro. Eur J Dermatol 2010; 20:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/38\">",
"      Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/39\">",
"      Um SJ, Lee SK, Kim YH, et al. Clinical features of drug-induced hypersensitivity syndrome in 38 patients. J Investig Allergol Clin Immunol 2010; 20:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/40\">",
"      Uhara H, Saiki M, Kawachi S, et al. Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids. J Eur Acad Dermatol Venereol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/41\">",
"      Davern TJ. Drug-induced liver disease. Clin Liver Dis 2012; 16:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/42\">",
"      Eshki M, Allanore L, Musette P, et al. Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure. Arch Dermatol 2009; 145:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/43\">",
"      Chen YC, Chang CY, Cho YT, et al. Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan. J Am Acad Dermatol 2013; 68:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/44\">",
"      Ushigome Y, Kano Y, Ishida T, et al. Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution. J Am Acad Dermatol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/45\">",
"      Bourgeois GP, Cafardi JA, Groysman V, et al. Fulminant myocarditis as a late sequela of DRESS: two cases. J Am Acad Dermatol 2011; 65:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/46\">",
"      Bourgeois GP, Cafardi JA, Groysman V, Hughey LC. A review of DRESS-associated myocarditis. J Am Acad Dermatol 2012; 66:e229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/47\">",
"      Hirsch LJ, Arif H, Nahm EA, et al. Cross-sensitivity of skin rashes with antiepileptic drug use. Neurology 2008; 71:1527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43929/abstract/48\">",
"      Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J 2006; 8:E20.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16420 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-3836C529BC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43929=[""].join("\n");
var outline_f42_57_43929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27761185\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761005\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2153359\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761041\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761048\">",
"      ETIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761056\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H872901\">",
"      HISTOPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761063\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H872883\">",
"      Skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H872928\">",
"      Systemic symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H872951\">",
"      Laboratory abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H872993\">",
"      Organ involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27761078\">",
"      - Liver",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27761085\">",
"      - Kidney",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27761092\">",
"      - Lung",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27761099\">",
"      - Other organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761113\">",
"      CLINICAL COURSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761127\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2711286\">",
"      When to suspect DRESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2711189\">",
"      Assessment of drug causality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1269651\">",
"      Laboratory investigations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1269682\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2711277\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761157\">",
"      DIFFERENTIAL DIAGNOSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H97599699\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23263789\">",
"      Drug withdrawal and supportive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H626586002\">",
"      Patients without severe organ involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H97704236\">",
"      Patients with severe organ involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97704096\">",
"      - Liver involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H97704053\">",
"      - Lung or kidney involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1269162\">",
"      Role of antiviral treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101654720\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52408472\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H873157\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27761185\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/16420\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16420|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/55/30583\" title=\"figure 1\">",
"      Lund and browder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16420|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?25/62/26596\" title=\"picture 1A\">",
"      Dress rash 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/22/42341\" title=\"picture 1B\">",
"      Dress 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/57/10134\" title=\"picture 1C\">",
"      Dress 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?11/30/11745\" title=\"picture 2\">",
"      Erythroderma in Sezary syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/41/4756\" title=\"picture 3A\">",
"      Acute lupus generalized 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/54/14179\" title=\"picture 3B\">",
"      Acute lupus generalized 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/16420|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/56/22411\" title=\"table 1\">",
"      Drugs associated with DRESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/9/32924\" title=\"table 2\">",
"      Burn class chart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?33/6/33899\" title=\"table 3\">",
"      DRESS lab tests and imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/43/28348\" title=\"table 4\">",
"      DRESS scoring system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 5\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/60/42951?source=related_link\">",
"      Acute generalized exanthematous pustulosis (AGEP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/36/27209?source=related_link\">",
"      Clinical manifestations and diagnosis of acute interstitial nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/1/10265?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of human herpesvirus-6 infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/14/34023?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of angioimmunoblastic T cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/31/9722?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38456?source=related_link\">",
"      Drug allergy: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/17/41241?source=related_link\">",
"      Drug eruptions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/4/13385?source=related_link\">",
"      Erythroderma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/50/24360?source=related_link\">",
"      Exanthematous (morbilliform) drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/50/9000?source=related_link\">",
"      Fixed drug eruption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/55/14201?source=related_link\">",
"      Human herpesvirus 7 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/48/3848?source=related_link\">",
"      Lichenoid drug eruption (drug-induced lichen planus)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/33/36378?source=related_link\">",
"      Mucocutaneous manifestations of systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/25/42393?source=related_link\">",
"      Nonspecific interstitial pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33801?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/28/34245?source=related_link\">",
"      Treatment of acute interstitial nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_57_43930="Infusion reactions to systemic chemotherapy";
var content_f42_57_43930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infusion reactions to systemic chemotherapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Ursula A Matulonis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?42/57/43930/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?42/57/43930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all chemotherapeutic agents have the potential to initiate infusion reactions, defined in this review as unexpected reactions that cannot be explained by the known toxicity profile of the drug. The cytotoxic agents that are most commonly associated with infusion reactions are the taxanes, platinum drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    , L-asparaginase,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    . While these are often referred to as \"hypersensitivity reactions\", many do not have an allergic component. Thus, the term infusion reaction is preferred.",
"   </p>",
"   <p>",
"    After an introductory section that summarizes the characteristics of infusion reactions and different approaches to classifying them, this review will focus on commonly used conventional cytotoxic drugs with a moderate to high incidence of infusion reactions, and the ways in which these reactions can be treated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevented. Infusion reactions in patients receiving therapeutic monoclonal antibodies for cancer treatment are discussed separately, as are other cutaneous adverse effects associated with chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=see_link\">",
"     \"Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Signs and symptoms of infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions may affect any organ system in the body. Most are mild in severity, although severe and even fatal reactions occur. The most common signs and symptoms of infusion reactions are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Flushing",
"     </li>",
"     <li>",
"      Itching",
"     </li>",
"     <li>",
"      Alterations in heart rate and blood pressure",
"     </li>",
"     <li>",
"      Dyspnea or chest discomfort",
"     </li>",
"     <li>",
"      Back or abdominal pain",
"     </li>",
"     <li>",
"      Fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shaking chills",
"     </li>",
"     <li>",
"      Nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea",
"     </li>",
"     <li>",
"      Various types of skin rashes",
"     </li>",
"     <li>",
"      Throat tightening",
"     </li>",
"     <li>",
"      Hypoxia",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Dizziness",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      syncope",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this review, infusion reactions involving these symptoms will be referred to as \"standard infusion reactions\" or SIRs. These represent the majority of reactions to systemic chemotherapeutic agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Signs and symptoms of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is a distinct reaction that is rare with most conventional cytotoxic agents, although it is well established that the platinum drugs and the taxanes can cause anaphylaxis. The most common signs and symptoms of anaphylaxis caused by intravenously-administered medications are the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous symptoms: flushing, itching, urticaria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema (usually of face, eyelids, or lips)",
"     </li>",
"     <li>",
"      Respiratory symptoms: repetitive cough, sudden nasal congestion, shortness of breath, chest tightness, wheeze, sensation of throat closure or choking,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      change in voice quality (due to laryngeal edema), hypoxia",
"     </li>",
"     <li>",
"      Cardiovascular symptoms: faintness, tachycardia (or less often bradycardia), hypotension, hypertension",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of consciousness",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms: nausea, vomiting, abdominal cramping,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea",
"     </li>",
"     <li>",
"      Neuromuscular symptoms: sense of impending doom, tunnel vision, dizziness,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seizure, severe back, chest, pelvic pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations of anaphylaxis (from all causes) are presented in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although there is overlap between the clinical features of anaphylaxis and those of SIRs, certain signs and symptoms are highly suggestive of anaphylaxis, and they should be specifically sought when evaluating a patient with an infusion reaction: urticaria, repetitive cough, wheeze, throat",
"    <span class=\"nowrap\">",
"     tightness/change",
"    </span>",
"    in voice, and hypotension. These stereotypical signs and symptoms result from the release of mediators from mast cells and basophils. In contrast, fever and prominent muscular pain are NOT features of anaphylaxis, and the presence of these signs and symptoms suggests the reaction is an SIR.",
"   </p>",
"   <p>",
"    It is critical to undress the patient and examine the skin carefully during infusion reactions in order to fully appreciate skin findings, especially urticaria. The neck, trunk, extremities, abdomen, and axillae are the sites where urticaria often appears first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Timing and risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a group, infusion reactions (including both SIRs and anaphylaxis) usually occur during or within a few hours of drug infusion. Occasionally, a reaction may occur one to two days after administration, and patients must be adequately informed of symptoms to watch for and the appropriate course of action to take if a problem arises. Although they most commonly occur with the first or second drug administration, infusion reactions are unpredictable and can occur at any time despite preventive measures.",
"   </p>",
"   <p>",
"    Attempts to identify patients who are likely to develop an infusion reaction have met with limited success, although infusion reactions are generally more common in the following settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With IV as compared to oral or intraperitoneal administration",
"     </li>",
"     <li>",
"      After multiple cycles of certain agents (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Platinum drugs'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      In patients with a prior infusion reaction to a drug of the same chemical class",
"     </li>",
"     <li>",
"      A history of multiple drug allergies, regardless of drug class",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF INFUSION REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NCI classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent version of the NCI Terminology Criteria for Adverse Events (CTCAE) for grading adverse reactions during chemotherapy administration has a scale for grading the severity of infusion reactions (",
"    <a class=\"graphic graphic_table graphicRef57843 \" href=\"mobipreview.htm?28/31/29179\">",
"     table 1",
"    </a>",
"    ) and separate grading scales for allergic reactions and anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While use of these separate grading scales may be useful for classifying the nature of an infusion reaction for research purposes, they are less useful for clinical care, since it may not be obvious if the patient is having an infusion reaction or an allergic reaction.",
"    <span class=\"nowrap\">",
"     Allergists/immunologists",
"    </span>",
"    have a different approach to classifying infusion reactions, which divides them into reactions with features of mast cell or basophil activation (signifying potential progression to anaphylaxis) and those without such features (ie, SIRs). The severity of the reaction is considered separately. This approach is intended to identify patients at risk for anaphylaxis upon reexposure, regardless of the severity of the initial reaction.",
"   </p>",
"   <p>",
"    Patients with even mild symptoms of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation (eg, urticaria and dyspnea) must be treated with caution, because reexposure to the causative agent could result in a fulminant and severe anaphylaxis. One of the authors (MC) is aware of unpublished cases in which failure to recognize anaphylaxis and manage it appropriately led to fatalities upon reexposure to the causative drug, despite the premedications and reduced infusion rates that would have adequately managed most SIRs.",
"   </p>",
"   <p>",
"    The NCI Common Terminology Criteria include fever as a possible sign of an allergic reaction. Fever is typically not a manifestation of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation, and the prominence of fever during an infusion reaction is more indicative of an SIR. Some monoclonal antibodies can induce fever during an allergic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, oncologists and other specialists working with chemotherapy drugs (eg, rheumatologists) should be familiar with the characteristics of anaphylactic reactions and manage these rare reactions differently from SIRs. We recommend that patients with even mild signs or symptoms of anaphylaxis not be reexposed to the causative agent until they have been evaluated by an allergy specialist with experience in drug allergy and desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/5\">",
"     5",
"    </a>",
"    ]. In particular, these patients should NOT be considered candidates for additional premedication and an attempt at drug readministration using a slower rate of infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Definition of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis was traditionally defined as a constellation of symptoms and signs that arose from an IgE-mediated allergic reaction which resulted in explosive release of vasoactive mediators from mast cells and basophils throughout the body. However, the definition of anaphylaxis has been broadened in recent years to include any reaction that leads to widespread activation of mast cells and basophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/6\">",
"     6",
"    </a>",
"    ]. Anaphylaxis is now diagnosed based upon clinical signs and symptoms (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/7\">",
"     7",
"    </a>",
"    ]. This more inclusive definition emphasizes the common endpoint of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation and the severity of the reactions that can result, and places less importance on the mechanism by which the cells are activated. In addition, clinicians should not equate anaphylaxis with anaphylactic shock, as the latter represents the severe end of a spectrum. The goal should be early recognition and appropriate management of anaphylaxis in its milder forms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All reactions with features of anaphylaxis should be considered potentially severe, because of the tendency of anaphylaxis to recur and worsen with reexposure. As an example, a patient who develops limited urticaria and mild wheezing after receiving a cytotoxic agent should be diagnosed with possible anaphylaxis and should not be considered a candidate for premedication and drug readministration at a slower rate of infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/8\">",
"     8",
"    </a>",
"    ]. Instead, referral to an allergist and use of a desensitization protocol should be pursued. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Agents associated with anaphylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In this topic review, as mentioned previously, anaphylaxis will be referred to as such, and all other infusion reactions will be grouped under the term standard infusion reactions (SIRs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cytotoxic agents implicated in anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis has been best established with the platinum drugs and the taxanes. Anaphylaxis to other cytotoxic agents is rare, although the possibility of anaphylaxis exists with any medication. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Platinum drugs'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H32\">",
"     'Taxanes'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Evaluation of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence that a reaction was anaphylaxis can be obtained from blood tests collected at the time of the reaction and from skin testing, a technique employed by allergy specialists to identify drugs which are capable of causing mast cell activation, especially through IgE-mediated immune mechanisms. These two diagnostic tools are discussed in this section.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum tests that support the diagnosis of anaphylaxis &mdash; Mast cells and basophils contain various chemical mediators that are transiently released into the circulation during anaphylaxis. Some of these are unique to these cell types and, if elevated, can help confirm that the reaction was anaphylaxis.",
"      <br/>",
"      <br/>",
"      The laboratory test that is most useful in this setting is a serum total tryptase level. Tryptase levels usually peak within three hours of the onset of symptoms, so blood should be drawn one to three hours after the reaction occurs. Blood drawn &le; 30 minutes from the onset of symptoms may be falsely negative. Blood can be collected in a standard red top tube and serum should be frozen (at zero degrees Celsius) if it cannot be assayed promptly. Tryptase in frozen serum is stable for up to one year.",
"      <br/>",
"      <br/>",
"      The upper limit of normal for serum total tryptase is approximately 11",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      depending on the assay system. Elevations in anaphylaxis can range from marginally elevated to greater than 100",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      Any elevation in serum tryptase is consistent with anaphylaxis, although a normal tryptase level does not exclude anaphylaxis because tryptase elevations are not seen in all anaphylactic reactions or may have resolved before the blood was collected. The interpretation of tryptase levels in anaphylaxis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If a patient's reaction was suggestive of anaphylaxis but tryptase levels were not elevated, skin testing may still be informative.",
"     </li>",
"     <li>",
"      Skin testing to evaluate anaphylaxis &mdash; Skin testing is a technique used by allergy specialists to determine if a drug is capable of activating mast cells in the skin and therefore potentially able to cause anaphylaxis if administered systemically. The utility of skin testing is best established in the evaluation of reactions to the platinum drugs and may be useful in some patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      reactions (although this is not routine practice). (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Skin testing'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H18018679\">",
"       'Drug versus vehicle'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     USE OF PREMEDICATION TO PREVENT INFUSION REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication can help prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce the severity of infusion reactions, particularly SIRs. In contrast, anaphylaxis is generally not prevented by premedication, although the severity of the reaction may be reduced in some cases.",
"   </p>",
"   <p>",
"    Pharmacologic prophylaxis with antihistamines, glucocorticoids, or both is recommended for certain drugs that have a high incidence of infusion reactions (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     cabazitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    ). However, these regimens have been derived empirically rather than established through randomized trials. Furthermore, they are not completely protective, even for SIRs. Therefore, even with premedication, patients must be monitored closely during and immediately after all chemotherapy infusions. Specific prophylactic regimens that are recommended for individual drugs are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PRINCIPLES OF TREATMENT AND RECHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be prepared for an infusion reaction to occur during each drug administration, and standing orders should be in place to allow immediate intervention if symptoms occur, without waiting for the clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/9\">",
"     9",
"    </a>",
"    ]. Medical equipment and supplies needed for resuscitation (pharmacologic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , antihistamines, intravenous fluids, and aerosolized bronchodilators as well as oxygen, tracheostomy equipment, and a defibrillator) should be readily available in any area where chemotherapy is administered.",
"   </p>",
"   <p>",
"    Treatment of an infusion reaction and possible rechallenge depends upon the type and severity or the reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment of mild to moderate SIRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate SIRs (ie, NCI grades 1 and 2 and infusion reactions that do not involve symptoms of anaphylaxis) are the most commonly-encountered reactions. These can usually be managed with temporary interruption of the infusion and symptom management. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics of reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;After all symptoms have resolved, rechallenge with a reduced infusion rate and additional premedication is usually successful.",
"   </p>",
"   <p>",
"    For patients who have recurrent SIRs despite premedication, desensitization protocols have allowed for continued use of the drug in some cases. Referral to an allergy specialist with experience in drug desensitization is an option for such patients, as a wider range of desensitization techniques can be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment of anaphylaxis and severe SIRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reactions with ANY features of anaphylaxis and severe SIRs (NCI grade 3 or higher) require discontinuation of the drug infusion and immediate treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    and antihistamines.",
"   </p>",
"   <p>",
"    Prompt recognition and treatment are critical in anaphylaxis. In series of fatal anaphylaxis from all causes, death typically ensues within 30 minutes from exposure to the trigger. Detailed guidelines for the management of anaphylaxis are available from the Joint Council of Allergy, Asthma, and Immunology, which are summarized in a rapid overview table for adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ) and children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/7\">",
"     7",
"    </a>",
"    ]. Similar recommendations have been made in the American Heart Association (AHA) Advanced Cardiac Life Support (ACLS) guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial management of anaphylaxis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop the infusion of the suspect medication",
"     </li>",
"     <li>",
"      Placement of the patient in the recumbent position to maintain blood flow to vital organs",
"     </li>",
"     <li>",
"      Intramuscular injection of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      ) in the lateral aspect of the quadriceps muscle",
"     </li>",
"     <li>",
"      Call for help (summon a resuscitation team in the hospital setting, call 911 or an equivalent service in the community setting)",
"     </li>",
"     <li>",
"      Supplemental oxygen",
"     </li>",
"     <li>",
"      Volume resuscitation",
"     </li>",
"     <li>",
"      Intravenous antihistamines (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Rechallenge after a severe SIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a severe SIR (NCI grade 3 or higher), rechallenge is usually discouraged. This is particularly true if the SIR included any symptoms suggestive of an allergic reaction, such as urticaria or angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/8\">",
"     8",
"    </a>",
"    ]. In most cases, the mechanism of severe SIRs is not known, and so it is difficult to predict the best technique for preventing recurrence. If a patient is felt to be a candidate for continuation of therapy because there is potential clinical benefit of further treatment and no other reasonable alternatives exist, then we suggest desensitization, as this technique offers the most graduated and controlled manner of administration. At the author's institution (MC), these reactions are managed in the same manner as anaphylaxis, with uniformly good outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Management after anaphylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management after anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rechallenge should not be attempted for suspected anaphylaxis. The platinum drugs, which are strongly associated with IgE-mediated anaphylactic reactions, cause recurrent reactions upon rechallenge in approximately 50 percent of cases. Instead, we suggest referral to an allergy specialist with experience in drug desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/5\">",
"     5",
"    </a>",
"    ]. With rare exception [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/12\">",
"     12",
"    </a>",
"    ], oncologists lack the expertise to evaluate and manage these patients by themselves.",
"   </p>",
"   <p>",
"    Mast cells and basophils, the cells involved in anaphylaxis, can be temporarily hyporesponsive immediately after a reaction and may be unable to be activated further. This phenomenon has probably contributed to the confusion that currently exists in the medical literature about the safety of rechallenge following severe infusion reactions. However, this phenomenon is unpredictable, and the patient is at high risk for a recurrence of anaphylaxis as soon as the cells have recovered their sensitivity, a process which takes days to weeks. Therefore, we DO NOT recommend that patients be rechallenged after a reaction with symptoms of anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Overview of skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing with most chemotherapy agents is of limited value because the positive and negative predictive values are not known. An important exception to this is skin testing with the platinum drugs, which is useful in the evaluation of infusion reactions with features of allergic reactions. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Platinum drugs'",
"    </a>",
"    below.) One single report of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    skin testing was able to identify a highly reactive patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/13\">",
"     13",
"    </a>",
"    ]. The utility of skin testing for taxane hypersensitivity should still be considered investigational.",
"   </p>",
"   <p>",
"    Skin testing with other chemotherapy drugs is considered investigational. Many chemotherapy agents can cause irritation and necrosis upon extravasation, and these should not be used for skin testing (",
"    <a class=\"graphic graphic_table graphicRef67517 \" href=\"mobipreview.htm?5/53/5981\">",
"     table 5",
"    </a>",
"    ). However, if investigational skin testing with other agents is undertaken and a positive result is obtained, then desensitization should be performed before readministration of the agent if there is no equivalent substitute therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Overview of desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization involves readministration of the implicated drug in a highly controlled manner using a series of sequential steps in which the dose is gradually increased. Desensitization is indicated for infusion reactions that have features of anaphylaxis. The technique can also be applied to severe SIRs that recur despite slower rates of infusion and premedications. Important points regarding this technique include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desensitization is absolutely contraindicated in patients with a history of chemotherapy-induced exfoliative dermatitis, Stevens-Johnson syndrome, or toxic epidermal necrolysis. Reexposure in this setting can induce a fatal recurrence. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"       \"Cutaneous complications of conventional chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Desensitization is not effective in preventing the recurrence of other idiosyncratic immunologic reactions such as serum sickness, hemolytic anemia, or drug fever.",
"     </li>",
"     <li>",
"      Desensitization should only be carried out under close medical supervision by experienced individuals who are comfortable with emergency management of anaphylaxis. In our view, all desensitization protocols should be performed by allergists, although as noted above, there are rare institutions at which experienced oncologists handle desensitization protocols by themselves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug desensitization protocols are based upon stepwise administration of increasing doses of medication, such that exposure begins at very low doses, increases gradually, and is uninterrupted. The protocols presented herein have been performed successfully in published reports, although modifications may be needed in individual cases, and experience with the technique is invaluable. Symptoms during the desensitization procedure are usually mild and occur most often during the final step [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11\">",
"     11",
"    </a>",
"    ]. Clinicians should avoid altering successful protocols to render them faster or significantly change the time interval between doses. Faster protocols may be acceptable for some types of infusion reactions, but are less likely to be successful in patients with IgE-mediated anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/14\">",
"     14",
"    </a>",
"    ]. Therefore, the authors suggest not using abbreviated protocols to desensitize to agents (such as the platinum drugs) in which an IgE-mediated mechanism has been implicated in infusion reactions.",
"   </p>",
"   <p>",
"    Desensitization induces a state of temporary tolerance to a drug that is dependent on continuous exposure. The state of tolerance is lost once the drug is cleared. Therefore,",
"    <strong>",
"     patients must be counseled that they remain allergic to the drug and must be desensitized for each subsequent administration",
"    </strong>",
"    .",
"   </p>",
"   <p>",
"    At some institutions, initial desensitizations are carried out in the medical intensive care unit. If the procedure is well tolerated, subsequent desensitizations can be performed on standard hospital floors or in hospital-associated infusion units with one-on-one nursing, using established policies and procedures, and after appropriate training of the nursing staff on desensitization procedures. Alternatively, the supervising allergist may stratify candidate patients for desensitization by risk. Patients without cardiac complications and with mild initial reactions can be desensitized in outpatient facilities for their first desensitization, under the supervision of the allergist and with one-to-one nursing care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     AGENTS ASSOCIATED WITH ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platinum drugs and the taxanes are the chemotherapeutic agents that most commonly cause anaphylaxis. However, any drug can cause anaphylaxis in a susceptible individual, and reactions with features of anaphylaxis have been reported with asparaginase,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     ixabepilone",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Signs and symptoms of anaphylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PLATINUM DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infusion reactions with the platinum drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) are classic type I IgE-mediated allergic reactions, characterized by pruritus, urticaria, bronchospasm, facial swelling, and hypotension (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 2",
"    </a>",
"    ). Abdominal pain, nausea, vomiting,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diarrhea are also relatively common in platinum drug-induced anaphylaxis.",
"   </p>",
"   <p>",
"    In addition to anaphylaxis, a few cases of type II (immune-mediated hemolytic anemia or thrombocytopenia) and type III reactions (delayed vasculitic urticaria) have been described with platinum drugs (",
"    <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/15-22\">",
"     15-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most centers do not routinely administer premedication before infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    because of the lack of data demonstrating that any premedication regimen successfully prevents infusion reactions. At least with oxaliplatin, the available data regarding benefit from a prophylactic regimen are conflicting:",
"   </p>",
"   <p>",
"    In one series of 272 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , despite the use of a primary prevention regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (8 mg) prior to all treatment cycles (with the addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    after cycle 4), 48 patients (18 percent) developed infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other investigators have suggested benefit from higher doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in conjunction with an H1 plus an H2 receptor blocker [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/24\">",
"     24",
"    </a>",
"    ]. In this retrospective cohort study of 181 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-FU (the FOLFOX regimen) for colon cancer, one cohort received standard premedication (dexamethasone 8 mg plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    ) prior to chemotherapy while a second cohort received higher doses of dexamethasone (20 mg) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    (20 mg) in addition to granisetron, starting with the sixth cycle of chemotherapy. The cohort receiving additional premedication had a lower incidence of hypersensitivity reactions (7 versus 20 percent), and the median number of treatment cycles increased from 9 to 12. Although increased premedication with dexamethasone may decrease the rate of hypersensitivity reactions, patients who react to oxaliplatin need to be skin tested and evaluated for desensitization. Increased premedication does not prevent anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Incidence and characteristics of infusion reactions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Carboplatin and cisplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall incidence of infusion reactions (of all types) with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is approximately 12 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1\">",
"     1",
"    </a>",
"    ]. However, a 42 percent incidence of infusion reactions has been noted in children receiving carboplatin for brain tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of infusion reactions increases with repeated drug exposure. In one study, the incidence of an infusion reaction in women with epithelial ovarian cancer (EOC) who had received seven or more treatment courses was 27 percent versus 1 percent in those receiving fewer courses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A common scenario is a reaction developing after a patient with EOC has completed a first course of therapy (often six cycles of a platinum-containing regimen), and restarted treatment with the same regimen at the time of a disease recurrence. Typically, this corresponds to the seventh to tenth exposure to the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1,11,25-27\">",
"     1,11,25-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=see_link\">",
"     \"First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics of infusion reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    are typical of anaphylaxis, with prominent flushing, urticaria, pruritus, facial swelling, wheezing, chest tightness, dyspnea, abdominal cramping, and hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1,26,28\">",
"     1,26,28",
"    </a>",
"    ]. Patients may report \"not feeling right\" or a sense of impending doom. One series described a case in which isolated chest pain progressing to cardiac arrest was the only detectable symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/29\">",
"     29",
"    </a>",
"    ]. We have had two similar cases referred to our center, in which patients reacted to carboplatin infusions with flushing and syncope followed by cardiac arrest (unpublished data).",
"   </p>",
"   <p>",
"    The incidence of infusion reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is not as well reported. In early trials, incidence rates were between 5 and 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , the incidence is higher in patients who receive a greater number of courses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/32\">",
"     32",
"    </a>",
"    ] and possibly in those undergoing concomitant cisplatin-based chemoradiotherapy, for unclear reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some authors suggest that incidence rates have declined over time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/34\">",
"     34",
"    </a>",
"    ]. Multiple factors may have contributed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Current regimens commonly include pretreatment glucocorticoids as a routine component of the antiemetic regimen, particularly with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=see_link\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In common diseases such as lung cancer, there is an appreciation that patients require fewer cycles of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      to achieve therapeutic end points than the number they may have received in the past. Many patients receive no more than four to six cycles of treatment, which is associated with a lower rate of infusion reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link&amp;anchor=H13#H13\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\", section on 'Duration of therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15801927\">",
"    <span class=\"h4\">",
"     Prophylactic approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;One center described an approach that appeared to",
"    <span class=\"nowrap\">",
"     prevent/delay",
"    </span>",
"    infusions reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    in women",
"    <strong>",
"     without",
"    </strong>",
"    a history of platinum-induced infusion reactions, but who were at high risk because they required retreatment with platinum drugs for relapsed ovarian and related cancers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/35\">",
"     35",
"    </a>",
"    ]. In this retrospective series, patients received carboplatin using a graduated infusion protocol that was essentially a short desensitization (1 percent of the total dose in the first hour, 9 percent in the second hour, and 90 percent in the third hour), combined with premedications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/35\">",
"     35",
"    </a>",
"    ]. Premedications consisted of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    20 mg the night before and again the morning of infusion, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (each 50 mg intravenously) given immediately before infusion. In an analysis of 707 patients treated over a 10-year period in the outpatient setting, the incidence, timing, and severity of infusion reactions in 174 patients given the three-hour protocol with premedication were compared to those of 533 patients who continued to receive the usual 30 minute infusion. Infusion reactions occurred in a lower percentage of patients receiving the three-hour infusion (3.4 versus 11 percent) and the time to first infusion reaction was longer (16 versus 9 treatments).",
"    <br/>",
"    <br/>",
"    Prospective confirmation of these results is needed to assess the true impact of these measures in an unselected high-risk patient population. However, for patients requiring re-exposure to carboplatin for treatment of recurrent ovarian cancer, empiric use of this protocol is an alternative to continuing with a standard 30 minute platinum infusion. This approach has been adopted at a number of institutions. If the patient develops a hypersensitivity reaction with any symptoms suggestive of anaphylaxis despite this approach, rechallenge should not be attempted. Instead, the patient should be referred to an allergist with experience in drug desensitization or to an oncology center that can perform formal desensitizations. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Rechallenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of infusion reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    seems to be increasing over time, perhaps the result of increasing clinical use for colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/23,36,37\">",
"     23,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    infusion reactions may occur within minutes of drug administration and with any cycle of therapy. However, as with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    , the incidence increases with multiple courses of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/17,22,38\">",
"     17,22,38",
"    </a>",
"    ]. Most of the severe reactions represent anaphylaxis.",
"   </p>",
"   <p>",
"    In several large series, acute infusion reactions were reported in 12 to 25 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ; up to one-third were severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/22,23,36,39-41\">",
"     22,23,36,39-41",
"    </a>",
"    ]. In the largest report, 308 of 1224 (25 percent) patients developed symptoms compatible with an oxaliplatin reaction, as verified by the development of similar symptoms on rechallenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/22\">",
"     22",
"    </a>",
"    ]. Most reactions occurred after the first five treatment courses (median nine, range 1 to 24). The reaction was mild in 63 percent, as characterized by pruritus and small area of erythema developing during the infusion or within several hours of receiving treatment; all were able to tolerate continued treatment with additional premedication.",
"   </p>",
"   <p>",
"    The reaction was severe in 37 percent (9 percent of all patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    ) and characterized by diffuse erythroderma, facial swelling, chest tightness, bronchospasm, and change in blood pressure which developed within minutes of drug infusion. Although rechallenge with a lower rate of drug infusion and two to three days of premedication was attempted in all patients, only 48 of the 113 patients (less than one-half) tolerated an additional two to four courses of therapy; the remaining patients required treatment discontinuation because of recurrence of severe reactions. Desensitization was not attempted.",
"   </p>",
"   <p>",
"    Six additional patients in this series developed immune thrombocytopenia or hemolytic anemia after 4 to 18 courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    . Following treatment discontinuation and glucocorticoid treatment, all cases were reversible within two to four weeks. Immune-mediated intravascular hemolysis is reported by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;At least 50 percent of patients who develop an infusion reaction to a platinum agent will react again if rechallenged, even after premedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/25,36-38\">",
"     25,36-38",
"    </a>",
"    ], and fatalities have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Patients with any symptoms suggestive of anaphylaxis should not be rechallenged, but instead, be referred to an allergist with experience in drug desensitization or to an oncology center with similar experience (see below).",
"   </p>",
"   <p>",
"    Rechallenge should be restricted to patients with mild to moderate reactions that do NOT include features of anaphylaxis. However, even mild reactions can escalate to severe reactions, underscoring the need for close monitoring during rechallenge. Rechallenge can be preceded by premedication with glucocorticoids plus an H1- (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , 50 mg) and H2-histamine receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    50 mg) 30 minutes prior to infusion. In addition, a slower infusion rate (over three to six as compared to two hours) should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/23,39\">",
"     23,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Evaluation and management of patients with possible anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving platinum drugs who have infusion reactions with any features of anaphylaxis should not receive further drugs until they have been evaluated by an allergy specialist with experience in drug allergy, skin testing, and desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/5\">",
"     5",
"    </a>",
"    ]. If referral to an experienced allergist is not possible, then the oncologist may either refer the patient to an oncology center with experience in skin testing and desensitization or change the patient's therapy to an alternative agent, if a reasonable alternative exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing protocols have been developed to identify patients who are at risk for platinum-induced anaphylaxis; these have been mainly tested in patients who have received multiple courses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    therapy and are most often performed after the patient has experienced a reaction suggestive of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/28,45-49\">",
"     28,45-49",
"    </a>",
"    ]. Skin testing is usually delayed for two to four weeks after anaphylaxis, since false negative results are possible during this period due to hyporeactivity of cutaneous mast cells. However, testing may be performed sooner if necessary, since positive tests are still meaningful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Skin testing is generally performed by",
"    <span class=\"nowrap\">",
"     allergy/immunology",
"    </span>",
"    specialists, with specific training in the technique, proper interpretation of results, and management of the rare allergic reactions that occur in response to the testing itself. A few oncology centers perform this testing and have acquired some experience with testing for specific drugs, although this is not a widespread practice. The technique of skin testing is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"     \"Overview of skin testing for allergic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patch testing, another form of skin testing that helps predict delayed cutaneous reactions, is not appropriate for the evaluation of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/46,48,50\">",
"     46,48,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergists perform",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    tests first, followed by intradermal tests if the",
"    <span class=\"nowrap\">",
"     prick/puncture",
"    </span>",
"    tests are negative. This is done because prick-puncture testing is less likely to induce a systemic allergic reaction in highly sensitive patients and also less likely to produce false positive, irritant responses. If prick-puncture testing is negative, then intradermal testing is performed. Appropriate positive (eg, histamine) and negative (saline or diluent for the therapeutic agent) must always be included.",
"   </p>",
"   <p>",
"    Some centers perform prick-puncture testing with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    solutions of 10",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    which is equivalent to the concentration at which the drug is infused. If the patient's history suggests extreme sensitivity, prick-puncture testing is performed with lower concentrations first (eg, 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    or lower) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/28,51\">",
"     28,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If prick-puncture testing is positive, then reactivity is confirmed and no further testing is required. If prick-puncture testing is negative, then intradermal testing is performed with 0.02 mL of the drug at a concentration of 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    initially. If this is negative, it is followed by 10",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    although some protocols use maximal concentrations of 3 or 5",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    and the optimal concentration has not been determined. Similar approaches have been described by different groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      skin testing, maximal concentrations of 1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      are used for both prick-puncture testing and intradermal testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      skin testing, maximal concentrations of 3 to 5",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      are used for both prick-puncture testing and intradermal testing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11,52\">",
"       11,52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The utility of skin testing in predicting infusion reactions to the platinum drugs can be illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 126 patients, skin testing with an intradermal injection of 0.02 mL of an undiluted aliquot of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      preparation for infusion was performed 30 minutes prior to each planned dose [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/47\">",
"       47",
"      </a>",
"      ]. All patients had gynecologic malignancies and had received at least six cycles of platinum-based chemotherapy. A positive skin test was defined as a wheal &ge;5 mm in diameter with a surrounding flare (although allergy specialists typically define a positive test as a wheal &ge;3 mm larger than the negative control).",
"      <br/>",
"      <br/>",
"      Thirty-nine patients (31 percent) had a positive skin test. Six of seven patients (86 percent) with a positive skin reaction who elected to proceed with carboplatin infusion developed an infusion reaction, compared to only 7 of 87 (8 percent) who had a negative skin test. Of the 39 patients with positive skin tests, seven others elected to undergo rechallenge using a desensitization protocol, of which six were successful.",
"     </li>",
"     <li>",
"      Another study performed skin tests on 10 patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"      without infusion reactions, four patients who had past infusion reactions to the drug, 15 control patients never exposed to platinum salts, and prior to each course of oxaliplatin in eight patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/49\">",
"       49",
"      </a>",
"      ]. The intradermal test was positive in all four patients with past reactions to oxaliplatin (although only one had a positive skin prick test) and negative in the 10 who had received oxaliplatin without a reaction, as well as all 15 unexposed patients. One of the eight patients had a positive test before the sixth cycle of oxaliplatin and reacted to subsequent oxaliplatin despite the use of a desensitization protocol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that the positive predictive value of skin testing to the platinum drugs is sufficiently high that challenge should not be attempted in patients with a positive prick or intradermal skin test result. Instead, these patients should receive further treatment using a desensitization protocol. While a negative result appears to have a high negative predictive value, some patients with a negative result may still develop a severe reaction after rechallenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7622392\">",
"    <span class=\"h3\">",
"     If skin testing is not available",
"    </span>",
"    &nbsp;&mdash;&nbsp;If evaluation by an allergy specialist is not possible and there is no reasonable alternative drug, then the patient should be assumed to be at risk for anaphylaxis and only receive subsequent doses of the platinum drug in question using a formal desensitization protocol.",
"   </p>",
"   <p>",
"    Desensitization should only be carried out under close medical supervision by experienced individuals who are prepared to deal with the allergic reactions that can occur during the procedure. Most desensitization protocols are carried out by allergists, although some oncology centers perform desensitization and have acquired some experience. Desensitization must be repeated each time the drug is given. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Desensitization protocols'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Desensitization protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical indications and general principles of desensitization are discussed above. As mentioned previously, desensitization induces a temporary state of tolerance and must be repeated each time the patient requires the same drug in the future. (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Overview of desensitization'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Desensitization protocols for platinum drugs have been developed independently by allergists (",
"    <a class=\"graphic graphic_table graphicRef51577 \" href=\"mobipreview.htm?36/45/37598\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11,28,51\">",
"     11,28,51",
"    </a>",
"    ] and by oncologists (",
"    <a class=\"graphic graphic_table graphicRef77173 graphicRef61477 \" href=\"mobipreview.htm?11/3/11325\">",
"     table 8A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1,32,53,54\">",
"     1,32,53,54",
"    </a>",
"    ]. The authors do not suggest using abbreviated protocols for platinum drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/14\">",
"     14",
"    </a>",
"    ], and longer protocols (or more dilute starting solutions) may occasionally be needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/55\">",
"     55",
"    </a>",
"    ]. Although there is less experience, desensitization protocols modeled upon those used for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    have been used successfully to permit continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/21,40,45,56\">",
"     21,40,45,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Cross reactivity among platinum drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cross-allergy between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    exists, but the incidence is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/43\">",
"     43",
"    </a>",
"    ]. Successful retreatment with either cisplatin or carboplatin following the use of a desensitization protocol has been reported in patients who had carboplatin infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/12,57,58\">",
"     12,57,58",
"    </a>",
"    ]. However, one series noted that 23 (96 percent) of 24 patients with infusion reactions to carboplatin tolerated rechallenge with cisplatin without desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/59\">",
"     59",
"    </a>",
"    ], so desensitization may not be necessary if an alternative platinum compound is administered.",
"   </p>",
"   <p>",
"    If a switch to an alternative agent is anticipated, it is the practice of one of the authors (MC) to perform skin testing to the platinum agent that is under consideration and desensitize the patient if the skin test is positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platinum drugs have all been associated with anaphylaxis, particularly after repeated cycles. The overall incidence ranges from 10 to 27 percent and typically occurs after the patient has completed an initial course of treatment, experienced a disease recurrence, and resumed therapy with the same platinum agent, or following at least six to seven cycles of continuous treatment.",
"   </p>",
"   <p>",
"    Routine premedication is not typically administered with any of the platinum agents in the absence of an infusion reaction. However, for patients who will be retreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    for recurrent ovarian cancer, a reasonable approach is to try to",
"    <span class=\"nowrap\">",
"     prevent/delay",
"    </span>",
"    the development of infusion reactions through the use of premedication and a graduated infusion rate, as previously described. (See",
"    <a class=\"local\" href=\"#H15801927\">",
"     'Prophylactic approaches'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Skin testing reliably predicts the majority of anaphylactic reactions to platinum-type drugs, and patients who have a positive skin test should NOT be rechallenged without use of a desensitization protocol. Where local expertise is available, we suggest skin testing in patients who experience a reaction suggestive of anaphylaxis. However, whether skin testing should be used to screen patients before they develop an anaphylactic reaction, and the criteria for selection of patients to be skin tested are unresolved issues. Predictive skin testing is not widely practiced.",
"   </p>",
"   <p>",
"    We suggest that a desensitization protocol be employed for patients with positive skin testing after an infusion reaction to a platinum drug. Desensitization should be repeated each time the patient needs the drug in the future. A patient who is sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    may tolerate the other agent without the need for desensitization. If evaluation by an allergy specialist is not possible, and there is no reasonable alternative drug, then patients with infusion reactions that have any features of anaphylaxis (regardless of severity), patients with severe SIRs, and patients with",
"    <span class=\"nowrap\">",
"     mild/moderate",
"    </span>",
"    SIRs that recurred despite premedication and slower rate should be assumed to be at risk for anaphylaxis and only receive subsequent doses of the platinum drug in question using a formal desensitization protocol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     TAXANES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3596216\">",
"    <span class=\"h2\">",
"     Paclitaxel and docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    are among the most widely used cytotoxic drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Characteristics and incidence of infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, acute reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    are characterized by dyspnea (with or without bronchospasm), urticaria, hypotension (or sometimes hypertension), and an erythematous rash (which may not begin until after the patient has returned home following drug infusion) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/8\">",
"     8",
"    </a>",
"    ]. Severe back, pelvic, chest and abdominal crushing pain may also occur.",
"   </p>",
"   <p>",
"    The clinical characteristics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    -related infusions reactions in a series of 102 cases included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Facial flushing (80 percent),",
"     </li>",
"     <li>",
"      Chest",
"      <span class=\"nowrap\">",
"       discomfort/pain",
"      </span>",
"      (67 percent),",
"     </li>",
"     <li>",
"      Back pain (51 percent)",
"     </li>",
"     <li>",
"      Tachycardia (45 percent)",
"     </li>",
"     <li>",
"      Erythematous rash (36 percent)",
"     </li>",
"     <li>",
"      Hypotension (25 percent)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Pruritus/urticaria",
"      </span>",
"      (20 percent)",
"     </li>",
"     <li>",
"      Facial swelling (18 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With both drugs, symptoms usually develop within the first 10 to 15 minutes of drug infusion, and nearly 95 percent occur during the first or second drug infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/32,61\">",
"     32,61",
"    </a>",
"    ]. The timing of these reactions suggests that they are mediated by a direct release of mast cell mediators such as histamine and tryptase. These reactions can occur with later infusions, even if they have not occurred with previous doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, some patients who do not develop reactions during the infusion develop cutaneous reactions few days up to one week after taxane infusion. These reactions can be the prelude for anaphylactic reactions and need to be evaluated by allergists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H643537181\">",
"    <span class=\"h4\">",
"     Paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;In early trials, acute infusion reactions developed in up to 30 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    and were dose-limiting. After the introduction of methods to diminish the incidence and severity of infusion reactions (eg, prolonging the drug infusion, and premedication with antihistamines and glucocorticoids), the rate of severe reactions was reduced to 2 to 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/61-64\">",
"     61-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With appropriate premedication, the incidence of infusion reactions is approximately the same (1 to 3 percent) whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is administered over 24, three, or one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. However, the incidence may be higher with infusion times under one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/67\">",
"     67",
"    </a>",
"    ]. Even with appropriate premedication, mild reactions (skin rash, flushing) still occur in a substantial number of patients. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Premedication regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H643537195\">",
"    <span class=\"h4\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based upon differences in formulation, it was thought that the rate of infusion reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    would be less than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Mechanisms of infusion reactions'",
"    </a>",
"    below). However, 30 percent of patients receiving docetaxel without premedication developed reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/68\">",
"     68",
"    </a>",
"    ]. Furthermore, even with standard premedication, potentially life-threatening infusion reactions occur in approximately 2 percent of docetaxel-treated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/60,69,70\">",
"     60,69,70",
"    </a>",
"    ]. Docetaxel-related fluid retention, which is not a true infusion reaction, is also discussed below (see",
"    <a class=\"local\" href=\"#H35\">",
"     'Other idiosyncratic reactions'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Mechanisms of infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The taxanes can cause both SIRs and anaphylaxis. To further complicate matters, there is evidence that both the taxane component and the vehicles used to solubilize these agents are capable of causing various types of infusion reactions. Among the proposed mechanisms underlying",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    infusion reactions are complement activation, direct mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation, and classic IgE-mediated anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/71\">",
"     71",
"    </a>",
"    ]. The mechanism underlying acute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    infusion reactions is less well characterized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18018679\">",
"    <span class=\"h4\">",
"     Drug versus vehicle",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is uncertain whether the taxanes themselves or the vehicles in which they are dissolved are responsible for the majority of infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    is formulated in Cremophor, a vehicle that is common to other drugs that cause infusion reactions, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/55/4983?source=see_link\">",
"     teniposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/75\">",
"     75",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    , and vitamin K [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/74\">",
"     74",
"    </a>",
"    ]. Paclitaxel should probably be avoided in patients who have had a severe reaction to one of these drugs (although Abraxane may be used) (see",
"    <a class=\"local\" href=\"#H41\">",
"     'Nab-paclitaxel'",
"    </a>",
"    below). There is some evidence that incomplete mixing of paclitaxel and Cremophor before administration may be at least partly responsible for first exposure reactivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    have been attributed to the vehicle, polysorbate 80, the same vehicle used for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/77\">",
"     77",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H64\">",
"     'Etoposide'",
"    </a>",
"    below). In animal models, polysorbate has been shown to induce histamine release and cause hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/78\">",
"     78",
"    </a>",
"    ]. The package insert for docetaxel lists reactions to other drugs containing polysorbate 80 as a contraindication to administration.",
"   </p>",
"   <p>",
"    However, the drugs themselves may be capable of initiating infusion reactions, independent of the solvent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/13,79\">",
"     13,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, there are multiple potential mechanisms for reactions to the taxane drugs, and this issue remains unresolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Other idiosyncratic reactions",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumonitis &mdash; In addition to the infusion reactions described above, there are multiple reports of acute, bilateral, transient pulmonary infiltrates developing during, within a few hours, or up to two weeks after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      administration. In one case in which the patient was subjected to intense investigation, paclitaxel (and not Cremophor) was judged responsible, and the mechanism appeared to be a cell-mediated (type IV) delayed reactions (",
"      <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/80\">",
"       80",
"      </a>",
"      ]. A similar reaction has been reported rarely with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38344?source=see_link\">",
"       \"Taxane-induced pulmonary toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      &nbsp;and fluid retention &mdash; Unlike",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , docetaxel has been associated with a fluid retention syndrome that is attributed to capillary leakage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/64,81,82\">",
"       64,81,82",
"      </a>",
"      ]. Fluid retention is cumulative.",
"      <br/>",
"      <br/>",
"      Glucocorticoid premedication (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      8 mg twice daily for 24 hours before and 48 hours following each docetaxel dose) reduces the incidence of severe cases of fluid retention from 20 to 6 percent, reduces the number of patients discontinuing treatment because of this adverse effect from 32 to 3 percent, and increases the median cumulative dose to onset of moderate to severe fluid retention from 490",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      to 790",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/34,82,83\">",
"       34,82,83",
"      </a>",
"      ]. Lower doses are needed for weekly treatment (see",
"      <a class=\"local\" href=\"#H36\">",
"       'Premedication regimens'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       Docetaxel",
"      </a>",
"      cutaneous toxicity &mdash; Docetaxel also causes skin toxicity that appears similar to acral erythema [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/84\">",
"       84",
"      </a>",
"      ]. A unique variant, termed fixed erythrodysesthesia plaque, develops as a fixed, solitary plaque proximal to the infusion site that does not involve the palms or soles. It usually resolves with desquamation, leaving hyperpigmentation five to six weeks later.",
"      <br/>",
"      <br/>",
"      These effects are more likely manifestations of direct skin toxicity than infusion reactions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"       \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Premedication regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication with a glucocorticoid reduces but does not eliminate the risk of infusion reactions in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    . At least one fatality despite premedication has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h4\">",
"     Paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;For",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , conventional practice is to administer 20 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    orally 12 and 6 hours prior to drug administration, with H1- and H2- receptor antagonists administered IV 30 minutes prior to drug infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/86\">",
"     86",
"    </a>",
"    ]. Using this approach, the rate of severe infusion reactions is only 1 to 2 percent, compared to 2 to 5 percent without treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/87\">",
"     87",
"    </a>",
"    ]. The nonsedating agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    may be substituted for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    after the first two courses of treatment in the absence of an infusion reaction.",
"   </p>",
"   <p>",
"    Alternative glucocorticoid regimens have been proposed to reduce glucocorticoid exposure. As an example, a single 20 mg dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    plus antihistamines can be administered intravenously 30 minutes prior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/73,88-90\">",
"     73,88-90",
"    </a>",
"    ]. This short course, single dose prophylactic regimen has been widely adopted. However, at least one direct comparison study showed a 10 percent higher rate of infusion reactions with one-dose compared to the two-dose regimen (17.3 versus 7.5 percent, respectively), although the majority were not severe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/65\">",
"     65",
"    </a>",
"    ]. In our view, the two-dose glucocorticoid regimen is preferred unless there are extenuating circumstances.",
"   </p>",
"   <p>",
"    At least some data suggest that prophylactic use of pemirolast, an oral mast cell stabilizing agent, may decrease the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    -induced infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/91\">",
"     91",
"    </a>",
"    ]. However, additional data are required to assess the role of this approach, and oral pemirolast is not available in the United States.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Weekly regimens",
"      </strong>",
"      &mdash; Patients who receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      on a weekly administration schedule have the potential to receive substantial doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ; ongoing glucocorticoid treatment is unnecessary for most [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/34,92,93\">",
"       34,92,93",
"      </a>",
"      ]. One approach is to administer a lower dexamethasone dose (10 mg IV) with an H1 and H2 receptor blocker 30 minutes prior to the first administration of weekly paclitaxel. Glucocorticoid doses can then be safely tapered by weekly 2 mg decrements after the third or fourth week in patients without infusion reactions and then discontinued [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/94\">",
"       94",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h4\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    every three weeks,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (8 mg orally twice a day for three consecutive days) is begun 24 hours before the docetaxel infusion. This regimen is effective for reducing both the",
"    <span class=\"nowrap\">",
"     incidence/severity",
"    </span>",
"    of infusion reactions and fluid retention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Weekly",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      &mdash; The optimal schedule of glucocorticoid administration in patients receiving weekly docetaxel is unclear, and practice is variable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/95\">",
"       95",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      At least two studies reported a low incidence of infusion reactions (3 percent in both studies) with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      8 mg the night before, just prior to, and the evening after the weekly dose (24 mg per week) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/34,96\">",
"       34,96",
"      </a>",
"      ]. Alternatively, a phase II trial of weekly docetaxel in 54 patients with metastatic breast cancer reported no hypersensitivity reactions with a single dose of 8 mg of dexamethasone prior to each weekly dose of docetaxel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/97\">",
"       97",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      However, in at least one other trial, there was a higher incidence of infusion reactions with the first dose of weekly docetaxel when patients were premedicated with a single dose of 10 mg of dexamethasone immediately prior to the infusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/98\">",
"       98",
"      </a>",
"      ]. The authors recommended dexamethasone 8 mg orally twice a day for 24 hours before the docetaxel infusion prior to the first two weekly doses, with a switch to the single dose regimen thereafter if there was no reaction after the first two weekly doses. We agree with this approach.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Test dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Test dosing does not predict which patients will develop initial or recurrent infusion reactions to taxanes and most oncologists do not perform it. \"Screening\" for hypersensitivity to taxanes by means of a test dose (prior to the first dose) was studied in a series of 206 patients receiving an initial dose of either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , 90 of whom received a test dose (1 mg of either paclitaxel or docetaxel administered in 3 mL of normal saline over two to five minutes by IV push, at least 30 minutes after premedications) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/99\">",
"     99",
"    </a>",
"    ]. Of the 22 patients who had an infusion reaction, only one of the five who required hospitalization was from the test dose group. Compared to patients who did not receive a test dose, the severity of the reaction after a test dose was significantly less (1.5 versus 3.3 on a scale of 1 to 4), and there was less need for acute hospitalization. However, others suggest that test doses are unreliable and argue against their routine use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/71\">",
"     71",
"    </a>",
"    ]. Test dosing is not a widely accepted practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients experiencing major infusion reactions have been successfully rechallenged after premedication with high dose glucocorticoids plus H1- and H2-receptor antagonists and taxane administration at a slower infusion rate, with or without desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/32,71,100,101\">",
"     32,71,100,101",
"    </a>",
"    ]. In one series, all eight patients were successfully rechallenged [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/100\">",
"     100",
"    </a>",
"    ]. Clinical indications and general principles of desensitization are discussed above (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Overview of desensitization'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    One study readministered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    to seven patients with past severe reactions and one with a mild reaction, using a protocol of escalating infusion rates, combined with premedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/32\">",
"     32",
"    </a>",
"    ]. The calculated total dose was mixed in 1000 cc, and the infusion was initiated at 3 to 6",
"    <span class=\"nowrap\">",
"     cc/hour,",
"    </span>",
"    and increased by 6",
"    <span class=\"nowrap\">",
"     cc/hour",
"    </span>",
"    every 10 to 15 minutes until reaching a maximum rate of 42",
"    <span class=\"nowrap\">",
"     cc/hour.",
"    </span>",
"    For patients who had only a mild reaction, treatment was initiated at 21",
"    <span class=\"nowrap\">",
"     cc/hour",
"    </span>",
"    for one hour, then if tolerated, the infusion was increased to 42",
"    <span class=\"nowrap\">",
"     cc/hour.",
"    </span>",
"    Seven of the eight patients were successfully treated using this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27068615\">",
"    <span class=\"h3\">",
"     Skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin testing is negative in the majority of patients with infusion reactions to taxanes. The authors previously did not advise skin testing in the routine evaluation of patients with taxane SIRs. However, one of the authors (MC) has now seen several patients with severe taxane infusion reactions with features of anaphylaxis, in whom skin testing was performed and was positive. These patients had reactions involving hypotension, dyspnea with oxygen desaturation, flushing, and severe chest, abdominal, or back pain. One such patient is described in a case report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/13\">",
"     13",
"    </a>",
"    ]. The concentrations used for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    skin testing at the author&rsquo;s clinic are 1",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    for prick-puncture testing. If prick puncture testing is negative, it should be followed by 0.001",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    and then 0.01",
"    <span class=\"nowrap\">",
"     mg/mL",
"    </span>",
"    administered intradermally. If skin test results to any step are positive, the patients should receive any further doses of paclitaxel using a desensitization protocol. If negative, the patient can be rechallenged with premedications and a slower infusion rate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4352965\">",
"    <span class=\"h3\">",
"     Taxane desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with recurrent infusion reactions despite premedication and a slower infusion rate, and for those with symptoms suggestive of anaphylaxis and positive skin test results, desensitization may allow continued taxane administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/60,102\">",
"     60,102",
"    </a>",
"    ]. In one series, 17 patients with documented infusion reactions to taxanes who needed continued treatment underwent a desensitization similar to that used for the platinum drugs (",
"    <a class=\"graphic graphic_table graphicRef51577 \" href=\"mobipreview.htm?36/45/37598\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/102\">",
"     102",
"    </a>",
"    ]. Only five minor reactions were observed in 77 subsequent administrations. In another series, five patients were successfully desensitized with a protocol that began with a 1:100,000 dilution of the standard preparation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/60\">",
"     60",
"    </a>",
"    ]. The mechanism of &ldquo;desensitization&rdquo; in such cases is unclear since the vast majority of studied patients had negative skin tests to the taxanes.",
"   </p>",
"   <p>",
"    Desensitization must be repeated each time the drug is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h4\">",
"     Nab-paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/29/8664?source=see_link\">",
"     Nanoparticle albumin bound paclitaxel",
"    </a>",
"    (nab-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , Abraxane&reg;) does not use Cremophor as the vehicle. Infusion reactions have not been seen in phase I, II, or III studies of nab-paclitaxel, despite the omission of routine premedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. In addition, this formulation can be administered over 30 minutes without the need for special tubing. Although successful use of nab-paclitaxel is reported in patients who experienced paclitaxel-associated infusion reactions in the past [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/106\">",
"     106",
"    </a>",
"    ], one of the authors (MC) has seen two patients who were reactive to both paclitaxel and nab-paclitaxel. Thus, we do not recommend administering a full dose of nab-paclitaxel to patients with past infusion reactions to paclitaxel. Instead, we administer nab-paclitaxel to such patients in the following manner: We give",
"    <span class=\"nowrap\">",
"     1/10",
"    </span>",
"    of the dose and wait 30 minutes, then",
"    <span class=\"nowrap\">",
"     1/4,",
"    </span>",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    and then the rest of the dose, with each step separated by 30 minute intervals. If this process is tolerated, then the patient can receive the next scheduled dose normally. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the risk of an infusion reaction to nab-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    is low, one of the authors (MC) has seen two patients who developed severe infusion reactions involving back pain, dyspnea and desaturation. Desensitization was not attempted because the diluent for Abraxane could not be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3596554\">",
"    <span class=\"h2\">",
"     Cabazitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     Cabazitaxel",
"    </a>",
"    , a semisynthetic taxane derivative, has been associated with infusion reactions, especially during the first and second doses. Symptoms may include generalized",
"    <span class=\"nowrap\">",
"     rash/erythema,",
"    </span>",
"    hypotension and bronchospasm.",
"   </p>",
"   <p>",
"    The overall incidence is unclear. In a phase I study of single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     cabazitaxel",
"    </a>",
"    , in which no patient received premedication, only 2 of 25 patients developed a grade 1 infusion reaction with flushing, dizziness and chest tightness; symptoms did not reoccur on retreatment despite the absence of premedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/107\">",
"     107",
"    </a>",
"    ]. On the other hand, in a phase II study of 71 patients receiving single agent cabazitaxel, and premedicated only with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , four (6 percent) had an infusion reaction, three severe (grade 3 or 4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/108\">",
"     108",
"    </a>",
"    ]. The phase III TROPIC trial of cabazitaxel in men with advanced prostate cancer utilized pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    8 mg, as well as an H1 and H2-receptor blocker, and no infusion reactions were observed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/109\">",
"     109",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=see_link&amp;anchor=H12#H12\">",
"     \"Chemotherapy in castrate-resistant prostate cancer\", section on 'Second-line chemotherapy: cabazitaxel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is unclear whether the infusions reactions seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/47/31478?source=see_link\">",
"     cabazitaxel",
"    </a>",
"    are attributable to the drug or its vehicle, polysorbate 80. The FDA-approved labeling lists reactions to other drugs containing polysorbate 80 (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) as a contraindication to use of cabazitaxel. The drug should be discontinued in the event of a severe reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     ANTHRACYCLINES AND RELATED AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs of the anthracycline class (including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    administered by the intravesical route [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/110,111\">",
"     110,111",
"    </a>",
"    ]) and related agents rarely cause infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/112\">",
"     112",
"    </a>",
"    ]. More often, a localized skin flare (erythema, pruritus, and localized urticaria at or adjacent to the site of drug administration) may follow the first IV infusion of anthracycline drugs, but it does not progress to a generalized reaction. Sometimes, this localized reaction may be confused with drug extravasation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/218?source=see_link\">",
"     \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When infusion reactions occur, signs and symptoms may include flushing, dyspnea, facial edema, headache, chills, back pain, tightness of the chest or throat, presyncope, and hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11,112\">",
"     11,112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of generalized infusion reactions is higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/53/9046?source=see_link\">",
"     liposomal daunorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/13/10458?source=see_link\">",
"     pegylated liposomal doxorubicin",
"    </a>",
"    (9 to 14 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/87,114\">",
"     87,114",
"    </a>",
"    ]) than with free drug. Infusion reactions to liposome-encapsulated formulations may involve a non-IgE-mediated mechanism, possibly directed against the liposomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/115\">",
"     115",
"    </a>",
"    ]. Most reactions are mild, and symptoms resolve when the infusion rate is slowed; for this reason, the initial infusion rate should not exceed 1",
"    <span class=\"nowrap\">",
"     mg/min.",
"    </span>",
"    More severe reactions should be treated as possible anaphylaxis, including reactions that involve more than one organ system (eg, flushing and chest pain, hypotension and dyspnea, other combinations).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Premedication and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both the localized flare reaction and generalized infusion reaction can be successfully blocked by pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/116\">",
"     116",
"    </a>",
"    ]. Reconstitution of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    in saline rather than distilled water seems to decrease the frequency of local flare reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although data are limited, for severe reactions, desensitization using the same protocol employed for the platinum agents and taxanes was reported to be successful in six patients, despite negative skin tests (",
"    <a class=\"graphic graphic_table graphicRef51577 \" href=\"mobipreview.htm?36/45/37598\">",
"     table 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11\">",
"     11",
"    </a>",
"    ]. Desensitization must be repeated each time the drug is given.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized infusion reactions are rare with free",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    but more common with liposomal anthracyclines. A localized skin reaction (flare) may develop around the infusion site, particularly after the first treatment, and usually does not cause generalized symptoms. It must be distinguished from drug extravasation. Recurrent reactions can be lessened by pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and glucocorticoids, by reconstituting the drug in saline, and by limiting the initial infusion rate to &le;1",
"    <span class=\"nowrap\">",
"     mg/min.",
"    </span>",
"    Successful desensitization has been reported for severe reactions, if reasonable therapeutic alternatives are not available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     L-ASPARAGINASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;L-asparaginase, a polypeptide of bacterial origin, is an important component of treatment for acute lymphoblastic leukemia. Hypersensitivity reactions range in severity from localized, transient erythema and rash at the site of injection to acute life-threatening anaphylaxis. The most common symptoms are pain, tenderness, swelling, and erythema at the injection site when given intramuscularly, and dyspnea, bronchospasm, pruritus, skin rash, and urticaria when given intravenously; uncommon symptoms include angioedema, laryngospasm, and hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/9,117\">",
"     9,117",
"    </a>",
"    ]. Most reactions occur within minutes but they can occur one to several hours after administration, or even later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/118\">",
"     118",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169043\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three formulations: the original Escherichia coli (E coli) derivative (Elspar), an Erwinia chrysanthemi (also known as Erwinia carotovora) derivative (Kidrolase, Erwinase), and a form of E coli asparaginase that is attached to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    , Oncaspar), which has a significantly longer half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypersensitivity reactions have been observed in up to 60 percent of patients at some time during therapy with nonpegylated asparaginase, depending on the treatment schedule and concomitant immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. The risk of a reaction appears to be similar with the E coli and Erwinia-derived products (5 to 8 percent per administered dose), and it increases with the number of doses; up to one-third of patients experience an infusion reaction by the fourth dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/50,122-124\">",
"     50,122-124",
"    </a>",
"    ]. An intermittent treatment schedule featuring long periods of absence of asparaginase treatment followed by re-challenge is associated with increased risk of hypersensitivity reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/122\">",
"     122",
"    </a>",
"    ]. This is one of the highest rates reported for chemotherapeutic agents, although less than 10 percent of reactions are \"serious\" (ie, accompanied by hypotension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory distress).",
"   </p>",
"   <p>",
"    Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    is the least immunogenic of the available formulations, infusion reactions still occur in up to 15 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/125-127\">",
"     125-127",
"    </a>",
"    ]. They are typically of lesser severity than seen with the nonpegylated E coli and Erwinia-derived products. Because of this property and because of its long half-life so that it can be given in a more convenient schedule (eg, every other week instead of three times per week), most treatment protocols now use pegaspargase upfront rather than reserving it for patients who develop an infusion reaction to Elspar.",
"   </p>",
"   <p>",
"    Hypersensitivity reactions are related to the production of anti-asparaginase antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/128\">",
"     128",
"    </a>",
"    ]. However, one-third of the patients without clinical hypersensitivity reactions may also develop IgG antibodies that can inactivate asparaginase and hence lead to suboptimal clinical efficacy, a phenomenon commonly referred to as &ldquo;silent inactivation&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/128\">",
"     128",
"    </a>",
"    ]. The presence of IgG antibodies, with or without clinical hypersensitivity, can also lead to increased clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    given concomitantly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/120,129\">",
"     120,129",
"    </a>",
"    ]. IgE anti-asparaginase antibodies have also been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/128,130,131\">",
"     128,130,131",
"    </a>",
"    ]; however, their clinical significance is less certain because of lack of data. Antibody formation is more commonly observed with the nonpegylated products compared with pegylated asparaginase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/117,120,132-134\">",
"     117,120,132-134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine antibody monitoring is not being implemented in current practice, partly because the prognostic impact of finding the antibody is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/135\">",
"     135",
"    </a>",
"    ]. However, antibody testing may be useful in some clinical conditions, such as supporting the clinical diagnosis of hypersensitivity in patients with ambiguous symptoms or signs of allergy during asparaginase therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/128,136\">",
"     128,136",
"    </a>",
"    ]. Some patients with hypersensitivity reactions may have antibodies to the nonprotein PEG moiety (instead of asparaginase) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/137\">",
"     137",
"    </a>",
"    ], and they may respond to native E coli asparaginase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/135\">",
"     135",
"    </a>",
"    ]. However, at this time, antibody testing is not readily available at most institutions and the practice of altering asparaginase therapy based upon antibody testing is not currently widespread.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3169036\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of infusion reactions with any form of asparaginase is also dependent on factors other than drug formulation. The risk is higher in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children have a higher rate than do adults partly because of increased use of asparaginase in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/138,139\">",
"       138,139",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Prior (even remote) exposure to asparaginase [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/9,140\">",
"       9,140",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      IV as compared to intramuscular (IM) or subcutaneous (SC) delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/141\">",
"       141",
"      </a>",
"      ]. With nonpegylated products, up to 45 percent of patients who receive the drug IV will have an infusion reaction, compared to 14 percent with intramuscular (IM) or subcutaneous (SC) delivery. For this reason, the nonpegylated form of the drug is almost always given SC or IM.",
"      <br/>",
"      <br/>",
"      More recent studies with the pegylated formulation have demonstrated comparable toxicity profiles with IV and IM administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/139,142,143\">",
"       139,142,143",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"       pegaspargase",
"      </a>",
"      is licensed for both IV and IM administration.",
"     </li>",
"     <li>",
"      Administration of L-asparaginase alone rather than administration as a part of a multidrug regimen (eg, in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/122\">",
"       122",
"      </a>",
"      ])",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no data on specific premedication regimens or other methods to prevent infusion reactions for patients receiving asparaginase other than to administer it after&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ). However, this approach is not fully protective.",
"   </p>",
"   <p>",
"    Because of the relatively high incidence of infusion reactions,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    should only be administered in a setting where anaphylaxis can be appropriately managed. The clinician must assume that each dose is capable of precipitating an infusion reaction and be prepared to deal with that possibility (ie, IV access,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    immediately available for use). General guidelines for immediate treatment of anaphylaxis in adults and children are outlined in the tables (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Test doses and skin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, administration of a test dose (0.1 mL of a 20",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    solution given SC) before each dose of L-asparaginase was suggested by the manufacturer in order to detect reactivity before administration of the full dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/87\">",
"     87",
"    </a>",
"    ]. However, administration of a test dose is not a reliable way to predict who will have a reaction. Small test doses rarely produce a reaction, and a negative test provides no assurance that an infusion reaction will not occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/122\">",
"     122",
"    </a>",
"    ]. Intradermal skin testing is of no value because of false-negative and false-positive results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/144\">",
"     144",
"    </a>",
"    ]. Therefore, neither test dosing nor skin testing can be routinely recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Options for rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who develop an anaphylactic reaction to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    , continued therapy is possible by switching to the Erwinia formulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/122,124,145,146\">",
"     122,124,145,146",
"    </a>",
"    ]. Cross reactivity is uncommon with the E coli and Erwinia derivatives of asparaginase, because the two are antigenically distinct.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/39/12917?source=see_link\">",
"     Erwinia asparaginase",
"    </a>",
"    was approved in the United States in November 2011. The recommended dose is Erwinia asparaginase 25,000",
"    <span class=\"nowrap\">",
"     IU/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IM X 6 doses on an every other day schedule (including weekends and holidays if possible) for each dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    that is replaced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/147\">",
"     147",
"    </a>",
"    ]. The recommended dose is Erwinia asparaginase 25,000",
"    <span class=\"nowrap\">",
"     IU/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IM X 6 doses on an every other day schedule (including weekends and holidays if possible) for each dose of pegaspargase that is replaced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/148\">",
"     148",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients who develop a reaction despite switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/39/12917?source=see_link\">",
"     Erwinia asparaginase",
"    </a>",
"    , the drug should be omitted from the treatment protocol. In centers where referral to an allergist is possible, desensitization may also be an option.",
"   </p>",
"   <p>",
"    Before",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    became available, a desensitization protocol was commonly used for nonpegylated asparaginase. It begins with premedication and with 1 IU of asparaginase given IV, and doubled the dose every 10 minutes, provided no reaction occurred, until the accumulated total drug amount equaled the planned dose for that day (",
"    <a class=\"graphic graphic_table graphicRef50483 \" href=\"mobipreview.htm?20/6/20589\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/149,150\">",
"     149,150",
"    </a>",
"    ]. A modified desensitization protocol has been developed by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/151\">",
"     151",
"    </a>",
"    ]. Because of the risk of anaphylaxis and the need for close monitoring, this approach should ideally be carried out by an allergist in a medically controlled environment. Desensitization must be repeated each time the drug is given. However, this approach is seldom used in current practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the high incidence of infusion reactions, asparaginase should only be administered in a facility that is capable of treating anaphylaxis if it occurs. Because of the lower immunogenicity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    and the greater convenience of the dosing schedule, this product has largely replaced nonpegylated E coli-derived asparaginase for frontline therapy of ALL. The administration of a test dose or skin testing is",
"    <strong>",
"     not",
"    </strong>",
"    routinely recommended prior to drug administration because of the inability of these tests to identify patients who are at risk for a reaction.",
"   </p>",
"   <p>",
"    There are no data on the utility of pretreatment with glucocorticoids or antihistamines. If a serious hypersensitivity reaction occurs with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/9/42133?source=see_link\">",
"     pegaspargase",
"    </a>",
"    , patients should be switched to the Erwinia product. Recurrent reactions should prompt discontinuation of asparaginase and in this scenario, the patient will be treated with alternative chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h1\">",
"     BLEOMYCIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several idiosyncratic reactions have been described in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    , although most do not appear to be allergic in nature.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 50 and 60 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    have a self-limited mild febrile reaction without any other symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/152\">",
"     152",
"    </a>",
"    ]. The incidence of fever decreases with subsequent doses, particularly if prophylactic antipyretics are administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Hyperpyrexia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    (predominantly for lymphoma) develop a high fever followed by excessive sweating. This may be accompanied by wheezing, mental confusion, anuria, and hypotension. A small number of these patients progress to disseminated intravascular coagulation and die from this complication (fulminant hyperpyrexia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/153-155\">",
"     153-155",
"    </a>",
"    ]. This idiosyncratic reaction may be immediate or delayed several hours to days following the dose. The incidence is highest after the first and second doses.",
"   </p>",
"   <p>",
"    In most cases, this syndrome appears to involve the release of pyrogenic cytokines and resembles the systemic inflammatory response syndrome (SIRS) (",
"    <a class=\"graphic graphic_table graphicRef79464 \" href=\"mobipreview.htm?3/39/3707\">",
"     table 10",
"    </a>",
"    ) more than a typical infusion reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/156\">",
"     156",
"    </a>",
"    ]. The observation that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    did not induce histamine release, tachycardia, or hypotension in a dog model also argues against an IgE-mediated mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics of reactions'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h3\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A test dose (IV injection of &le;2 units of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    followed by monitoring of vital signs every 15 minutes for a minimum of one hour) followed by administration of the remainder of the dose is recommended by the manufacturer prior to the first one to two doses of bleomycin in patients with lymphoma. However, many institutions (including that of the authors) do not do this because of the very low likelihood of a reaction, particularly after pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    . Furthermore, whether a reaction to the test dose implies a contraindication to further bleomycin is unclear. Given that the reaction is almost always seen only after the first or second doses, successful rechallenge is usually possible with premedication.",
"   </p>",
"   <p>",
"    Anecdotal reports suggest that the hyperpyrexia syndrome can be treated with temporary drug discontinuation, hydration, glucocorticoids, antipyretics, and H1-receptor antagonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/154\">",
"     154",
"    </a>",
"    ]. Treating preexisting fever with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    also may increase the patient's \"margin\" for tolerating drug-induced hyperpyrexia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Hypersensitivity pneumonitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    is more often associated with interstitial pneumonia and pulmonary fibrosis, it may cause acute hypersensitivity pneumonitis, presenting as dyspnea, cough, and rash. This syndrome is radiographically and clinically similar to the more common interstitial pneumonitis, except that it occurs at lower cumulative doses, is associated with peripheral eosinophilia, and lung biopsy is more consistent with a hypersensitivity reaction. Drug rechallenge has not consistently produced a recurrence of the syndrome, suggesting that it is not immune-mediated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=see_link\">",
"     \"Bleomycin-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Acute chest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chest pain during infusion may represent another manifestation of acute",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    toxicity, although the mechanism appears to be an acute pleuropericarditis rather than an infusion reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Other rare reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;One fatal case of fulminant angioedema to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/158\">",
"     158",
"    </a>",
"    ]. This reaction was preceded by eosinophilia, developed 48 hours after the end of a course of bleomycin, and involved angioedema and a generalized punctate, hemorrhagic rash that was not responsive to glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     Bleomycin",
"    </a>",
"    infusions are commonly accompanied by a febrile reaction. In approximately 1 percent of patients, mainly those undergoing treatment for lymphoma, high fever may be accompanied by diaphoresis, hypotension, confusion, and wheezing.",
"   </p>",
"   <p>",
"    Fatalities have been reported in patents who develop the hyperpyrexia syndrome. Because of this, a small test dose is recommended prior to the first and second doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    in patients receiving the drug for lymphoma. For patients who develop the hyperpyrexia syndrome, temporary drug discontinuation along with hydration, glucocorticoids, antipyretics, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    is recommended. Most patients can be rechallenged successfully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10520016\">",
"    <span class=\"h1\">",
"     CARFILZOMIB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/24/13702?source=see_link\">",
"     Carfilzomib",
"    </a>",
"    is a second generation proteasome inhibitor that is used in the treatment of multiple myeloma. It is administered at a dose of 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily on days 1, 2, 8, 9, 15, and 16 of the first 28-day cycle, with a dose escalation to 27",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    with the same schedule of administration during cycle 2 and thereafter. In early trials, fever, chills, dyspnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rigors were observed in a small subset of patients during cycle 1 and occasionally during cycle 2. This prompted the recommendation that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (4 mg orally or IV) be administered prior to each dose during cycle 1 and prior to the first of the higher doses during cycle 2. With this low-dose concomitant premedication, however, the incidence of fever and dyspnea during therapy is still high (19 to 28 percent in one phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/159\">",
"     159",
"    </a>",
"    ]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=see_link&amp;anchor=H22222487#H22222487\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Carfilzomib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h1\">",
"     CYTARABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to one-third of patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    for acute myeloid leukemia (most of whom have had prior exposure to the drug) develop a characteristic \"cytarabine syndrome\" within 6 to 12 hours of drug infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/160-164\">",
"     160-164",
"    </a>",
"    ]. This flu-like syndrome consists of fever, rigors, diaphoresis, myalgias, arthralgias, conjunctivitis, a macular skin eruption, and occasionally, hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/165\">",
"     165",
"    </a>",
"    ]. While the etiology is unclear, it is probably related to cytokine release rather than immune-mediated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/163,164\">",
"     163,164",
"    </a>",
"    ], although at least one study reports the presence of circulating immune complexes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/165\">",
"     165",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, IgE-mediated reactions (anaphylaxis with angioedema, urticaria, hypotension) are reported rarely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/166-168\">",
"     166-168",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other types of skin reactions are reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dose-related acral erythema (hand-foot syndrome) is characterized by intense, painful erythema predominantly involving the palms and soles, which may progress to bullae and desquamation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H23#H23\">",
"       \"Cutaneous complications of conventional chemotherapy agents\", section on 'Acral erythema (hand-foot skin reaction)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neutrophilic eccrine hidradenitis is another dermatologic condition that may represent a hypersensitivity reaction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/169\">",
"       169",
"      </a>",
"      ], although it is more likely the result of direct cutaneous drug toxicity. The characteristic skin lesions are erythematous plaques or nodules that may be tender or pruritic. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H28#H28\">",
"       \"Cutaneous complications of conventional chemotherapy agents\", section on 'Neutrophilic eccrine hidradenitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Prevention and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     Cytarabine",
"    </a>",
"    is typically administered as a multi-day regimen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H11#H11\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'High dose cytarabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    prior to and following each day's drug infusion may reduce the frequency of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    syndrome. Glucocorticoids may also be beneficial for both treatment and prevention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/160,163\">",
"     160,163",
"    </a>",
"    ]. Retreatment after cytarabine syndrome can usually be safely accomplished with increased premedication, even in patients with multiple reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/170,171\">",
"     170,171",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Up to one-third of patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    develop a flu-like syndrome consisting of fever, rigors, diaphoresis, myalgias, arthralgias, conjunctivitis, a macular skin eruption, and occasionally, hypotension. Pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , a glucocorticoid, or both may reduce the frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity. Retreatment is generally safe using higher doses of glucocorticoids for premedication.",
"   </p>",
"   <p>",
"    Anaphylaxis following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    administration is rare, and patients with suggestive signs and symptoms should be referred to an allergist with experience in drug desensitization if continued therapy is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h1\">",
"     CYCLOPHOSPHAMIDE AND IFOSFAMIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    has rarely been associated with anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/172-175\">",
"     172-175",
"    </a>",
"    ]. The antigenic compound appears to be the active metabolite rather than the parent compound, which explains why reactions may develop up to 16 hours after drug administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infusion reactions are also reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"     MESNA",
"    </a>",
"    , which may be given with high-dose regimens to prevent hemorrhagic cystitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/175,176\">",
"     175,176",
"    </a>",
"    ]. A desensitization protocol was effective one case report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/174\">",
"     174",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    is rarely reported to cause anaphylaxis; in all cases, it was given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"     MESNA",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/177,178\">",
"     177,178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h1\">",
"     DENILEUKIN DIFTITOX",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    (Ontak&reg;) is a recombinant fusion toxin in which the receptor-binding domain of native diphtheria toxin is replaced by sequences encoding the interleukin-2 (IL-2) gene. Once bound to the IL-2 receptor (CD25, which is expressed by a large number of cutaneous T-cell lymphomas), the fusion toxin is internalized and proteolytically cleaved in the cytosol, where the diphtheria toxin inhibits protein synthesis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome\", section on 'Denileukin diftitox'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute infusion-related events are frequent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/179,180\">",
"     179,180",
"    </a>",
"    ], and there have been postmarketing reports of death during infusion. Symptoms are described as flu-like with chills, fever, asthenia, arthralgias, hypotension, back pain, myalgias, and headache.",
"   </p>",
"   <p>",
"    In a pivotal phase III trial, acute infusion-related events developed during or within one hour of drug infusion in 60 percent of patients treated for cutaneous T-cell lymphoma (CTCL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/179\">",
"     179",
"    </a>",
"    ]. Symptoms included hypotension (17 percent), dyspnea (20 percent), chest",
"    <span class=\"nowrap\">",
"     pain/tightness",
"    </span>",
"    (13 percent), back pain (17 percent), pruritus (13 percent), and flushing of the face",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    upper body (13 percent).",
"   </p>",
"   <p>",
"    In all cases, the reaction was managed by temporarily interrupting or decreasing the rate of the infusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    by administration of antihistamines or glucocorticoids. Pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and antihistamine was encouraged for subsequent doses (which might explain, at least in part, the lower incidence of adverse effects after the first two doses). Two patients whose acute infusion-related back pain responded to glucocorticoids were subsequently pretreated with a glucocorticoid, without a recurrence of the reaction.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     Denileukin diftitox",
"    </a>",
"    also has a black box warning for a severe, potentially fatal capillary leak syndrome, which develops typically between day 1 and day 14 of drug administration. The clinical presentation and treatment of capillary leak syndrome is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/426?source=see_link\">",
"     \"Idiopathic systemic capillary leak syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h2\">",
"     Premedication",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manufacturer's label recommends premedication with antihistamine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    prior to each infusion of the drug. However, at least some data suggest that routine premedication with a glucocorticoid also decreases both infusion-related events and the edema associated with vascular leak syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/181\">",
"     181",
"    </a>",
"    ]. Of the 15 patients who received pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20 mg or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    8 mg in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    in this trial, only three had an infusion reaction (20 percent), all in the first cycle of therapy, and only two developed vascular leak syndrome. Disease response was not compromised.",
"   </p>",
"   <p>",
"    Furthermore, a phase II trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/57/918?source=see_link\">",
"     denileukin diftitox",
"    </a>",
"    in 41 patients with advanced non-small cell lung cancer, all of whom received pretreatment",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , reported no acute infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/182\">",
"     182",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most clinicians who treat mycosis fungoides pretreat, at least for the first two courses, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    . One commonly used regimen is dexamethasone 8 mg the night before, and again the morning of each dose for the first cycle. If there are no reactions, the dose can be decreased to 4 mg for each dose for the second course, and then if no reactions, discontinuation of dexamethasone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h1\">",
"     ETOPOSIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 to 3 percent of patients who receive intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    develop angioedema, chest discomfort, bronchospasm,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension, usually within minutes of starting the drug infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/183,184\">",
"     183,184",
"    </a>",
"    ]. Although the mechanism is unclear, the clinical pattern is consistent with anaphylaxis.",
"   </p>",
"   <p>",
"    The reaction is thought due to the vehicle rather than the drug. The vehicle, polysorbate-80, is the same as that used for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H34\">",
"     'Mechanisms of infusion reactions'",
"    </a>",
"    above). Additional support for this hypothesis is provided by the lack of allergic reactions in patients receiving oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    , which does not contain polysorbate-80. However, there are at least two case reports of hypersensitivity reactions with an alternative formulation of etoposide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/8/15495?source=see_link\">",
"     etoposide phosphate",
"    </a>",
"    , which does not contain polysorbate-80 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/185\">",
"     185",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    hypersensitivity may be managed by pretreatment with a glucocorticoid and antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/169,186\">",
"     169,186",
"    </a>",
"    ], several reports indicate that switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/8/15495?source=see_link\">",
"     etoposide phosphate",
"    </a>",
"    is safe in patients who develop an infusion reaction with IV etoposide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/187,188\">",
"     187,188",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h1\">",
"     IXABEPILONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is a microtubule inhibitor in the epothilone class that has been approved for treatment of patients with metastatic breast cancer. Like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    , it is formulated in Cremophor. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Single agent chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infusion reactions, including anaphylaxis, are reported in approximately 1 percent of patients.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is",
"    <strong>",
"     contraindicated",
"    </strong>",
"    in patients with prior reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in Cremophor. As with the taxanes, treatment with ixabepilone requires premedication with glucocorticoids and H1 as well as H2-receptor antagonists approximately one hour prior to chemotherapy administration. (See",
"    <a class=\"local\" href=\"#H36\">",
"     'Premedication regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H66\">",
"    <span class=\"h1\">",
"     METHOTREXATE AND PEMETREXED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/189\">",
"     189",
"    </a>",
"    ]. Patients with recurrent reactions for whom other therapeutic options are not available may benefit from a desensitization protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/190-192\">",
"     190-192",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infusion reactions are also rare with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    , although at least one case of urticarial vasculitis has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/193\">",
"     193",
"    </a>",
"    ]. Early studies noted a high rate of maculopapular skin rash with pemetrexed (15 percent overall, severe in approximately 1 percent). Both the incidence and severity of skin rash have been reduced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    premedication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link&amp;anchor=H30#H30\">",
"     \"Cutaneous complications of conventional chemotherapy agents\", section on 'Exanthematous (morbilliform) rashes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67\">",
"    <span class=\"h1\">",
"     PROCARBAZINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     Procarbazine",
"    </a>",
"    , an oral agent used in the treatment of Hodgkin lymphoma and brain tumors, has been associated with several different patterns of infusion reactions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common is characterized by a diffuse, pruritic, erythematous maculopapular rash, but urticaria and angioedema, and high fever have also been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/9,157,194\">",
"       9,157,194",
"      </a>",
"      ]. The true incidence of these various reactions is uncertain, but seems higher among patients treated for brain tumors (30 to 50 percent versus 5 to 10 percent in patients with Hodgkin lymphoma) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/195-197\">",
"       195-197",
"      </a>",
"      ]. One reason may be the concomitant use of cytochrome (CYP 3A)-enhancing anticonvulsants (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ) in such patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/198\">",
"       198",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum sickness-like reactions (Gell and Coombs immunologic reaction type III) are rare (",
"      <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/195,199-201\">",
"       195,199-201",
"      </a>",
"      ]. These cases are characterized by the delayed onset of cough, arthralgias, and rash; evaluation typically reveals an interstitial pneumonitis and peripheral blood eosinophilia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/199,202,203\">",
"       199,202,203",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"       Procarbazine",
"      </a>",
"      withdrawal and glucocorticoid therapy may improve symptoms, but rechallenge is usually unsuccessful (see below).",
"     </li>",
"     <li>",
"      Other cutaneous disorders include toxic epidermal necrolysis and fixed drug eruptions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/204\">",
"       204",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"       \"Cutaneous complications of conventional chemotherapy agents\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68\">",
"    <span class=\"h2\">",
"     Treatment and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no reliable way to predict which patients will have infusion reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     procarbazine",
"    </a>",
"    . Since many patients develop reactions despite receiving glucocorticoids as part of their lymphoma regimen, it is unlikely that prophylaxis with additional doses of glucocorticoids will be beneficial. In the few available reports, rechallenge has been unsuccessful, even with concomitant glucocorticoids and antihistamines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/9,157,194,201\">",
"     9,157,194,201",
"    </a>",
"    ] and may result in life-threatening symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/195\">",
"     195",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/45/24279?source=see_link\">",
"     Procarbazine",
"    </a>",
"    infusion reactions are rare and cannot be predicted. Rechallenge is usually unsuccessful, even with premedication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70\">",
"    <span class=\"h1\">",
"     TEMSIROLIMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     Temsirolimus",
"    </a>",
"    is a specific inhibitor of the mammalian target of rapamycin (mTOR) and is the first agent of this drug class to be used clinically for the treatment of renal cell cancer (RCC). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=see_link\">",
"     \"Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although allergic reactions are described, their nature and severity are poorly documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/205-207\">",
"     205-207",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a phase II trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      as a single agent in advanced RCC, six patients (8 percent) had an \"allergic reaction\" but the specific symptoms, severity, and management were not described [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/205\">",
"       205",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The final report of a phase III trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      versus interferon versus both drugs in the treatment of advanced RCC did not note any grade 3 or 4 allergic reactions in patients receiving temsirolimus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/206\">",
"       206",
"      </a>",
"      ]. However, unpublished observations indicate that 5 percent of patients had an allergic reaction, none severe [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/207\">",
"       207",
"      </a>",
"      ]. Reported symptoms were flushing, sensation of warmth, and headache.",
"     </li>",
"     <li>",
"      The FDA-approved manufacturer's brochure also lists anaphylaxis, dyspnea, and chest discomfort as potential symptoms of an allergic reaction, but does not specify their incidence or severity.",
"     </li>",
"     <li>",
"      Reactions may be attributed to the drug or its vehicle, polysorbate 80, an agent that has been associated with infusion reactions with other drugs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The manufacturer recommends pretreatment with an H1 receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) before the start of each infusion and avoidance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    in patients who have had a history of hypersensitivity to the related drug",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Guidelines for management of an infusion reaction include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop the infusion and observe the patient for at least 30 to 60 minutes.",
"     </li>",
"     <li>",
"      At the clinician's discretion, treatment may be resumed with the administration of an H1 receptor antagonist, if not previously administered,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an H2-receptor blocker (IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"      20 mg or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      50 mg) approximately 30 minutes before restarting the infusion. The infusion may be resumed at a slower rate (up to 60 minutes).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all chemotherapeutic agents have the potential to initiate infusion reactions. Certain drugs, most commonly the platinum agents and taxanes, are associated with anaphylaxis, a type of reaction that arises from sudden and widespread activation of mast cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophils. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Infusion reactions range in severity from mild pruritus and flushing to life-threatening hypotension and bronchospasm. Most reactions are mild and occur during or within one hour of drug administration. Infusion reactions may occur after the first or any subsequent course of therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics of reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The NCI-CTC system of classifying infusion reactions is based upon severity. However, allergists have a different approach, which emphasizes the differentiation of anaphylaxis from all other types of infusion reactions (ie, SIRs). Although there is some overlap with symptoms of SIR, characteristic symptoms of anaphylaxis include urticaria, wheezing, hypotension, and gastrointestinal symptoms, but not fever. The distinction between anaphylaxis and other reactions is emphasized because anaphylaxis is likely to recur despite premedication and can typically become more severe upon reexposure, regardless of the severity of the initial symptoms. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Classification of infusion reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication can help prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce the severity of infusion reactions, although it is less effective in preventing anaphylaxis. Specific premedication regimens for individual agents are addressed in the individual sections above. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Use of premedication to prevent infusion reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Even in patients who receive premedication, clinicians must be prepared for an infusion reaction to occur during each drug administration. Standing orders should be in place to allow immediate intervention without waiting for the clinician to arrive. Medical equipment and supplies needed for resuscitation (including pharmacologic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"     epinephrine",
"    </a>",
"    , antihistamines, and aerosolized bronchodilators as well as oxygen, tracheostomy equipment, and a defibrillator) should be readily available in any area where chemotherapy is administered. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Principles of treatment and rechallenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of skin testing to screen patients before they develop an infusion reaction remains uncertain, and most institutions do not routinely perform skin tests to predict the likelihood of a reaction to any agent. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Skin testing'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H40\">",
"     'Rechallenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73\">",
"    <span class=\"h2\">",
"     Immediate treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate management is tailored to the clinical situation. The following represent general guidelines for management of a patient who is suspected of having an infusion reaction to a chemotherapeutic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74\">",
"    <span class=\"h3\">",
"     Mild to moderate SIRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the reaction is limited to mild or moderate symptoms of SIR (grades 1 or 2), without features suggestive of anaphylaxis, drug infusion should be temporarily stopped and assessment of airway, breathing, circulation, and mentation accomplished rapidly. IV administration of 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    may provide symptomatic relief. Once symptoms have resolved, resumption of the drug infusion at a slowed rate may permit treatment continuation with close monitoring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75\">",
"    <span class=\"h3\">",
"     Severe SIR or anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe SIRs (grades 3 or 4) or reactions with any features of anaphylaxis (eg, generalized urticaria, wheezing, hypotension, and angioedema) require prompt recognition and treatment. In fatal anaphylaxis, death typically ensues within 30 minutes from exposure to the trigger. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment of anaphylaxis and severe SIRs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Initial management of anaphylaxis is summarized in a rapid overview table for adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ) and children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    ), and includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediately discontinue drug infusion",
"     </li>",
"     <li>",
"      Place the patient in the supine position with legs elevated (if tolerated)",
"     </li>",
"     <li>",
"      Assess airway, breathing, circulation, and adequacy of mentation",
"     </li>",
"     <li>",
"      Call for help (summon a resuscitation team in the hospital setting, call 911 or an equivalent service in the community setting)",
"     </li>",
"     <li>",
"      Administer intramuscular",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/63/35824?source=see_link\">",
"       epinephrine",
"      </a>",
"      into the anterolateral thigh (0.3 to 0.5 mg aqueous epinephrine, 1:1000 dilution)",
"     </li>",
"     <li>",
"      Establish IV access with two 14 to 16 gauge catheters",
"     </li>",
"     <li>",
"      Administer both an H1- (eg, 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ) and an H2- (eg, 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ) antihistamine IV",
"     </li>",
"     <li>",
"      Systemic administration of a glucocorticoid (eg, 125 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      IV) may not help acutely, although it may prevent a prolonged or recurrent reaction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rapid recognition and treatment of anaphylaxis is covered in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76\">",
"    <span class=\"h2\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the acute event has subsided, the issue of rechallenge needs to be addressed. The decision to attempt retreatment depends upon the drug, the severity of the reaction, the cancer being treated and the intent of treatment (ie, potentially curative or palliative), and whether there are reasonable treatment alternatives. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Principles of treatment and rechallenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the reaction was mild or moderate (NCI grades 1 or 2)",
"      <strong>",
"       and lacking",
"      </strong>",
"      signs or symptoms to suggest anaphylaxis, rechallenge is often possible with premedication (glucocorticoids, antihistamines) and a slower rate of infusion.",
"     </li>",
"     <li>",
"      For severe SIRs (NCI grade 3 or higher) and any reactions with symptoms of anaphylaxis, retreatment should not be attempted. Instead, we suggest referral to an allergy or oncology center with experience in drug desensitization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/32,155\">",
"       32,155",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Skin testing is helpful in the evaluation of severe SIRs to platinum drugs. Preliminary evidence suggests that it may also be helpful in patients with SIRs to taxanes that have features of anaphylaxis, although it cannot yet be considered a routine component of the evaluation of taxane reactions. If skin testing is positive, then the patient should not be rechallenged. If there is no equivalent substitute drug, then such patients should be given that medication only through desensitization in the future. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Overview of skin testing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Overview of desensitization'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization protocols have been developed at centers with expertise in drug allergy, and they have been most successfully applied to taxanes and platinum drugs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?42/57/43930/abstract/32,160\">",
"     32,160",
"    </a>",
"    ]. However, experience with desensitization is not widespread, and the success of these protocols in other settings has not been reported. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Platinum drugs'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H32\">",
"     'Taxanes'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Desensitization should only be carried out under close medical supervision by experienced individuals who are prepared to deal with emergency management of anaphylaxis. Most, if not all desensitization protocols are performed by allergists. Desensitization must be repeated each time the patient requires the drug in the future.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/1\">",
"      Markman M, Kennedy A, Webster K, et al. Clinical features of hypersensitivity reactions to carboplatin. J Clin Oncol 1999; 17:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/2\">",
"      Gomes ER, Demoly P. Epidemiology of hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2005; 5:309.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) available online at file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/4\">",
"      Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259.",
"     </a>",
"    </li>",
"    <li>",
"     Academic centers in the United States and Europe with departments of Allergy and Immunology are likely to have such experience. In the United States, these centers include Brigham and Women's Hospital, John's Hopkins, the Mayo Clinic, Massachusetts General Hospital, National Institutes of Health, University of California and Los Angeles, Scripps Clinic, and University of Texas (Southwestern Medical Center).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/6\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/7\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/8\">",
"      A fatal anaphylactic reaction to paclitaxel is described, which was preceded by a possible delayed reaction to the initial infusion. Allergy Asthma Proc 2011; 32:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/9\">",
"      Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/10\">",
"      2005 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2005; 112:IV-143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/11\">",
"      Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/12\">",
"      Markman M, Hsieh F, Zanotti K, et al. Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions. J Cancer Res Clin Oncol 2004; 130:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/13\">",
"      Prieto Garc&iacute;a A, Pineda de la Losa F. Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 2010; 20:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/14\">",
"      Gastaminza G, de la Borbolla JM, Goikoetxea MJ, et al. A new rapid desensitization protocol for chemotherapy agents. J Investig Allergol Clin Immunol 2011; 21:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/15\">",
"      Cinollo G, Dini G, Franchini E, et al. Positive direct antiglobulin test in a pediatric patient following high-dose cisplatin. Cancer Chemother Pharmacol 1988; 21:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/16\">",
"      Marani TM, Trich MB, Armstrong KS, et al. Carboplatin-induced immune hemolytic anemia. Transfusion 1996; 36:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/17\">",
"      Thomas RR, Quinn MG, Schuler B, Grem JL. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer 2003; 97:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/18\">",
"      Desrame J, Broustet H, Darodes de Tailly P, et al. Oxaliplatin-induced haemolytic anaemia. Lancet 1999; 354:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/19\">",
"      de Vries RS, Mattijssen EJ, van Sorge AA. Serious delayed hypersensitivity reaction to oxaliplatin. Ann Oncol 2006; 17:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/20\">",
"      Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clin Colorectal Cancer 2005; 5:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/21\">",
"      Meyer L, Zuberbier T, Worm M, et al. Hypersensitivity reactions to oxaliplatin: cross-reactivity to carboplatin and the introduction of a desensitization schedule. J Clin Oncol 2002; 20:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/22\">",
"      Polyzos A, Tsavaris N, Gogas H, et al. Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience. Oncology 2009; 76:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/23\">",
"      Suenaga M, Mizunuma N, Shinozaki E, et al. Management of allergic reactions to oxaliplatin in colorectal cancer patients. J Support Oncol 2008; 6:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/24\">",
"      Kidera Y, Satoh T, Ueda S, et al. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. Int J Clin Oncol 2011; 16:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/25\">",
"      Lafay-Cousin L, Sung L, Carret AS, et al. Carboplatin hypersensitivity reaction in pediatric patients with low-grade glioma: a Canadian Pediatric Brain Tumor Consortium experience. Cancer 2008; 112:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/26\">",
"      Polyzos A, Tsavaris N, Kosmas C, et al. Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology 2001; 61:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/27\">",
"      Navo M, Kunthur A, Badell ML, et al. Evaluation of the incidence of carboplatin hypersensitivity reactions in cancer patients. Gynecol Oncol 2006; 103:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/28\">",
"      Lee CW, Matulonis UA, Castells MC. Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol 2004; 95:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/29\">",
"      Gadducci A, Tana R, Teti G, et al. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int J Gynecol Cancer 2008; 18:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/30\">",
"      Cheng E, Cvitkovic E, Wittes RE, Golbey RB. Germ cell tumors (II): VAB II in metastatic testicular cancer. Cancer 1978; 42:2162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/31\">",
"      Gralla RJ, Casper ES, Kelsen DP, et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/32\">",
"      Robinson JB, Singh D, Bodurka-Bevers DC, et al. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies. Gynecol Oncol 2001; 82:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/33\">",
"      Koren C, Yerushalmi R, Katz A, et al. Hypersensitivity reaction to cisplatin during chemoradiation therapy for gynecologic malignancy. Am J Clin Oncol 2002; 25:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/34\">",
"      Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/35\">",
"      O'Cearbhaill R, Zhou Q, Iasonos A, et al. The prophylactic conversion to an extended infusion schedule and use of premedication to prevent hypersensitivity reactions in ovarian cancer patients during carboplatin retreatment. Gynecol Oncol 2010; 116:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/36\">",
"      Siu SW, Chan RT, Au GK. Hypersensitivity reactions to oxaliplatin: experience in a single institute. Ann Oncol 2006; 17:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/37\">",
"      Lee MY, Yang MH, Liu JH, et al. Severe anaphylactic reactions in patients receiving oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 2007; 15:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/38\">",
"      Kim BH, Bradley T, Tai J, Budman DR. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology 2009; 76:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/39\">",
"      Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 2003; 89:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/40\">",
"      Gowda A, Goel R, Berdzik J, et al. Hypersensitivity Reactions to oxaliplatin: incidence and management. Oncology (Williston Park) 2004; 18:1671.",
"     </a>",
"    </li>",
"    <li>",
"     Kim BH, Bradley TP, Tai JY, Budman DR. Five-year analysis of hypersensitivity reactions to oxaliplatin: Determination of incidence and identification of risk factors (abstract). J Clin Oncol 2008; 26:121s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/42\">",
"      Ulusakarya A, Misra S, Haydar M, et al. Acute renal failure related to oxaliplatin-induced intravascular hemolysis. Med Oncol 2010; 27:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/43\">",
"      Dizon DS, Sabbatini PJ, Aghajanian C, et al. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol 2002; 84:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/44\">",
"      Zweizig S, Roman LD, Muderspach LI. Death from anaphylaxis to cisplatin: a case report. Gynecol Oncol 1994; 53:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/45\">",
"      Herrero T, Tornero P, Infante S, et al. Diagnosis and management of hypersensitivity reactions caused by oxaliplatin. J Investig Allergol Clin Immunol 2006; 16:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/46\">",
"      Zanotti KM, Rybicki LA, Kennedy AW, et al. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J Clin Oncol 2001; 19:3126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/47\">",
"      Markman M, Zanotti K, Peterson G, et al. Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity. J Clin Oncol 2003; 21:4611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/48\">",
"      Leguy-Seguin V, Jolimoy G, Coudert B, et al. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity. J Allergy Clin Immunol 2007; 119:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/49\">",
"      Pagani M, Bonadonna P, Senna GE, Antico A. Standardization of skin tests for diagnosis and prevention of hypersensitivity reactions to oxaliplatin. Int Arch Allergy Immunol 2008; 145:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/50\">",
"      Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr Allergy Asthma Rep 2008; 8:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/51\">",
"      Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/52\">",
"      Garufi C, Cristaudo A, Vanni B, et al. Skin testing and hypersensitivity reactions to oxaliplatin. Ann Oncol 2003; 14:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/53\">",
"      Rose PG, Fusco N, Smrekar M, et al. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol 2003; 89:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/54\">",
"      Broome CB, Schiff RI, Friedman HS. Successful desensitization to carboplatin in patients with systemic hypersensitivity reactions. Med Pediatr Oncol 1996; 26:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/55\">",
"      Choi J, Harnett P, Fulcher DA. Carboplatin desensitization. Ann Allergy Asthma Immunol 2004; 93:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/56\">",
"      Rosique-Robles D, Vicent Verge JM, Borr&aacute;s-Blasco J, et al. Successful desensitization protocol for hypersensitivity reactions caused by oxaliplatin. Int J Clin Pharmacol Ther 2007; 45:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/57\">",
"      Jones R, Ryan M, Friedlander M. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecol Oncol 2003; 89:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/58\">",
"      Kandel MJ, Loehr A, Harter P, et al. Cisplatinum rechallenge in relapsed ovarian cancer patients with platinum reinduction therapy and carboplatin hypersensitivity. Int J Gynecol Cancer 2005; 15:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/59\">",
"      Callahan MB, Lachance JA, Stone RL, et al. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer. Am J Obstet Gynecol 2007; 197:199.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/60\">",
"      Syrigou E, Dannos I, Kotteas E, et al. Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 2011; 156:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/61\">",
"      Weiss RB. Hypersensitivity reactions. Semin Oncol 1992; 19:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/62\">",
"      Wiernik PH, Schwartz EL, Strauman JJ, et al. Phase I clinical and pharmacokinetic study of taxol. Cancer Res 1987; 47:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/63\">",
"      Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol 2000; 27:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/64\">",
"      Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 1996; 14:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/65\">",
"      Kwon JS, Elit L, Finn M, et al. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol Oncol 2002; 84:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/66\">",
"      Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/67\">",
"      Tsavaris NB, Kosmas C. Risk of severe acute hypersensitivity reactions after rapid paclitaxel infusion of less than 1-h duration. Cancer Chemother Pharmacol 1998; 42:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/68\">",
"      Schrijvers D, Wanders J, Dirix L, et al. Coping with toxicities of docetaxel (Taxotere). Ann Oncol 1993; 4:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/69\">",
"      Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002; 70:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/70\">",
"      Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/71\">",
"      Price KS, Castells MC. Taxol reactions. Allergy Asthma Proc 2002; 23:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/72\">",
"      Ardavanis A, Tryfonopoulos D, Yiotis I, et al. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 2004; 15:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/73\">",
"      Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/74\">",
"      Szebeni J, Muggia FM, Alving CR. Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 1998; 90:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/75\">",
"      O'Dwyer PJ, King SA, Fortner CL, Leyland-Jones B. Hypersensitivity reactions to teniposide (VM-26): an analysis. J Clin Oncol 1986; 4:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/76\">",
"      Liau-Chu M, Theis JG, Koren G. Mechanism of anaphylactoid reactions: improper preparation of high-dose intravenous cyclosporine leads to bolus infusion of Cremophor EL and cyclosporine. Ann Pharmacother 1997; 31:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/77\">",
"      Fossella FV, Lee JS, Murphy WK, et al. Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/78\">",
"      Eschalier A, Lavarenne J, Burtin C, et al. Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 1988; 21:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/79\">",
"      Essayan DM, Kagey-Sobotka A, Colarusso PJ, et al. Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 1996; 97:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/80\">",
"      Fujimori K, Yokoyama A, Kurita Y, et al. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/81\">",
"      Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16:3426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/82\">",
"      Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/83\">",
"      Burris HA. Optimal use of docetaxel (Taxotere): maximizing its potential. Anticancer Drugs 1996; 7 Suppl 2:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/84\">",
"      Zimmerman GC, Keeling JH, Burris HA, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 1995; 131:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/85\">",
"      Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Cancer 2004; 90:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/86\">",
"      Bookman MA, Kloth DD, Kover PE, et al. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Semin Oncol 1997; 24:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/87\">",
"      Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. Clin Rev Allergy Immunol 2003; 24:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/88\">",
"      Gennari A, Salvadori B, Tognoni A, Conte PF. Rapid intravenous premedication with dexamethasone prevents hypersensitivity reactions to paclitaxel. Ann Oncol 1996; 7:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/89\">",
"      Markman M, Kennedy A, Webster K, et al. Simplified regimen for the prevention of paclitaxel-associated hypersensitivity reactions. J Clin Oncol 1997; 15:3517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/90\">",
"      Bookman MA, Kloth DD, Kover PE, et al. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions. Ann Oncol 1997; 8:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/91\">",
"      Yahata H, Saito M, Sendo T, et al. Prophylactic effect of pemirolast, an antiallergic agent, against hypersensitivity reactions to paclitaxel in patients with ovarian cancer. Int J Cancer 2006; 118:2636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/92\">",
"      Seidman AD, Hudis CA, Albanell J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998; 16:3353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/93\">",
"      Quock J, Dea G, Tanaka M, et al. Premedication strategy for weekly paclitaxel. Cancer Invest 2002; 20:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/94\">",
"      Braverman AS, Rao S, Salvatti ME, et al. Tapering and discontinuation of glucocorticoid prophylaxis during prolonged weekly to biweekly paclitaxel administration. Chemotherapy 2005; 51:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/95\">",
"      Hainsworth JD. Practical aspects of weekly docetaxel administration schedules. Oncologist 2004; 9:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/96\">",
"      Hainsworth JD, Burris HA 3rd, Litchy S, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000; 89:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/97\">",
"      Stemmler J, Mair W, Stauch M, et al. High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 2005; 68:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/98\">",
"      Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/99\">",
"      Krieger JA, Stanford BL, Ballard EE, Rabinowitz I. Implementation and results of a test dose program with taxanes. Cancer J 2002; 8:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/100\">",
"      Peereboom DM, Donehower RC, Eisenhauer EA, et al. Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol 1993; 11:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/101\">",
"      Laskin MS, Lucchesi KJ, Morgan M. Paclitaxel rechallenge failure after a major hypersensitivity reaction. J Clin Oncol 1993; 11:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/102\">",
"      Feldweg AM, Lee CW, Matulonis UA, Castells M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol 2005; 96:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/103\">",
"      Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/104\">",
"      Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005; 23:6019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/105\">",
"      Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/106\">",
"      Fader AN, Rose PG. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int J Gynecol Cancer 2009; 19:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/107\">",
"      Mita AC, Denis LJ, Rowinsky EK, et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009; 15:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/108\">",
"      Pivot X, Koralewski P, Hidalgo JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 2008; 19:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/109\">",
"      de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/110\">",
"      Birch BR, Crisp JC. Allergic reaction to intravesical adriamycin. Br J Urol 1988; 61:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/111\">",
"      Crawford ED, McKenzie D, Mansson W, et al. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: report of 6 cases. J Urol 1986; 136:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/112\">",
"      Solimando DA Jr, Wilson JP. Doxorubicin-induced hypersensitivity reactions. Drug Intell Clin Pharm 1984; 18:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/113\">",
"      Vogelzang NJ. \"Adriamycin flare\": a skin reaction resembling extravasation. Cancer Treat Rep 1979; 63:2067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/114\">",
"      Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54 Suppl 4:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/115\">",
"      Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/116\">",
"      Rahman A, Treat J, Roh JK, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990; 8:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/117\">",
"      Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/118\">",
"      Spiegel RJ, Echelberger CK, Poplack DG. Delayed allergic reactions following intramuscular L-asparaginase. Med Pediatr Oncol 1980; 8:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/119\">",
"      Asselin BL. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv Exp Med Biol 1999; 457:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/120\">",
"      Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004; 26:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/121\">",
"      Pieters R, Hunger SP, Boos J, et al. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase. Cancer 2011; 117:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/122\">",
"      Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982; 49:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/123\">",
"      Jones B, Holland JF, Glidewell O, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Med Pediatr Oncol 1977; 3:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/124\">",
"      Larson RA, Fretzin MH, Dodge RK, Schiffer CA. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998; 12:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/125\">",
"      Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/126\">",
"      Graham ML, Asselin BL, Herndon JE 2nd, et al. Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplant 1998; 21:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/127\">",
"      Ettinger LJ, Kurtzberg J, Vo&ucirc;te PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995; 75:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/128\">",
"      Liu C, Kawedia JD, Cheng C, et al. Clinical utility and implications of asparaginase antibodies in acute lymphoblastic leukemia. Leukemia 2012; 26:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/129\">",
"      Kawedia JD, Liu C, Pei D, et al. Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia. Blood 2012; 119:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/130\">",
"      Khan A, Hill JM. Atopic hypersensitivity to L-asparaginase. Resistance to immunosuppression. Int Arch Allergy Appl Immunol 1971; 40:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/131\">",
"      Fabry U, K&ouml;rholz D, J&uuml;rgens H, et al. Anaphylaxis to L-asparaginase during treatment for acute lymphoblastic leukemia in children--evidence of a complement-mediated mechanism. Pediatr Res 1985; 19:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/132\">",
"      Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/133\">",
"      Albertsen BK, Schr&oslash;der H, Jakobsen P, et al. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase. Med Pediatr Oncol 2002; 38:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/134\">",
"      Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002; 99:1986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/135\">",
"      Pui CH, Mullighan CG, Evans WE, Relling MV. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? Blood 2012; 120:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/136\">",
"      Willer A, Gerss J, K&ouml;nig T, et al. Anti-Escherichia coli asparaginase antibody levels determine the activity of second-line treatment with pegylated E coli asparaginase: a retrospective analysis within the ALL-BFM trials. Blood 2011; 118:5774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/137\">",
"      Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007; 110:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/138\">",
"      Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol 2009; 7:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/139\">",
"      Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007; 109:2744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/140\">",
"      M&uuml;ller HJ, Beier R, L&ouml;ning L, et al. Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment. Br J Haematol 2001; 114:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/141\">",
"      Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/142\">",
"      Vieira Pinheiro JP, Wenner K, Escherich G, et al. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97. Pediatr Blood Cancer 2006; 46:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/143\">",
"      M&uuml;ller HJ, Beier R, da Palma JC, et al. PEG-asparaginase (Oncaspar) 2500 U/m(2) BSA in reinduction and relapse treatment in the ALL/NHL-BFM protocols. Cancer Chemother Pharmacol 2002; 49:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/144\">",
"      Land VJ, Sutow WW, Fernbach DJ, et al. Toxicity of L-asparginase in children with advanced leukemia. Cancer 1972; 30:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/145\">",
"      Clavell LA, Gelber RD, Cohen HJ, et al. Four-agent induction and intensive asparaginase therapy for treatment of childhood acute lymphoblastic leukemia. N Engl J Med 1986; 315:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/146\">",
"      Ohnuma T, Holland JF, Meyer P. Erwinia carotovora asparaginase in patients with prior anaphylaxis to asparaginase from E. coli. Cancer 1972; 30:376.",
"     </a>",
"    </li>",
"    <li>",
"     Erwinia asparaginase available through Fisher Bioservices, Dr. Teicher Haney, phone 1-301-315-8426 (toll free 1-888-625-7774), email erwinase@thermofisher.com.",
"    </li>",
"    <li>",
"     Erwinase Master Treatment protocol available online at file://clinicaltrials.gov/ct2/show/NCT00590915?spons=%22EUSA+Pharma+(US)%2C+Inc.%22&amp;spons_ex=Y&amp;rank=2 (Accessed on June 02, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/149\">",
"      Bonno M, Kawasaki H, Hori H, et al. Rapid desensitization for L-asparaginase hypersensitivity. J Allergy Clin Immunol 1998; 101:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/150\">",
"      Soyer OU, Aytac S, Tuncer A, et al. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia. J Allergy Clin Immunol 2009; 123:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/151\">",
"      LeBras MH, Saccente SL, Saylors RL, et al. Modified desensitization protocol using two formulations of L-asparaginase in a pediatric population with recurrent acute lymphoblastic leukemia (ALL) (abstract). J Allergy Clin Immunol 2008; 117:S230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/152\">",
"      Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients. Ann Intern Med 1972; 77:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/153\">",
"      Carter JJ, McLaughlin ML, Bern MM. Bleomycin-induced fatal hyperpyrexia. Am J Med 1983; 74:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/154\">",
"      Leung WH, Lau JY, Chan TK, Kumana CR. Fulminant hyperpyrexia induced by bleomycin. Postgrad Med J 1989; 65:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/155\">",
"      Ma DD, Isbister JP. Cytotoxic-induced fulminant hyperpyrexia. Cancer 1980; 45:2249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/156\">",
"      Dinarello CA, Ward SB, Wolff SM. Pyrogenic properties of bleomycin (NSC-125066). Cancer Chemother Rep 1973; 57:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/157\">",
"      Glovsky MM, Braunwald J, Opelz G, Alenty A. Hypersensitivity to procarbazine associated with angioedema, urticaria, and low serum complement activity. J Allergy Clin Immunol 1976; 57:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/158\">",
"      Khansur T, Little D, Tavassoli M. Fulminant and fatal angioedema caused by bleomycin treatment. Arch Intern Med 1984; 144:2267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/159\">",
"      Vij R, Wang M, Kaufman JL, et al. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma. Blood 2012; 119:5661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/160\">",
"      Castleberry RP, Crist WM, Holbrook T, et al. The cytosine arabinoside (Ara-C) syndrome. Med Pediatr Oncol 1981; 9:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/161\">",
"      Shah SS, Rybak ME, Griffin TW. The cytarabine syndrome in an adult. Cancer Treat Rep 1983; 67:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/162\">",
"      Ek T, Pinkava M, Abrahamsson J. Ara-C fever and infections after high-dose ara-C treatment in pediatric lymphoid malignancies. J Pediatr Hematol Oncol 2005; 27:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/163\">",
"      Ek T, Jarfelt M, Mellander L, Abrahamsson J. Proinflammatory cytokines mediate the systemic inflammatory response associated with high-dose cytarabine treatment in children. Med Pediatr Oncol 2001; 37:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/164\">",
"      Manoharan A. The cytarabine syndrome in adults. Aust N Z J Med 1985; 15:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/165\">",
"      Williams SF, Larson RA. Hypersensitivity reaction to high-dose cytarabine. Br J Haematol 1989; 73:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/166\">",
"      Rassiga AL, Schwartz HJ, Forman WB, Crum ED. Cytarabine-induced anaphylaxis. Demonstration of antibody and successful desensitization. Arch Intern Med 1980; 140:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/167\">",
"      Markman M, Howell SB, King M, et al. Anaphylactic reaction to cytarabine: in vitro evidence that the response is immunoglobulin E mediated. Med Pediatr Oncol 1984; 12:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/168\">",
"      Berkowitz FE, Wehde S, Ngwenya ET, et al. Anaphylactic shock due to cytarabine in a leukemic child. Am J Dis Child 1987; 141:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/169\">",
"      Hoetelmans RM, Schornagel JH, ten Bokkel Huinink WW, Beijnen JH. Hypersensitivity reactions to etoposide. Ann Pharmacother 1996; 30:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/170\">",
"      Blanca M, Torres MJ, Gir&oacute;n M, et al. Successful administration of cytarabine after a previous anaphylactic reaction. Allergy 1997; 52:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/171\">",
"      Metz KA, Johnson T, Hershey GK, et al. Successful administration of cytarabine in a 16-month-old girl with acute myelogenous leukemia and cytarabine syndrome. Ann Allergy Asthma Immunol 2009; 102:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/172\">",
"      Salles G, Vial T, Archimbaud E. Anaphylactoid reaction with bronchospasm following intravenous cyclophosphamide administration. Ann Hematol 1991; 62:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/173\">",
"      Rosas-Vargas MA, Casas-Becerra B, Vel&aacute;zquez-Armenta Y, et al. Cyclophosphamide hypersensitivity in a leukemic child. Ther Drug Monit 2005; 27:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/174\">",
"      Popescu NA, Sheehan MG, Kouides PA, et al. Allergic reactions to cyclophosphamide: delayed clinical expression associated with positive immediate skin tests to drug metabolites in five patients. J Allergy Clin Immunol 1996; 97:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/175\">",
"      Khaw SL, Downie PA, Waters KD, et al. Adverse hypersensitivity reactions to mesna as adjunctive therapy for cyclophosphamide. Pediatr Blood Cancer 2007; 49:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/176\">",
"      Allergic reactions to mesna. Lancet 1991; 338:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/177\">",
"      Case DC Jr, Anderson J, Ervin TJ, Gottlieb A. Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study 8552. Med Pediatr Oncol 1988; 16:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/178\">",
"      Pratt CB, Sandlund JT, Meyer WH, Cain AM. Mesna-induced urticaria. Drug Intell Clin Pharm 1988; 22:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/179\">",
"      Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19:376.",
"     </a>",
"    </li>",
"    <li>",
"     Negro-Vilar A, Dziewanowska Z, Groves ES, et al. Efficacy and safety of denileukin diftitox in a phase III, double blind, placebo-controlled study of CD25+ patients with cutaneous T-cell lymphoma (CTCL) (abstract). J Clin Oncol 2007; 25:447s.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/181\">",
"      Foss FM, Bacha P, Osann KE, et al. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 2001; 1:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/182\">",
"      Gerena-Lewis M, Crawford J, Bonomi P, et al. A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. Am J Clin Oncol 2009; 32:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/183\">",
"      O'Dwyer PJ, Weiss RB. Hypersensitivity reactions induced by etoposide. Cancer Treat Rep 1984; 68:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/184\">",
"      O'Brien ME, Souberbielle BE. Allergic reactions to cytotoxic drugs--an update. Ann Oncol 1992; 3:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/185\">",
"      Millward MJ, Newell DR, Mummaneni V, et al. Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481). Eur J Cancer 1995; 31A:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/186\">",
"      Hudson MM, Weinstein HJ, Donaldson SS, et al. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease. J Clin Oncol 1993; 11:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/187\">",
"      Siderov J, Prasad P, De Boer R, Desai J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br J Cancer 2002; 86:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/188\">",
"      Collier K, Schink C, Young AM, et al. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. J Oncol Pharm Pract 2008; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/189\">",
"      Alkins SA, Byrd JC, Morgan SK, et al. Anaphylactoid reactions to methotrexate. Cancer 1996; 77:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/190\">",
"      Kohli A, Ferencz TM, Calderon JG. Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic lymphoma. Allergy Asthma Proc 2004; 25:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/191\">",
"      MacGinnitie AJ, Walensky LD, Turvey SE, et al. Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge. Pediatr Allergy Immunol 2003; 14:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/192\">",
"      Davis KA, Williams P, Walker JC. Successful desensitization to high-dose methotrexate after systemic anaphylaxis. Ann Allergy Asthma Immunol 2003; 90:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/193\">",
"      Lopes G, Vincek V, Raez LE. Pemetrexed-associated urticarial vasculitis. Lung Cancer 2006; 51:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/194\">",
"      Andersen E, Videbaek A. Procarbazine-induced skin reactions in Hodgkin's disease and other malignant lymphomas. Scand J Haematol 1980; 24:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/195\">",
"      Coyle T, Bushunow P, Winfield J, et al. Hypersensitivity reactions to procarbazine with mechlorethamine, vincristine, and procarbazine chemotherapy in the treatment of glioma. Cancer 1992; 69:2532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/196\">",
"      Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/197\">",
"      Sandberg-Wollheim M, Malmstr&ouml;m P, Str&ouml;mblad LG, et al. A randomized study of chemotherapy with procarbazine, vincristine, and lomustine with and without radiation therapy for astrocytoma grades 3 and/or 4. Cancer 1991; 68:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/198\">",
"      Lehmann DF, Hurteau TE, Newman N, Coyle TE. Anticonvulsant usage is associated with an increased risk of procarbazine hypersensitivity reactions in patients with brain tumors. Clin Pharmacol Ther 1997; 62:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/199\">",
"      Brooks BJ Jr, Hendler NB, Alvarez S, et al. Delayed life-threatening pneumonitis secondary to procarbazine. Am J Clin Oncol 1990; 13:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/200\">",
"      Millward MJ, Cohney SJ, Byrne MJ, Ryan GF. Pulmonary toxicity following MOPP chemotherapy. Aust N Z J Med 1990; 20:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/201\">",
"      Ecker MD, Jay B, Keohane MF. Procarbazine lung. AJR Am J Roentgenol 1978; 131:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/202\">",
"      Jones SE, Moore M, Blank N, Castellino RA. Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction. Cancer 1972; 29:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/203\">",
"      Lewis LD. Procarbazine associated alveolitis. Thorax 1984; 39:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/204\">",
"      Eyre HJ, Quagliana JM, Eltringham JR, et al. Randomized comparisons of radiotherapy and CCNU versus radiotherapy, CCNU plus procarbazine for the treatment of malignant gliomas following surgery. A Southwest Oncology Group Report. J Neurooncol 1983; 1:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/205\">",
"      Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol 2007; 25:3958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?42/57/43930/abstract/206\">",
"      Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356:2271.",
"     </a>",
"    </li>",
"    <li>",
"     Unpublished data from the phase III temsirolimus versus interferon in advanced renal cell cancer trial. Personal communication, Michael Atkins, MD, November 14, 2008.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2835 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-16712FB15A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43930=[""].join("\n");
var outline_f42_57_43930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H71\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHARACTERISTICS OF REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Signs and symptoms of infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Signs and symptoms of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Timing and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLASSIFICATION OF INFUSION REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NCI classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Definition of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cytotoxic agents implicated in anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Evaluation of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      USE OF PREMEDICATION TO PREVENT INFUSION REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PRINCIPLES OF TREATMENT AND RECHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment of mild to moderate SIRs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment of anaphylaxis and severe SIRs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Rechallenge after a severe SIR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management after anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Overview of skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Overview of desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      AGENTS ASSOCIATED WITH ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PLATINUM DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Incidence and characteristics of infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Carboplatin and cisplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15801927\">",
"      Prophylactic approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Evaluation and management of patients with possible anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7622392\">",
"      - If skin testing is not available",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Desensitization protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Cross reactivity among platinum drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      TAXANES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3596216\">",
"      Paclitaxel and docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Characteristics and incidence of infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H643537181\">",
"      Paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H643537195\">",
"      Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Mechanisms of infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18018679\">",
"      Drug versus vehicle",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Other idiosyncratic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Premedication regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Test dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27068615\">",
"      - Skin testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4352965\">",
"      - Taxane desensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Nab-paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3596554\">",
"      Cabazitaxel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      ANTHRACYCLINES AND RELATED AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Premedication and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      L-ASPARAGINASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3169043\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3169036\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Test doses and skin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Options for rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      BLEOMYCIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Hyperpyrexia syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      - Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Hypersensitivity pneumonitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Acute chest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Other rare reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10520016\">",
"      CARFILZOMIB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      CYTARABINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      CYCLOPHOSPHAMIDE AND IFOSFAMIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      DENILEUKIN DIFTITOX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      Premedication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      ETOPOSIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      IXABEPILONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H66\">",
"      METHOTREXATE AND PEMETREXED",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H67\">",
"      PROCARBAZINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H68\">",
"      Treatment and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H69\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H70\">",
"      TEMSIROLIMUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H71\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H72\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73\">",
"      Immediate treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H74\">",
"      - Mild to moderate SIRs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H75\">",
"      - Severe SIR or anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76\">",
"      Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2835\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2835|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/31/29179\" title=\"table 1\">",
"      Grade of infusion related reactions NCI CTCAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 2\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/26/16813\" title=\"table 3\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 4\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/53/5981\" title=\"table 5\">",
"      Antineoplastic drugs that act as vesicants or irritants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/23/13692\" title=\"table 6\">",
"      Types of allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/45/37598\" title=\"table 7\">",
"      Platinum desens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/4/23628\" title=\"table 8A\">",
"      Desensitiz for chemo hypersens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/14/22763\" title=\"table 8B\">",
"      Chemo escalate for desensitiz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/6/20589\" title=\"table 9\">",
"      Asparaginase desensitiz",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/39/3707\" title=\"table 10\">",
"      Systemic inflammatory response",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28170?source=related_link\">",
"      Anti-angiogenic and molecularly targeted therapy for advanced renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/8/6280?source=related_link\">",
"      Chemotherapy in castrate-resistant prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/218?source=related_link\">",
"      Extravasation injury from chemotherapy and other non-neoplastic vesicants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/11/21689?source=related_link\">",
"      First-line chemotherapy for advanced (stage III or IV) epithelial ovarian, fallopian tubal, and peritoneal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/26/426?source=related_link\">",
"      Idiopathic systemic capillary leak syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/19/38202?source=related_link\">",
"      Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/53/29528?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Single agent chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38344?source=related_link\">",
"      Taxane-induced pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36410?source=related_link\">",
"      Treatment of advanced stage (IIB to IV) mycosis fungoides and S&eacute;zary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f42_57_43931="Initiation of volume-cycled NPPV in NM disease";
var content_f42_57_43931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F72444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F72444&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Protocol for initiation of noninvasive positive pressure ventilation using volume-cycled ventilator",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        1. Choose appropriately monitored location.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2. Obtain baseline vital signs, arterial blood gas, and oximetry, as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3. Direct patient to sit in bed or chair at &gt;30 angle. Ensure patient comfort.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4. Select and fit interface (nasal or oronasal mask).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5. Apply headgear; avoid excessive strap tension (one&nbsp;to two fingers should fit under strap).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6. Select ventilator.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7. Connect interface to ventilator tubing and turn on ventilator.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8. For volume-cycled ventilator, start with synchronized mandatory ventilation mode, tidal volume 6 to 10 mL/kg, and PEEP&nbsp;4 to 5 cm H",
"        <sub>",
"         2",
"        </sub>",
"        O. Set&nbsp;a back up rate of 2 breaths per minute below the patient's spontaneous nocturnal rate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9. Gradually increase tidal volume by 250 to 500 mL increments, as tolerated, to achieve alleviation of dyspnea, decreased respiratory rate, increased tidal volume (if being monitored), and good patient-ventilator synchrony.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10. Check for air leaks, readjust straps as needed. Add chin strap if oral air leak noted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11. Add heated humidification, as indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12. Provide encouragement, reassurance, and frequent checks and adjustments as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13. Monitor vital signs and oximetry during trial; obtain occasional blood gases (within 1 to 2 hours) and then as needed.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43931=[""].join("\n");
var outline_f42_57_43931=null;
var title_f42_57_43932="ECOG performance scale";
var content_f42_57_43932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F72901%7EPC%2F58785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F72901%7EPC%2F58785&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Eastern Cooperative Oncology Group (ECOG, Zubrod, WHO) performance scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Performance status",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        0",
"       </td>",
"       <td>",
"        Fully active; no performance restrictions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Strenuous physical activity restricted; fully ambulatory and able to carry out light work",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Capable of all selfcare but unable to carry out any work activities. Up and about &gt;50 percent of waking hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Capable of only limited selfcare; confined to bed or chair &gt;50 percent of waking hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        Completely disabled; cannot carry out any selfcare; totally confined to bed or chair",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Excerpted from: Oken MM, et al. Am J Clin Oncol 1982; 5:649.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Karnofsky performance status scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Value",
"       </td>",
"       <td class=\"subtitle1\">",
"        Level of functional capacity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Definition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        Normal, no complaints, no evidence of disease",
"       </td>",
"       <td rowspan=\"3\">",
"        Able to carry on normal activity and to work; no special care needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        90",
"       </td>",
"       <td>",
"        Able to carry on normal activity, minor signs or symptoms of disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        Normal activity with effort, some signs or symptoms of disease",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        Cares for self, unable to carry on normal activity or to do active work",
"       </td>",
"       <td rowspan=\"3\">",
"        Unable to work; able to live at home and care for most personal needs; various degrees of assistance needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60",
"       </td>",
"       <td>",
"        Requires occasional assistance, but is able to care for most needs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        Requires considerable assistance and frequent medical care",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        Disabled, requires special care and assistance",
"       </td>",
"       <td rowspan=\"5\">",
"        Unable to care for self; requires equivalent of institutional or hospital care; disease may be progressing rapidly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Severely disabled, hospitalization is indicated although death is not imminent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        Hospitalization is necessary, very sick, active supportive treatment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        Moribund, fatal processes progressing rapidly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Dead",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43932=[""].join("\n");
var outline_f42_57_43932=null;
var title_f42_57_43933="Abnormal adult behavior diagnosis algorithm";
var content_f42_57_43933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77387&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic approach to the adult with altered mental status",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 349px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43933=[""].join("\n");
var outline_f42_57_43933=null;
var title_f42_57_43934="Dx small intestinal villus atrophy";
var content_f42_57_43934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F61019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F61019&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagnostic algorithm for small intestinal villous atrophy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 447px; height: 478px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NCE: non-celiac enteropathy; tTG: tissue transglutaminase antibody; IgA: immunoglobulin A; IgG: immunoglobulin G; DGP: deamidated gliadin peptide; HLA: human leukocyte antigen; NRCD: nonresponsive celiac disease; CVID: common variable immunodeficiency; CD: celiac disease.",
"    </div>",
"    <div class=\"reference\">",
"     From: Pallav K, Leffler DA, Tariq S, et al. Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice. Aliment Pharmacol Ther 2012; 35:380. Copyright &copy; 2012. Reproduced with permission of John Wiley &amp; Sons, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43934=[""].join("\n");
var outline_f42_57_43934=null;
var title_f42_57_43935="Periungual erythema PI";
var content_f42_57_43935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F75841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F75841&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Periungual erythema in a patient with dermatomyositis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 397px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John H Stone, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f42_57_43935=[""].join("\n");
var outline_f42_57_43935=null;
